Please can you provide the following information for financial years FY2016/17, FY2017/18, FY2018/19, FY2019/20, FY2020/21, current financial year to date (FY2021/22 YTD):
1) Please provide the top 5 ON framework 3rd Party providers for nursing staff, by name, used by your trust for each of the listed financial years
2) Please provide the total annual expenditure for each of the top 5 ON framework 3rd Party providers, for nursing staff, used by your trust for each of the listed financial years
3) Please provide the top 5 OFF framework 3rd Party providers for nursing staff, by name, used by your trust for each of the listed financial years
4) Please provide the total annual expenditure for each of the top 5 OFF framework 3rd Party providers, for nursing staff, used by your trust for each of the listed financial years

3rd Party Temporary Staffing Providers. 110222.docx

1. The amount spent on employing agency, temporary and/or locum doctors in A&E departments in each month in 2019 and 2020.
2. The number of FTE roles in A&E departments covered by agency, temporary and/or locum doctors in each month in 2019 and 2020.
3. The total number of FTE doctors (including agency, temporary and/or locum and permanent staff) working in A&E departments in each month in 2019 and 2020.

Download response A&E agency staff and cost. 141021.docx

1. The amount spent on employing agency, temporary and/or locum doctors in A&E departments in each month in 2017 and 2018
2. The number of FTE roles in A&E departments covered by agency, temporary and/or locum doctors in each month in 2017 and 2018
3. The total number of FTE doctors (including agency, temporary and/or locum and permanent staff) working in A&E departments in each month in 2017 and 2018

Download response A&E staffing. 080519

You asked:
1) The total amount you spend on Agency Locum Doctors for 2017-2018: – £
2) For the above information to be broken down by grade and specialty (example provided below)
Specialty FY1/2 ST1/2 ST3-6 Staff Grade Consultant
A&E
Medicine
Anaesthetics
Medicine
Surgery
Paeds
Pathology
O & G
Ophthalmology
3) Your Bank spend on Doctors for 2017-2018 broken down as question (2): – £
4) The total number of hours filled and unfilled each month for Agency medical locums for 2017-2018.
5) The highest bank rate paid in 2017-2018, providing confirmation of the grade and speciality.
6) Your current Bank rates for each grade and speciality, including any specialities or sub specialities which have an escalated Bank rate.
7) The Trusts average rates for Agency medical locums from September, October, November and December collectively broken down by grade and specialty (example provided below).
Specialty FY1/2 ST1/2 ST3-6 Staff Grade Consultant
A&E
Medicine
Anaesthetics
Medicine
Surgery
Paeds
Pathology
O & G
Ophthalmology
(8) The spend for medical locums through off-framework agencies for 2017-2018 and confirmation of the off-framework agencies used.
(9) Please confirm any contracts you have in place for medical locums and please confirm the list of suppliers used for medical locums.

Download response Agency and Bank Doctors. 051218

Would you be able to provide me with the highest and lowest rates that have been paid for the below specialities please.
Could you please cover from January 2020 to present
General Nurse Band 5
ITU Nurse Band 6
Theatre Nurse Band 6
ODP Band 6
Advanced Scrub Practitioner
Radiographer Band 8
Pharmacist Band 8

Download response Agency and bank pay rates. 130421

All questions are shown as received by the Trust.
In the period 1st February 2024 to 30th April 2024 please provide a breakdown of:
1. Total trust spend with framework agencies for locum doctors
Please provide a further breakdown for locum doctors by:
a. Spend per grade
b. Spend per specialty
c. Spend per agency name

In the period of 1st February 2024 to 30th April 2024 please provide a breakdown of:
2. Total trust spend with off-framework agencies for locums doctors
Please provide a further breakdown for locum doctors by:
a. Spend per grade
b. Spend per specialty
c. Spend per agency name

In the period of 1st February 2024 to 30th April 2024 please provide a breakdown of:
3. Total trust spend with the internal trust bank or associated external provider for locum doctors
Please provide a further breakdown for locum doctors by:
a. Spend per grade
b. Spend per specialty
c. Spend per internal or associated external provider

4. Please confirm your allocated budget for agency locum doctors for the period 1st February 2024 to 30th April 2024.

Agency and Bank spend.070624.docx

Sourced Staffing Arrangements
1a. Do you have a master vendor or neutral vendor arrangement in place for sourcing agency staff? If so, please state which arrangement is in place
1b. Please state the name of the appointed supplier for the above arrangement
1c. Please state the start date of the contract with this supplier
1d. Please state the end date of the contract with this supplier
1e. Annual cost of your supplier in 18/19?

Agency Spend and Supply
2a. Please state the organisations total expenditure on agency (non-contract) staff for the financial year 18/19 (April 2018 – March 2019). Split by the following staffing groups
2b. Please state the name of the framework(s) you source your agency staff under, for each of the following staffing groups

Direct Engagement
3a. Does the organisation use a third party to provide a Direct Engagement/Outsourced Employment Solution? (This is where the NHS organisation sources agency staff via a recruitment agency but hold a direct contract between the organisation and the worker – there is often VAT savings associated to this employment model)
3b. Please state the name of the Direct Engagement/Outsourced Employment supplier (e.g. 247Time/Allocate, PlusUs, Retinue, Liaison etc.)
3c. Please state all staffing groups that are managed via your direct engagement provider; for example; Medical, Admin, Scientific staff
3d. Please state the start date of the contract with the DE supplier
3e. Please state the end date of the contract with the DE supplier
3f. What was the annual cost to the organisation for the provision of the direct engagement service in 18/19?
3g. Did the organisation procure these services via a framework? If so, please provide the full name of the framework

Internal Bank Spend
4. Please state the organisations total expenditure on internal bank staff for the financial year 18/19 (April 2018 – March 2019). Split by the following staffing groups

Medical Bank Supplier
5a. Please state the name of the technology provider used to manage the supply of your medical bank staff, inclusive of any outsourced or managed arrangements (i.e. NHSP, Patchwork, Allocate, Liaison, PlusUs, Locum’s Nest etc., please state if in-house)
5b. Please state the start date of the contract with your medical bank provider
5c. Please state the end date of the contract with your medical bank provider
5d. What was the annual cost to the organisations for the provision of bank provider services/software in 18/19
5e. Did the organisation procure these services via a framework? If so, please provide the full name of the framework

Download response Agency and bank staff. 021019

1. The total amount spent on agency temporary staff for the year 2021/22 (April ’21 to March ‘22) and between 31/10/2021 to 31/10/2022 for the following categories:
• Doctors
• Nurses
• AHP (all categories)
• Health Care Assistants
2. Bank Spend – Total amount spent on bank staff for the year 2021/22 (April ’21 to March ‘22) and between 31/10/2021 and 31/10/2022 year split into the Trusts’ staff groups (E.g. Medical, Nursing, Admin, AHP etc.) and speciality/grade (E.g. Consultants, GP, ICU Nurse, Acute Nurse, Occupational therapists, Pharmacists, Health Care Assistants, etc.) depending on how this is reported within the Trust.
3. Confirmation on whether the trust bank is currently operated by the trust themselves or by a private provider. If the latter please confirm the name of the provider.
The names and contact information of the individual divisional directors of Surgery covering the following treatment areas:
• General Surgery
• Urology
• Trauma and Orthopaedic
• Ear, Nose and Throat
• Ophthalmology
• Oral Surgery
• Neurosurgical Service
• Cardiothoracic
• Cardiology Service
• Dermatology Service
• Respiratory Medicine Service
• Gynaecology Service
• Rheumatology Service

Agency and Bank staff.100223.docx

1. Please quantify Agency recruitment splits (total spending and total WTE numbers) for medical, nursing and other employees (Forecasts 2019/20 and 2018/2019, and actuals 2018/19, 2017/2018, and 2016/2017)
2. Please quantify Bank recruitment splits (total spending and total WTE numbers) for medical, nursing and other employees (Forecasts 2019/20 and 2018/2019, and actuals 2018/19, 2017/2018, and 2016/2017)

Download response Agency and Bank Staff. 120320

Q1: Please can you confirm what percentage of your wage bill is spent on
(a) Agency staff?
(b) Bank staff?
Q2: What does the answer to Q1 (a) equate to in Pounds Sterling (£)?
Q3: What percentage of all your medical and clinical patient facing shifts are filled with staff that are paid above the ‘break glass’ ceiling rate (above the agency rules pay cap)?

Agency and Bank Staff costs.290623.docx

1)The total amount spent by the Trust on bank staff in 2021/22
2) The total amount spent by the Trust on agency staff in 2021/22
3) The total amount spent by the Trust on bank nurses in 2021/22
4) The total amount spent by the Trust on agency nurses in 2021/22
5) The largest amount spent by the Trust on a single agency nurse shift in 2021/22

Agency and Bank staff spend.181022.docx

1. Please provide agency spend for the staff group for 2019-20
2. Please provide bank spend for the staff group for 2019-20
3. Please confirm which model you have in place for managing the staff group: Email to preferred supplier List, a Master Vendor, a Neutral Vendor, or a Software cascade to a preferred supplier list
4. If you have a master vendor or neutral vendor in place, please confirm who this contract is with and the date on which this contract expires
5. Please confirm what percentage of bookings over the last 6 months have been within the NHSI/E agency caps (an approximation based on NHSI data submissions is fine)
6. Please confirm which provider manages your direct engagement process, the fee for the service and the date on which this contract expires (no this is not relevant for Nursing)
7. Please confirm what percentage of bookings are processed with a VAT savings by your direct engagement provider
8. Is your bank managed by an external bank provider (e.g. NHS Professionals, Bank Partners) or in-house? Please confirm who is the external bank provider and when the contract expires if relevant
9. Is your bank managed via software? If so, please confirm which software.
Is the Trust likely to undertake any procurement activity over the next 18 months related to provision or bank or agency services or software for the relevant staff group.

Download response Agency and Bank staffing. 240620

1. Please provide agency spend for the staff group for 2019-20
2. Please provide bank spend for the staff group for 2019-20
3. Please confirm which model you have in place for managing the staff group: Email to preferred supplier List, a Master Vendor, a Neutral Vendor, or a Software cascade to a preferred supplier list
4. If you have a master vendor or neutral vendor in place, please confirm who this contract is with and the date on which this contract expires
5. Please confirm what percentage of bookings over the last 6 months have been within the NHSI/E agency caps (an approximation based on NHSI data submissions is fine)
6. Please confirm which provider manages your direct engagement process, the fee for the service and the date on which this contract expires (no this is not relevant for Nursing)
7. Please confirm what percentage of bookings are processed with a VAT savings by your direct engagement provider
8. Is your bank managed by an external bank provider (e.g. NHS Professionals, Bank Partners) or in-house? Please confirm who is the external bank provider and when the contract expires if relevant
9. Is your bank managed via software? If so, please confirm which software.
Is the Trust likely to undertake any procurement activity over the next 18 months related to provision or bank or agency services or software for the relevant staff group.

Download response Agency and Bank staffing. 240620

1. Please provide agency spend for the staff group for the Financial Year 2021-22 (please specify your start and end date used) Financial Year indicating what percentage is on and off-framework (for example, “£4,650,000 – c80% framework / 20% off-framework”).
2. Please provide bank spend for the staff group for Financial Year 2021-22 (please specify your start and end date used)
3. Please confirm which model you have in place for managing agency within the staff group: Email to preferred supplier List, a Master Vendor, a Neutral Vendor, or a Software cascade to a preferred supplier list
4. Please confirm what percentage of bookings over the last 6 months have been within the NHSI agency caps (an approximation based on NHSI data submissions is fine)
5. Please confirm which provider manages your direct engagement process, the fee for the service and the date on which this contract expires (no this is not relevant for Nursing)
6. Please confirm what percentage of bookings are processed with a VAT savings by your direct engagement (DE) provider (average for last 3 months –December, January and February)
7. Is your bank managed by an external bank provider (e.g., NHS Professionals, Bank Partners) or in-house? Please confirm who is the external bank provider and when the contract expires if relevant
8. Is your bank managed via software? If so, please confirm which software.
9. Is the Trust likely to undertake any procurement activity over the next 18 months related to provision or bank or agency services or software for the relevant staff group?
10. If you have a managed service, master vendor or neutral vendor in place for Agency medics/Agency doctors please confirm who this contract is with and the date on which this contract expires
11. If you have a managed service, master vendor or neutral vendor in place for Agency Nurses please confirm who this contract is with and the date on which this contract expires

Agency and Bank staffing and spend.150822.docx

1. What is the total value of spend by your NHS Trust with on-framework and off-framework recruitment agencies by staff group (see staff groups below) on a temporary basis? Please provide this information for the following years (please fill in the tables below).
Note: Please provide total spend inclusive of salaries and agency margin / fees.
Note: If cannot provide split of spend by on- vs off- framework agencies, please provide total spend.
2. Do you use insourcing providers?
Note: Insourcing definition: Insourcing of Clinical Services – NHS SBS
3. If yes to previous question (use of insourcing providers), what is the total value of spend, listed by speciality and insourcing provider used for Apr-22 to Mar-23?
Note: If an insourcing provider covers multiple specialities, please list that provider multiple times (one row for each speciality).

Agency and insourcing spend.260723.docx

1.) A) Last financial year agency locum spend
B) Please break down into Specialty and Grade
2.) A) The retention rates for permanent and fixed term staff – Doctors and Nurses only
B) Please break down into Specialty and Grade
3.) A) Please provide the Names of agencies used to fill vacancies
B) how much each agency charges
4.) Please provide your trust wide budgeted establishment per specialty and grade for Doctors
– Name of Speciality / Division or Directorate
– Consultants, Locum Consultant Contract and Associate Specialists
– CT/ST3 – CT/ST7, Specialty Doctors, Senior Clinical Fellows, CESR Fellow or Middle Grade Level
– FY1-ST2, Trust Grade, Junior Clinical Fellow or SHO level
5.) Please what is your actual current establishment for Doctor
– Name of Speciality / Division or Directorate
– Consultants, Locum Consultant Contract and Associate Specialists
– CT/ST3 – CT/ST7, Specialty Doctors, Senior Clinical Fellows, CESR Fellow or Middle Grade Level
– FY1-ST2, Trust Grade, Junior Clinical Fellow or SHO level

Agency and Staff details.260423.docx

How much have you spent on agency staff during days in which industrial action was taken by staff in your trust since 1st December 2022?

Agency costs during industrial action.030823.docx

All questions are shown as received by the Trust.
How much have you spent on agency staff during days in which industrial action was taken by staff in your trust since 1st December 2022?

Agency costs during industrial action.170823.docx

1. The Trust’s spend on agency workers (both on-framework and off-framework);
2. By role type;
3. With which provider/s and how much the Trust spends;
4. and when the current contract ends with your agency staffing provider.

Agency details.230623.docx

1) Since 1st April 2020, what are the top three / most expensive hourly rates (including all cost elements i.e. pay, agency fee, NI, PAYE taxes, VAT and any associated managed service / master vendor fee) paid for agency doctors working at each of the following grades?
Please respond to question one by populating the template below as per the example.
Please clarify the Specialty for which each of the rates was paid as shown.

2) Since 1st April 2020, what are the bottom three / least expensive hourly rates (including all cost elements i.e. pay, agency fee, NI, PAYE taxes, VAT and any associated managed service / master vendor fee) paid for agency doctors working at each of the following grades?
Please respond to question one by populating the template below as per the example.
Please clarify the Specialty for which each of the rates was paid as shown.

3) For each of the “job titles” (Grade / Specialty) mention in your response to questions 1 and 2, please disclose the average hourly rate paid for agency doctors of the same Grade and Specialty since 1st April 2020.
There should be a maximum of 18 unique “job titles” in the tables above; please use the template below as per the example given at the bottom.

Download response Agency doctor pay rates. 130421

You asked:
1. What percentage fill rates (doctors) were reached between January and present?
2. Does your organisation use a Direct Engagement scheme? If so, who provides it and when does their contract expire?
3. What percentage of bookings are made outside of the DE model (non-DE)?
4. Do you outsource any of the following services to external companies:
• Provision of Residential Medical Officers
• Gastroenterology/Endoscopy
• Dermatology
• Radiology
5. Do you use agencies for national and international permanent doctor and/or nursing recruitment? If so, do you employ nurses from the Philippines?

Download response Agency locum doctor supply. 151118

1. Over the last 5 years, broken down by year, the total number of hours of work provided to the trust by non-substantive doctors, either via a locum agency or a bank staffing system, and the total cost to the trust of those hours.
2. The above information broken down by staff sourced through agency and those sourced through your bank staffing arrangement.
3. The figures (hours and spend for each of locum and bank) provided in answer to 2. broken down first by specialty and then grade of doctor.
4. The standard hospital hourly rate of pay for each of the specialties and grades listed in answer to 3.
5. The hospital and NHS capped rates for each of the specialties and grades listed in 3. if different to the rate listed in 4.
6. For each category created in response to 3. (i.e bank haematology registrars), the percentage of hours worked at standard rate, above the standard rate, and above the capped rate if different from the standard rate.
7. What penalties, if any, are levied against the trust if it exceeds the ‘capped’ rate.
8. What penalties were levied against the trust for breaking the cap in each of the years for which data has been provided.
9. If the trust utilises a Bank Partner, what is the cost of said Partner and how does this cost manifest e.g. lump sum, fee per position filled etc.

Download response Agency, locum or bank staff. 181019

How much did the trust spend on agency locums last year? Broken down into SHO, Middle Grade and Consultants

If I could please have this information on the following specialities: A&E, Acute Medicine, General Medicine, Radiology and Paediatrics I would be appreciative.

Download response Agency locum spend. 010818

1. Last financial year agency locum and bank spend
• Please break down into Specialty and grade
2. Names of agencies used to fill vacancies
– How much does each agency charge
3. What is your trust wide budgeted establishment per specialty and grade for doctors
– Name of Speciality / Division or Directorate:
– Consultants, Locum Consultant Contract and Associate Specialists:
– CT/ST3 – CT/ST7, Specialty Doctors, Senior Clinical Fellows, CESR Fellow or Middle Grade Level:
– FY1-ST2, Trust Grade, Junior Clinical Fellow or SHO level:
4. What is your actual current establishment for doctor
• Name of Speciality / Division or Directorate:
– Consultants, Locum Consultant Contract and Associate Specialists:
– CT/ST3 – CT/ST7, Specialty Doctors, Senior Clinical Fellows, CESR Fellow or Middle Grade Level:
– FY1-ST2, Trust Grade, Junior Clinical Fellow or SHO level:

Download response Agency locums and Doctors. 301120

You asked: All questions are shown as received by the Trust.
1. How much have you spent on agency midwives each of the last five years?

2. What was the most expensive agency midwife shift over the last five years?

Agency midwives.140923.docx

1. On how many occasions in the 2019/20 financial year did you spend £1,500 or more to employ an agency nurse for a single shift? For each occasion, please state the amount paid, how many hours they were asked to work as well as the job title and department the nurse was deployed in.
2. On how many occasions in the 2019/20 financial year did you spend £3,000 or more to employ an agency doctor for a single shift? For each occasion, please state the amount paid, how many hours they were asked to work as well as the job title and department the nurse was deployed in.

Download response Agency nurse and locum doctor expenditure. 261020

Average Band 5 Agency Nurse Rates
Please respond to question one by populating the template below.
a) Average cost per hour (inclusive of base pay, agency margin, NI, PAYE etc. but excluding VAT) paid for Band 5 agency Nurses for Standard Day hours between 1st April 2020 and 31st January 2021
b) Average cost per hour (inclusive of base pay, agency margin, NI, PAYE etc. but excluding VAT) paid for Band 5 agency Nurses for Saturday & Evening hours between 1st April 2020 and 31st January 2021.
c) Average cost per hour (inclusive of base pay, agency margin, NI, PAYE etc. but excluding VAT) paid for Band 5 agency Nurses for Sunday & Bank Holiday hours between 1st April 2020 and 31st January 2021

Part 2 – High Rate Band 5 Nurse Hours
For the below questions, please answer number of shifts rather than number of hours if this figure is easier to obtain – please clarify which unit you’re referring to within your response. Please also indicate how many individual nurses make up the figure in response to each of the below.
a) For Band 5 Agency Nurses, regardless of rate type (i.e. Days, Nights, Bank Holidays etc.), how many hours since 1st April cost £50 per hour or more?
b) For Band 5 Agency Nurses, regardless of rate type (i.e. Days, Nights, Bank Holidays etc.), how many hours since 1st April cost £75 per hour or more?
c) For Band 5 Agency Nurses, regardless of rate type (i.e. Days, Nights, Bank Holidays etc.), how many hours since 1st April cost £100 per hour or more?

Download response Agency Nurse Rates and hours. 130421

Could the trust please provide information on how much has been spent on agency nurses?

1) This financial year to date
2) 2018/19 financial year
3) 2017/18 financial year

Are these amounts higher, lower or within the budgets allocated for agency staff?

Are there any measures being implemented to lower the reliance or use of agency staff?

Download response Agency nurses. 041019

All questions are shown as received by the Trust.
1.
(a) Who is the head of procurement that is responsible for approving Nursing agency usage?
(b) Secondly, who is the temporary / flexible staffing lead responsible for the management of this service ?
2. Please can you provide the contact number and email address in relation to both question 1 (a) and (b)
3.
(a) Can you please confirm the names of all OFF-Framework agencies currently supplying to your trust for the following staffing groups: Registered General Nurses (RGNs) & Registered Mental-health Nurses (RMNs), Accident & Emergency (A&E)/Intensive Therapy Unit (ITU) Nurses, Prison nurses and Theatre Nurses
(b) Secondly, Can you please confirm the volume of supply, by number of shifts filled and & shift type, by each OFF-Framework agency during October 1st 2023 – February 29th 2024
4. How much was your OFF-Framework agency spend for each of the following staff groups between January 2024 – April 2024
(a) RGN’s
(b) Chemotherapy Nurses
(c) RMN
(d) ITU Nurse
(e) A&E nurse
(f) Prison Nurses
(g) Theatre nurses
(h) Neonatal nurses

Agency nurses.250424.docx

Could you provide me with a breakdown of spend on agency nurses and midwives between May 2022 and May 2023 as below
1. Number of shifts invoiced by each provider trust has used for agency nursing
2. Framework spend on agency nursing and midwifery broken down to spend per Framework provider
3. Off-framework spend on agency nursing and midwifery broken down to spend per off-framework provider

Agency nurses and midwives.240523.docx

1) How many agency nursing shifts have your Trust used SNG or Thornbury Nursing Services for between 1st October 2020 and 30th November 2020?
2) Please provide a breakdown of the amount of shifts per ward or department where SNG or Thornbury Nursing Services were used in 1st October and 30th November 2020?
3) How many agency nursing shifts have your Trust used Nutrix nursing agency for between 1st October 2020 and 30th November 2020?
4) Please provide a breakdown of the amount of shifts per ward or department where Nutrix were used between 1st October 2020 and 30th November 2020.
5) Please name any other OFF CONTRACT SUPPLIERS who have been utilised by the Trust between 1st October 2020 and 30th November 2020 above the NHS Improvement + 50% caps and how many shifts each of these agencies have filled.

Download response Agency nursing. 130421

All questions are shown as received by the Trust.
Please can you confirm how much was spent on agency nursing between the period April 1st 2023 and 31st June 2023?

Further to this, please can you confirm how much of this total was spent with Off-framework agencies?

Agency nursing.160823.docx

Please could you answer the following questions in relation to the trusts agency nursing usage in financial year 2022-2023
1. How much in total did the trust spend on agency nursing supply?
2. How was that total split between Community/ Acute/ Mental Health Nursing (please delete as appropriate)?
3. Of the total spend, how much of it was spent with off-framework agencies?
4. Who within the trust is responsible for reporting on off-framework usage?

Agency Nursing.200723.docx

All questions are shown as received by the Trust.
Please answer all questions with the relevant data for the month of March 2023 ( 1st to the 31st March ) for your nursing – inclusive of Adult, Mental Health, Critical, Community and District where applicable for both frameworks and off frameworks Agencies.
Information requested :
1. The total number and spend of nursing shifts sent to agencies to fill ( frameworks and off frameworks ) Please provide these totals separately
2. The total number and spend of nursing shifts filled by agencies ( frameworks and off frameworks ) Please provide these totals separately
3. The total number and spend of critical banded nursing shifts sent to agencies to fill. ( frameworks and off frameworks ) Please provide these totals separately
4. The total number and spend of critical banded nursing shifts filled by agencies. ( frameworks and off frameworks ) Please provide these totals separately
5. The total number and spend of ‘breaches’ for filling a shift with agency nurses (Registered Nurses) not within the NHSI capped charge rates.
6. Please provide a list of all frameworks agencies that are currently ‘breaching’ ‘breaches’ when filling a shift with agency nurses (Registered Nurses) not within the NHSI capped charge rates.
7. Please provide a list of all frameworks agencies which supply the trust with nursing staff.
8. Please provide a list of off framework agencies which have supplied (from 1st January 2023 to 31st March 2023) into the trust with nursing staff across all sites.
9. From 1st March 2023 to 31st March 2023, please list the wards/ departments you have requested shifts for off framework agencies.

Agency Nursing.230823.docx

All questions are shown as received by the Trust.
For nursing registered and unregistered please could you share the below agency data:
1. For registered Nursing
a. How many hours were used in the last year?
b. What is your spend over the corresponding period?
2. For unregistered Nursing
a. How many hours were used in the last year?
b. What is your spend over the corresponding period?
Please could you also confirm if you have a:
3. Master vendor and their contract end date?
4. Neutral vendor and their contract end date?

Agency Nursing, Master Vendor and Neutral Vendor.160823.docx

1) How many agency nursing shifts have your Trust used SNG or Thornbury Nursing Services for between 01 December 2020 and 10 February 2021
2) Please provide a breakdown of the amount of shifts per ward or department where SNG or Thornbury Nursing Services were used between 01 December and 10 February 2021
3) How many agency nursing shifts have your Trust used Nutrix or Greenstaff for between 01 December 2020 and 10 February 2021?
4) Please provide a breakdown of the amount of shifts per ward or department where Nutrix, or Greenstaff were used between 01 December 2020 and 10 February 2021
5) Please name any other OFF CONTRACT SUPPLIERS who have been utilised by the Trust between 01 December 2020 and 10 February 2021above the NHS Improvement + 50% caps and how many shifts each of these agencies have filled.
6) If for any reason you are unable to supply data up until 10 February please provide the data until 31 January 2021

Download response Agency nursing shifts. 130421

1) How many agency nursing shifts have your Trust used SNG or Thornbury Nursing Services for between 1st December 2021 and 10th February 2022
2) Please provide a breakdown of the number of shifts per ward or department where SNG or Thornbury Nursing Services were used between 1st December 2021 and 10th February 2022
3) How many agency nursing shifts have your Trust used Nutrix, MED GEN, Greenstaff for between 1st December 2021 and 10th February 2022?
4) Please provide a breakdown of the number of shifts per ward or department where Nutrix, or Greenstaff were used between 1st December 2021 and 10th February 2022
5) Please name any other OFF CONTRACT SUPPLIERS who have been utilised by the Trust between 1st December 2021 and 10th February 2022
6) If for any reason you are unable to supply data up until 10th February please provide the data until 31st January 2022

Agency nursing shifts. 210222.docx

1) How many agency nursing shifts have your Trust used Thornbury nursing services for between 1st July 2019 and 31st July 2019?

2) How many agency nursing shifts have your Trust used Thornbury nursing services for between the dates of 1/8/2019 and 18/8/2019?

3) Please provide a breakdown of the amount of shifts per ward or department where Thornbury were used in July 2019 and 1/8/19- 18/8/19/.

4) Please provide a breakdown for July 2019 of the amount of shifts filled at your Trust by other off contract nursing providers (ie non-framework). Please break this down in the same format (i.e. by ward or department) as question 3.

Download response Agency nursing shifts. 260919

1. Which agency filled the most nursing shifts at your Trust in the last 30 days and how many hours or shifts did they fill?
2. How many of the shifts filled by agency nurses in the last 30 days were above cap?
3. Which wards or departments and sites within your Trust utilised agency nurses in the last 30 days and how many shifts were booked on each?
4. How many nursing shifts were filled by Framework agencies above the 50% NHS Improvement increased caps in the last 30 days?
5. Please list the nursing agencies utilised in the last 30 days above the 50% increased NHS Improvement capped rates by your Trust.

Download response Agency Nursing shifts. 2609192

1. How many agency nursing shifts have your Trust used Thornbury nursing services for in the last 30 days?
2. Please provide a breakdown of the amount of shifts per ward or Departments that Thornbury filled for agency nurses in the last 30 days.
3. What other nursing agencies do you use off contract/off framework?
4. How many nursing shifts did other off contract agencies fill in the last 30 days?
5. Are there any other services linked to your Trust that utilise TNS or any other off contract supplier re Prisons, or community based services? If so please provide a list of these services and the amount of nursing shifts filled in each over the last 30 days

Download response Agency nursing shifts. 2609193

1. Can you confirm names of all agencies supplying into the trust directly or via the NHS Professionals platform for nursing staff specifically for both Band 2 and Band 5 requirements, including off-framework agencies.
a. With the above information, can this be broken down by
• Volume of supply (per month for the last 12 months)
• Total trust spend per agency (per month for the last 12 months)
• By AfC banding of shift request and speciality of nurse
2. Please can you confirm how many shifts have been filled by agencies supplying Band 5 Registered Nursing staff at or below NHSI agency capped rates within the last 12 month period?
3. Please can you confirm how many shifts have been filled by agencies supplying Band 5 Registered Nursing staff above NHSI agency capped rates within the last 12 month period?
4. For the same 12 month period, can you confirm the average charge rate per hour for Band 5 Nursing agency staff across:
Week Days:
Night Shift/Saturday shifts:
Sunday shift/Bank Holiday:
5. Lastly can you confirm the highest agency nurse hourly charge rate, and their speciality?

Agency Nursing Spend.260822.docx

1. Breakdown of shifts (Numbers only) filled by individual Nursing Agencies (by name of agency) in Trust operated theatre wards for ‘Surgical First Assistants’, Operating Department Practitioners’ and ‘SCRUB Nurses’ for March 1st 2021- April 30th 2021
2. Individual Charge rates for nursing agencies for theatre staff March 1st 2021- April 30th 2021
3. Number of shifts filled by individual ‘Off Framework Agencies’ March 1st 2021-April 30th 2021
4. Total Cost for each Nursing Agency used by theatre departments financial year April 2020- April 2021

Download response Agency nursing usage. 250521

1. Please provide the 10 largest individual agency payments for core hours your trust has authorised above the agency worker price caps set by NHS Improvement for each of the following medical grades for (a) 2017-18 and (b) 2018-19 (to date).
• Foundation Year 1
• Foundation Year 2
• Registrar ST1-2
• Registrar ST3
• Speciality staff/staff grade
• Associate specialist
• Consultant

Please provide the figures excluding VAT, as a rate per hour, what the cap was at that particular point in time, the month it was paid and the type of shift being filled.

2. Please provide the 10 largest individual agency payments for unsocial hours your trust has authorised above the agency worker price caps set by NHS Improvement for each of the following medical grades for (a) 2017-18 and (b) 2018-19 (to date).
• Foundation Year 1
• Foundation Year 2
• Registrar ST1-2
• Registrar ST3
• Speciality staff/staff grade
• Associate specialist
• Consultant

Download response Agency Payments. 090419

I would like you to send me the locum agency spend in the AHP/HSS division of the hospital for Pharmacists and Pharmacy Technicians. I would like to know the spend for 2018 with each agency- if this is not possible then I’d like to know overall spend for the year for both Pharmacists and Pharmacy Technicians.

Download response Agency Pharmacists and Pharmacy Technicians. 240119

1. Can you provide the total number of times you have exceeded the agency price cap limits for each year from 2016 -2020 broken down by each quarter right up to the most recent available data?
2. Can you provide the maximum amount paid on a per hour basis for an agency shift for each year from 2016 -2020 broken down by each quarter right up to the most recent available data?
3. I am aware that there are country wide NHSI caps but for some areas (such as medical), there are agreed Pan London ceiling rates which are higher than the NHSI caps. Could another column in the data be provided to show when those London caps are exceeded?

Download response Agency price caps. 100821.docx

You asked:
1. How many doctors have been booked outside of IR35 since April 2017?
2. What is your yearly trust spend on agency locum doctors via framework agencies, broken down into grade and specialty?
3. What is your yearly trust spend on agency locum doctors via OFF-framework agencies, broken down into grade and specialty?
4. What is your average total charge rate for a locum consultant doctor?
5. Who is the highest paid locum Consultant, what is the hourly rate and in what specialty do they practice?
6. Please can you outline your spend per agency, broken down by grade and specialty of doctor over the past 12 months?

Download response Agency Recruitment. 051218

Please can you outline your agency spend into each 52 weeks or 12 months for the year 2018 (I understand the year has not finished yet so up to OCTOBER 2018) would be sufficient.
1. How many agencies did your trust use in the year of 2018?
2. How much was spent on agency nurses in 2018?
3. On December 25th 2017, how many shifts went nursing shifts went unfilled?
4. What is the highest hourly rate paid to a locum agency in 2018 and what band was this nurse i.e. band 5 general.
5. Please list the names of agencies that we used in year 2018 and list the total amount of spend for each used.
6. What is the total number of different nurse locums did the trust use in 2018.
7. What was the highest hourly rate paid to an agency for a nurse in 2018 – Please state what agency this was and what band they were.
8. Of all agencies used, were any off framework? If so, what are the agencies called?
9. Who is the head of procurement at your Trust who approves agency use?
10. Who approves above-cap and/or off-framework usage?
11. Who are your tier 1 and tier 2 agencies?

Download response Agency spend.260219

Please can I have the following information under The Freedom of Information Act (FOIA)
Total Spend on Temporary Locums broken down into the following specialties and sites of the Trust – From April 2022 – April 2023
Medicine
Surgery
Trauma & Orthopaedics
Paediatrics
A&E
Anaesthetics
Obstetrics & Gynaecology

Agency spend.300623.docx

All questions are shown as received by the Trust.
1. Total Spend on Temporary Locums broken down into the following specialties and sites of each Trust belonging to NHS England – From April 2023 – May 2024

Surgery – Breast
Surgery – Cardiothoracic
Surgery – Colorectal
Surgery – ENT
Surgery -General Surgery
Surgery – Lower GI
Surgery – Max Fax
Surgery – Neurosurgery
Surgery – Ophthalmology
Surgery – Plastic
Surgery – Upper GI
Surgery – Vascular
Surgery – Trauma & Orthopaedics
Paediatrics
Neonates
A&E
Anaesthetics
Obstetrics & Gynaecology

2. Locum Agency providers – Please can you advise which locum agencies you use to fill the following areas.

Surgery – Breast
Surgery – Cardiothoracic
Surgery – Colorectal
Surgery – ENT
Surgery -General Surgery
Surgery – Lower GI
Surgery – Max Fax
Surgery – Neurosurgery
Surgery – Ophthalmology
Surgery – Plastic
Surgery – Upper GI
Surgery – Vascular
Surgery – Trauma & Orthopaedics
Paediatrics
Neonates
A&E
Anaesthetics
Obstetrics & Gynaecology

3. Department contact’s – Please can you provide name and email address of the following departments,

Surgery – Breast
Rota Coordinator
Service Manager
Clinical Lead

Surgery – Cardiothoracic
Rota Coordinator
Service Manager
Clinical Lead

Surgery – Colorectal
Rota Coordinator
Service Manager
Clinical Lead

Surgery – ENT
Rota Coordinator
Service Manager
Clinical Lead

Surgery -General Surgery
Rota Coordinator
Service Manager
Clinical Lead

Surgery – Lower GI
Rota Coordinator
Service Manager
Clinical Lead

Surgery – Max Fax
Rota Coordinator
Service Manager
Clinical Lead

Surgery – Neurosurgery
Rota Coordinator
Service Manager
Clinical Lead

Surgery – Ophthalmology
Rota Coordinator
Service Manager
Clinical Lead

Surgery – Plastic
Rota Coordinator
Service Manager
Clinical Lead

Surgery – Upper GI
Rota Coordinator
Service Manager
Clinical Lead

Surgery – Vascular
Rota Coordinator
Service Manager
Clinical Lead

Surgery – Trauma & Orthopaedics
Rota Coordinator
Service Manager
Clinical Lead

Paediatrics
Rota Coordinator
Service Manager
Clinical Lead

Neonates
Rota Coordinator
Service Manager
Clinical Lead

A&E
Rota Coordinator
Service Manager
Clinical Lead

Anaesthetics
Rota Coordinator
Service Manager
Clinical Lead

Obstetrics & Gynaecology
Rota Coordinator
Service Manager
Clinical Lead

Agency Spend, Agency Locums, Department Contacts.240624.docx

I would like to request the following information:

The trusts total temp agency spend for the financial year 22/23 broken down by Doctors, Nursing and AHP spend.

Agency spend for 2022-2023.210623.docx

I would like you to send me the locum agency spend for Doctors for the hospital in acute settings as well as the community for each specialism.

I would like to know the spend from January 2018 – present, also including the amount of locums that this refers to per month, broken down on a monthly basis. In the breakdown if you could please include the agencies that provide the locums also broken down numerically.

Download response Agency spend for doctors. 240119

The total amount spent on agency temporary staff between January 21 – December 21 for the following categories:
Doctors
Nurses
AHP’s

Agency Spend for Doctors, Nurses and Allied Health Professionals. 070222.docx

I would like to request the below information from the trust for year 2021/2022.
1. What was your agency spend for nursing and midwifery for the year April 2021- April 2022?
2. How much of the spend was above the NHSI rate caps April 2021- April 2022?
3. Have you used off-framework in the last 6 months?
4. If so, what was the total spend?
5. Which off-framework agencies have you used?
6. How many unfilled shifts have you had for:
a. A&E
b. ITU
c. General
d. Theatres
e. Mental Health
f. CPN
g. Midwifery
h. Paediatrics
i. Neonatal
j. HCA
7. If this cannot be provided via speciality, please could I have an over-all number?
8. How many vacancies do you have for band 5/6 nurses in the following areas?
a. A&E
b. ITU
c. General
d. Theatres
e. Mental Health
f. CPN
g. Midwifery
h. Paediatrics
i. Neonatal
j. HCA
9. How many incident/critical incidents have been declared as a result of staffing?
10. Who is the nurse bank/temporary staffing manager?
11. What are the contact details for the Nurse Bank / Temporary Staffing Manager?

Agency spend for nursing and midwifery.211122.docx

1. Since January 2018, have you allowed an Agency to fill a shift or booking above the April Cap (implemented in 2016) via the CPP Framework (otherwise known as the National Clinical Staffing Framework Agreement (Reference CPP2015/01))? For reference the term ‘shift’ can include any general nursing or critical nursing role.

2. If the answer is yes to the above question, please inform us of how many such shifts have been filled above cap via the CPP Framework.

3. What was the total value of charges paid under all of the call-off agreements identified in response to request 1 (above)?

4. Any information relating to the decision(s) of the Trust to enter into call-off agreements that include pay rates that exceed the maximum pay rates allowed under the Framework Agreement.

Download response Agency staff. 010818

1. In relation to the value of the contracts in your previous response of 1 August 2018, the value of which was £514,072.20, please state the total costs that the Trust paid in excess of the rates allowed under the fee caps (those fee caps being the April Caps (implemented in 2016) for the National Clinical Staffing Framework Agreement (Reference CPP20 15/011) (otherwise known as CPP Framework) (the “Framework Agreement”).
2. In relation to your answer to point 1, please state how much of this sum was attributed to shifts for Nursing & Midwifery staff.
3. In the event that the anticipated costs of providing all of the information requested under points 1 and 2 above are likely to exceed the appropriate limit specified in Regulation 3 of the Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulations 2004, please provide instead the total costs that the Trust paid in excess of the rates allowed under the fee caps in June 2018.
4. In the event that you provided a substantive response to point 3, please provide us with how many such shifts have been filled above cap via the Framework Agreement in June 2018.
5. In the event that the anticipated costs of providing all of the information requested under point 3 above is likely to exceed the appropriate limit specified in Regulation 3 of the Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulations 2004, please provide instead the total costs that the Trust paid in excess of the rates allowed under the fee caps for the period Monday 4 June 2018 to Sunday 10 June 2018.
6. In the event that you provided a substantive response to point 5, please provide us with how many such shifts have been filled above cap via the Framework Agreement, for the period Monday 4 June 2018 to Sunday 10 June 2018.
7. In your response of 1 August 2018, you stated that 16,754 shifts were for Medical & Dental staff. Please provide a breakdown of this figure and categorise the shifts into grades of staff.

Download response Agency staff.01118

All questions are shown as received by the Trust.
1. How much have you spent on agency staff each of the last five years?
a. What was the most expensive agency midwife shift last year?
b. How much on bank midwives each of the past five years?

Agency staff.040923.docx

Please can you provide the following information regarding use of agency staff in your NHS Trust.
Please note there are three parts to this request.
1. Please can you provide the total spend on agency staff in your NHS Trust in the financial year ending April 2022
2. Please can you provide the total spend on agency staff in your NHS Trust in the financial year ending April 2019
3. Please can you provide the total spend on agency staff in your NHS Trust in the financial year ending April 2017

Agency Staff.100822.docx

1. What was your trust spend on agency for the period 1 January 2022 to 31 December 2022 inclusive for the following staff groups: –
a. Registered nurse (RN)
b. Health care support workers/healthcare assistants/nursing associates?

2. What was your trust spend on agency for the period 1 January 2021 to 31 December 2021 inclusive for the following staff groups: –
a. Registered nurse (RN)
b. Health care support workers/healthcare assistants/nursing associates?

3. What was your trust spend on agency for the period I January 2020 to 31 December 2020 inclusive for the following staff groups: –
a. Registered nurse (RN)
b. Health care support workers/healthcare assistants/nursing associates?

Agency Staff.210323.docx

Nurses:
1. Total number of hours of agency nurses used by the Trust in the month of February 2023
2. Of the total number of agency nurse hours used, the number of hours procured ‘off-framework’
3. Of the total number of agency nurse hours used, the number of hours procured at ‘break glass’ or rates above the NHSI rate caps.
4. Of the total number of agency nurse hours used, the number of hours procured at an increased AFC banding i.e. band 5 offered band 6 as an incentive
Healthcare Assistants:
1. Total number of hours of agency healthcare assistants used by the Trust in the month of February 2023
2. Of the total number of agency healthcare assistants hours used, the number of hours procured ‘off-framework’
3. Of the total number of agency healthcare assistants hours used, the number of hours procured at ‘break glass’ or rates above the NHSI rate caps.
Pharmacy Staff:
1. Total number of hours of agency pharmacy staff used by the Trust in the month of February 2023
2. Of the total number of agency pharmacy staff hours used, the number of hours procured ‘off-framework’
3. Of the total number of agency pharmacy staff hours used, the number of hours procured at ‘break glass’ or rates above the NHSI rate caps.

Agency Staff.210823.docx

Please could you advise the number of hours or shifts filled from 01th April 2018 – 31st March 2019 with qualified nursing staff within the Trust with agency staff?

Download response Agency staff. 260919

For Hospitals
1. Hospitals in trust
2. Names of off-framework agencies used between 2021- to date
3. Names of on-framework agencies used between 2021- to date
4. Do you have a master vendor in place?
5. If yes, please provide your account manager’s email
6. Temporary agency staff manager full name
7. Temporary agency staff manager email
8. Temporary agency staff manager telephone
9. Permanent agency staff manager full name
10. Permanent agency staff manager email
11. Permanent agency staff manager telephone
12. Off-framework agency spend between Feb 2021-date
13. Framework agency spend between Feb 2021 – date
14. Total agency shift cancelations Feb 2021-date
For Urgent Care Centres/Walk-in Clinics
1. Urgent treatment / walk-in centres
2. Names of off-framework agencies used between 2021- to date
3. Names of on-framework agencies used between 2021- to date
4. Do you have a master vendor in place?
5. If yes, please provide your account manager’s email
6. Temporary agency staff manager full name
7. Temporary agency staff manager email
8. Temporary agency staff manager telephone
9. Permanent agency staff manager full name
10. Permanent agency staff manager email
11. Permanent agency staff manager telephone
12. Off-framework agency spend between Feb 2021-date
13. Framework agency spend between Feb 2021 – date
14. Total agency shift cancelations Feb 2021-date

Agency Staff Bank.250322.docx

The total amount spent on agency temporary staff for the year 2021/22 (April ’21 to March ‘22) and between 31/10/2021 to 31/10/2022 for the following categories:
• Doctors
• Nurses
• AHP (all categories)
• Health Care Assistants

Agency Staff costs.101122.docx

All questions are shown as received by the Trust.
1. From 1st January 2024 to 1st March 2024, within your Emergency Medicine Departments, how many locum agency doctors were employed by the trust at Middle grade level (ST3 – ST8 level)?
2. From 1st January 2024 to 1st March 2024, within your Emergency Medicine Departments, how much money was spent on agency locum doctors working in the Middle grade (ST3 – ST8 level)?
3. From 1st January 2024 to 1st March 2024, within your Emergency Medicine Departments, how much money was spent on bank doctors covering vacant shifts within the department?

Agency staff in Emergency Medicine.100524.docx

All questions are shown as received by the Trust.
For the most recent month available please provide your usage in terms of financial spend of agency staff for the job types below. Where the information is available, indicate the percentages ‘on-framework’ and ‘off-framework’.

The job types are:
1. Nursing
2. HCAs
3. Pharmacists
4. Pharmacy Technicians

Agency staff spend.050224.docx

All questions are shown as received by the Trust.
For the most recent month available please provide your usage in terms of financial spend of agency staff for the job types below.

Agency staff spend.100524.docx

1. Agency spend on Medical Locums/Doctors
2. Agency spend on AHP’s (Allied Health Professionals) and HSS (Health and Social Sciences)
3. Agency spend on Nursing
4. Agency spend on NMNC (Non-Medical, Non Clinical)
5. Do you use a Direct Engagement model to engage locum staff?
6. If so, please state the name of the company used
7. What is the expiry date for this contract?

Download response Agency Staffing. 050718

All questions are shown as received by the Trust.
1. The total (£) spent by the trust on agency nurses and healthcare staff in April 2023 – April 2024?
2. Of the amount spent above, how much was the total (£) spent within Mental Health services?
3. Which agencies have the highest agency spend for temporary nurses?
4. What is the current model for dealing with agency staff, such as NHSP / temporary staffing or other such as master or neutral vendor?
5. If the Trust does have a master or neutral vendor agreement in place for the supply of qualified nursing, when does this end?
6. The total off framework agency spend on temporary nurses and healthcare assistant staff in April 2023 – April 2024.

Agency staffing.070624.docx

1. (a) Who is the head of procurement at your trust responsible for approving Nursing agency usage?
(b)Secondly, who is the temporary / flexible staffing lead responsible for the management of this service?
2. Please can you provide the contact information in relation to both question 1 (a) and (b)
3. Please can you outline your Off-Framework agency spend for each of the following staff groups between April 2019 – June 2019: (a) RGN’s (b) RCN’s (c) RN’s and (d) HealthCare Assistants (e) RMN (f) Specialist RN (ITU) (g) Medical Locums
4. Following the same breakdown of staff groups in Question 3, how many Off-framework shifts have been unfilled between April 2019 – June 2019
5. Since the start of January 2019 – present, please provide the current charge rates from your Off Framework, Nursing providers, providing a clear breakdown between the workers pay rate and agency commission
6. Based on the above information, who are your current Nursing Off-Framework agencies and how many shifts have been booked for each month from January 2019 – June 2019

Download response Agency Staffing. 260919

1. Please can you confirm whether the Trust is contracted to a managed service provider for the supply of agency staff under each of the following categories
a. Medical Locums
b. Nurses
c. Allied Health Professionals or Health Scientists
2. Please confirm which company provides the managed service for each staff category and the contract expiry date
a. Medical Locums
b. Nurses
c. Allied Health Professionals or Health Scientists
3. For Medical Locums and for AHPs, please confirm whether the Trust utilises a Direct Engagement solution for VAT efficiency
a. Medical Locums
b. Nurses
c. Allied Health Professionals or Health Scientists
4. Please confirm which company provides the Direct Engagement solution and the contract expiry date

Download response Agency staffing. 280621

1. What contractual relationships are in place for supplying agency Nursing and who is responsible for managing them?
2. Who is your primary point of contact for decision making regarding supply chain for Agency Nursing?
3. How many agencies are used to supply agency doctors?
4. Of these agencies, how many are off framework – please list them?
5. Over the past 6 months, how many shifts have been filled via an off framework agency?
6. Who is your highest paid agency nurse, what is their speciality and their hourly charge?
7. Please outline your spend per agency, broken down by grade and speciality of nurse over the past 6 months?
8. Do you have a Master Vendor for Agency Nurses In place? If so, who are they and when are they contracted until?
9. If you have a Master Vendor in place, how many hours of work for Nursing have been booked outside of your Master Vendor arrangement in the past 6 months?
10. If you have a Master Vendor in place, what % of bookings by your Master Vendor Provider are at the NHSI capped rates in the past 6 months?
11. What is your total (£) off framework agency spend for Agency Nursing?

Download response Agency staffing. 290621

1. Please can you confirm how and how regularly you confirm you and your suppliers are IR35 compliant?
2. Please can you confirm the percentage of agency shifts in the past financial year that were NHSI cap compliant? Please could you break this down by staff group?
a. Nursing
b. Doctors
c. AHP/HSS
d. Other clinical
3. Please can you confirm the number of permanent vacancies you have in the following staff groups?
a. Nursing
b. AHP/HSS

Download response Agency staffing and vacancies. 061119

All questions are shown as received by the Trust.
1. Does the Trust have a Managed Service (MSP) or MV or an external Bank supplier for the recruitment of agency staff? Please break this down into Doctors, Nursing & AHP if appropriate.
2. If yes, who is that contract with and when does it end?
3. If yes, how did the Trust review whether the supplier followed ethical business practices, what ethical insights did they gather?
4. What steps do the Trust take to ensure suppliers are paying their fair share of taxes and acting with integrity.
5. Who is responsible within the Trust, for ensuring that suppliers follow ethical business practices?

Agency Supply and Ethical Business Practices.190324.docx

1. For the last year (2020-2021) please supply a list of the agencies the trust uses for medical locums.
2. A breakdown of the monetary spend per agency for Medical Locums
3. Please supply the total number of days worked by locum RMO’s or junior doctors for 2020-2021 at your trust.
4. The hourly rate paid to agencies supplying casual RMO’s or junior doctors.

Download response Agency usage. 270521

1. Who is the head of procurement responsible for approving agency usage for Physiotherapy, Occupational Therapy, Pharmacy, Radiography, Speech and Language Therapy and Sterile Services?
2. Who are the managers responsible for agency usage (on and off framework) for the following departments at all hospitals associated with the Trust:
(a) Physiotherapy
(b) Occupational Therapy
(c) Pharmacy
(d) Radiography
(e) Sterile Services
(d) Speech and Language Therapy
3. Please can you provide the contact number and email addresses for the managers listed in relation to question 1 and 2?
4. Have you used off-framework agency staff between March 2021 – March 2022 in the following departments:
(a) Physiotherapy
(b) Occupational Therapy
(c) Pharmacy
(d) Radiography
(e) Sterile Services
(d) Speech and Language Therapy
5. How much was your Off-Framework agency spend for each of the following staff groups between March 2021 – March 2022?
(a) Physiotherapy
(b) Occupational Therapy
(c) Pharmacy
(d) Radiography
(e) Sterile Services
(d) Speech and Language Therapy
6. How many unfilled agency roles did you have between March 2021 – March 2022 for each of the departments outlined in question 5?

Agency usage for Physiotherapy, Occupational Therapy, Pharmacy, Radiography, Speech and Language Therapy and Sterile Services.220422.docx

1. Who is the person in charge for approving agency usage for the Decontamination department at your trust?
2. Who is responsible for agency usage (on and off framework) in the Decontamination department at all hospitals associated with the Trust?
3. If the decontamination service is not managed by the trust, please confirm which company runs your decontamination service.
4. Please can you provide the contact number and email address for the manager(s) in question 1 and 2.
5. Have you used off-framework agency staff between March 2022 – March 2023 in Decontamination and endoscopy?
6. How much was your Off-Framework agency spend for Decontamination and Endoscopy from March 2022 – March 2023?

Agency usage for the Decontamination department.200723.docx

1. Who is the head of procurement responsible for approving agency usage for the Physiotherapy department?
2. Who is responsible for agency usage (on and off framework) in the Physiotherapy department at all hospitals associated with the Trust for the following areas within Physiotherapy?
– Musculoskeletal
– Community
– Rehabilitation
– Neurology
– Paediatrics
– Trauma and Orthopaedics
– Acute Medical/Surgical/inpatient
– Respiratory
3. Please can you provide the contact number and email address for the manager(s) in question 1 and 2.
4. How much was your Off-Framework agency spend for Physiotherapy from June 2022-June2023
5. What agencies were providing the Off-Framework services.

Agency usage for the Physiotherapy department.040823.docx

1. Who is the head of procurement responsible for approving agency usage for the Sonography/Ultrasound department at your trust?
2. Who is responsible for agency usage (on and off framework) in the Sonography/Ultrasound department at all hospitals associated with the Trust? 3. Please can you provide the contact number and email address for the manager(s) in question 1 and 2. 4. Have you used off-framework agency staff between March 2022 – March 2023 in Sonography/Ultrasound?
5. How much was your Off-Framework agency spend for Sonography/Ultrasound from March 2022 – March 2023?

Agency usage for the Sonography and Ultrasound department.310323.docx

1) Which Frameworks do you use for the supply of;
a) Locum Doctors
b) Locum Nurses
2) Do you operate a master vend arrangement or preferred supplier list?
3) Please list the agencies on your preferred supplier list for a and b. Please provide the supply list in tearing order or PSL if applicable.
a) Locum Doctors
b) Locum Nurses
4) Please provide contact details for the member of staff in charge of this process.

Download response Agency use. 010818

I am writing to request specific information regarding your trust’s agency workforce spend for the period of January 2023 to December 2023.

1. Please provide the agency workforce spend for the specified period, broken down into the following categories:

• Medical Staff
• Nursing Staff
• Allied Health Professionals (AHP)

2. Additionally, could you provide the percentage of the total workforce is agency in each of the mentioned categories?

Agency Workforce Spend (January 1st -December 31st 2023).080524.docx

For the last 12 months can you provide me details on the Trusts agreement with Altrix.

Specifically:
The monthly spend for the last 12 months.
The number of hours covered monthly for the last 12 months.
Agreed rates for shifts covered.
Clarification on workers under this models Tax/IR35 status and if they are paid in line with the NHS Frameworks expectations.

Download response Altrix and agency spend. 240919

All questions are shown as received by the Trust.
I. The total amount spent by the Trust on bank and agency doctors in each of the last 5 financial years (including 2023/24 so far)
II. The total amount spent by the Trust on bank and agency nurses in in each of the last 5 financial years (including 2023/24 so far)
III. The largest amount spent by the Trust on a single agency nurse shift in 2023/24
IV. The largest amount spent by the Trust on a single agency doctor’s shift in 2023/24

Bank and agency costs.070324.docx

How much did the Trust spend on a) agency midwives b) bank midwives in each calendar month in 2018 (calendar year)?

Download response Bank and Agency Midwife spend. 110319

Please disclose the information listed in the below table rows for each of the 4 staff groups in the table columns by return email within 20 days as per the Freedom of Information Act 2000.
1. Please provide agency spend for the staff group for the year 2022.
2. Please provide bank spend for the staff group for the year 2022.
3. Please confirm which model you have in place for managing the staff group: Email to preferred supplier List, a Master Vendor, a Neutral Vendor, or a Software cascade to a preferred supplier list.
4. If you have a master vendor or neutral vendor in place, please confirm who this contract is with and the date on which this contract expires.
5. Please confirm what percentage of bookings over the last 6 months have been within the NHSI/E agency caps (an approximation based on NHSI data submissions is fine).
6. Please confirm which provider manages your direct engagement process, the fee for the service and the date on which this contract expires (no this is not relevant for Nursing).
7. Please confirm what percentage of bookings are processed with a VAT savings by your direct engagement provider
8. Is your bank managed by an external bank provider (eg. NHS Professionals, Bank Partners) or in-house? Please confirm who is the external bank provider and when the contract expires if relevant.
9. Is your bank managed via software? If so, please confirm which software.
10. Please confirm what the percentage is on framework (for example, “£6,650,000 – 99% framework /20% off-framework”) for the year 2022.
11. Please confirm what percentage is off-framework (for example, “£6,650,000 – 99% framework /20% off-framework”) for the year 2022.
12. Please confirm the direct engagement- DE% uptake for the year 2022.
13. Please confirm the direct engagement- DE provider.
14. Please confirm the direct engagement- DE contract end date.

Bank and Agency spend.050423.docx

1) Please detail your Bank and Agency Spend in the format provided by the following NHSIE Staff Groups for the past financial year (April 2020 – March 2021)
2) Please detail your Bank and Agency usage in hours in the format provided by the following NHSIE Staff Groups for the past financial year (April 2020 – March 2021)

Download response Bank and agency spend and usage. 260421

1. The number of agency staff used in the Audiology department
2. The number of hours filled by agency staff in the Audiology department.
3. The number of hours filled by bank staff in the Audiology department.
4. The Trusts total spend on agency workers in the audiology department
5. The Trusts total spend on bank workers in the audiology department
I would like the above information for the 2019 calendar year (Jan-Dec) if possible.

Download response Bank and Agency staff in Audiology. 161120

1. Please could you confirm your current bank spend (FY 18/19), broken down by the following staff groups:
a. Nursing staff
b. Medical locums (Doctors)
c. AHP/HSS
d. Other clinical
e. Non-clinical
2. Please confirm your current bank fill rate (FY 18/19), broken down by the following staff groups:
a. Nursing staff
b. Medical locums (Doctors)
c. AHP/HSS
d. Other clinical
e. Non-clinical
3. Please could you confirm your current agency spend (FY 18/19), broken down by the following staff groups:
a. Nursing staff
b. Medical locums (Doctors)
c. AHP/HSS
d. Other clinical
e. Non-clinical
4. Please could you confirm your current agency engagement procedure (i.e. MV, PSL etc) and which agencies you are currently working with, broken down by the following staff groups:
a. Nursing staff
b. Medical locums (Doctors)
c. AHP/HSS
d. Other clinical
e. Non-clinical
5. Do you have DE supplier, if so who, broken down by staff group? When is the expiry date for this contract?
6. Do you have an MV supplier, if so who, broken down by staff group? When is the expiry date for this contract?
7. Do you have an external Bank supplier, if so who, broken down by staff group? When is the expiry date for this contract?
8. Please could you confirm what your agency spend is for permanent staff in the past 24 months, broken down by the following staff groups. How much of this is international recruitment?
a. Nursing staff
b. Medical locums (Doctors)
c. AHP/HSS
d. Other clinical
e. Non-clinical
9. How many permanent vacancies do you have as per the below table. Do you have a current supplier for these roles?

Download response Bank and Agency Staffing. 181019

1. Please confirm which model is in place for managing each staff group: preferred supplier list, master vendor or neutral vendor
Locum
Nurse
Allied Health Professionals
Non-medical/non-clinical
2. If you have a master vendor or neutral vendor in place, please confirm who this contract is with
3. Please confirm the contract end date with the provider
4. Is your bank managed by an external bank provider (e.g., NHS Professionals,
Bank Partners).
5. Please confirm who is the external bank provider and when the contract expires if relevant
6. Is your bank managed via software? If so, please confirm which software.

Bank and agency systems.080323.docx

All questions are shown as received by the Trust.
Rostering
For each of the staff group categories:
1 Does your Trust use an E-Rostering provider? (YES/NO)
2 What is the name of your current E-Rostering provider?
3 What is the contract start date for your e-rostering software? (dd/mm/yyyy)
4 What is the contract end date for your e-rostering software? (dd/mm/yyyy)
5 How many licenses is your contract for?
Bank
For each of the staff group categories:
1 Do you have an in- house temporary staffing team to manage your bank OR is this outsourced to a company? (In-house/Outsourced)
2 If outsourced, what is the name of this company?
3 What was the start date for the contract with this outsourced provider? (dd/mm/yyyy)
4 What is the expiry date for the contract with this outsourced provider? (dd/mm/yyyy)
For each of the staff group categories:
5 Does your organistion use digital technology/software to manage it’s staff bank? (YES/NO)
6 If the response was YES to question 1, what is the name of your digital staff bank technology (e.g. Allocate, Patchwork, Locum’s Nest)?
7 What was the contract start date for the provider you currently use for your Digital staff bank? (dd/mm/yyyy)
8 What is the contract expiry date for the provider you currently use for your Digital staff bank? (dd/mm/yyyy)

Bank and Rostering.170624.docx

1. The total internal bank spend broken down by Dr, Nurses and AHP for period Jan 19 – Dec 19
2. Is this contracted to a third party or ran by the Trust (e.g. NHSP, Bank Partners etc.)
a. If contracted to a third party the expiry date of the agreement

Download response Bank staff. 310320

1. Bank Spend – Total amount spent on bank staff for the year 2021/22 (April ’21 to March ‘22) and between 31/10/2021 and 31/10/2022 year split into the Trusts’ staff groups (E.g. Medical, Nursing, Admin, AHP etc.) and speciality/grade (E.g. Consultants, GP, ICU Nurse, Acute Nurse, Occupational therapists, Pharmacists, Health Care Assistants, etc.) depending on how this is reported within the Trust.
2. Confirmation on whether the trust bank is currently operated by the trust themselves or by a private provider. If the latter please confirm the name of the provider.

Bank Staff costs.101122.docx

1. Do you have a Master Vendor or Neutral Vendor arrangement in place?
2. If yes, who is your current Master Vendor or Neutral Vendor Provider and which disciplines do they supply?
3. What fill rates are achieved with your Master Vendor or Neutral Vendor Provider in the various disciplines?
4. Are you charged a fee for the service and if so, what is the cost?
5. What is the expiry date for your current contract/contracts?
6. Do you use any external/3rd parties to manage your bank workforce?
7. If so, please provide the name of the provider and contract start and end dates.
8. Which bank software do you use and how long are you in contract with them?

Download response Bank Workforce & VMS Arrangements. 190421

1. Could you please provide me with a breakdown of all the healthcare staffing disciplines provided by agencies in which the trust are breaking glass / being charged escalated rates?
2. Could you please state how many agency workers, per discipline, the break glass / escalated rates applies to re question 1?
3. Could you please state how many healthcare agency workers, per discipline, the Trust are being charged the maximum capped rate as stipulated by their governed framework?

Download response Break glass and escalated agency rates. 171218

1. How many staff do you have in your clinical coding department?
2. How many vacancies do you currently have in your clinical coding department?
3. Do you have any 3rd party’s providing you with clinical coding service?
A. If yes, which external organisations (3rd parties or other NHS) provide you with clinical coding services?
B. When did you start these contracts, how long are they for and what procurement framework did you use?
4. How much did the Trust spend last year on bank staff for clinical coding?
5. How much did the Trust spend on consultancy relating to clinical coding last year?

Download response Clinical Coding staff. 060220

We would like to understand how much money MTW have spent with Cloud21 Broken Down for each financial year
16/17
17/18
18/19
19/20
20/21
21/22

Cloud21. 120422.docx

Please could you tell me how much money your trust spent on bank and/or agency and/or locum staff – and/or non-contractual rates to consultants or other medical staff employed by the trust – to cover junior doctors’ shifts during industrial action by the British Medical Association on:
A) March 13-15 2023
and
B) April 11-15 2023
Please provide as much detail as possible on the staff category (i.e. agency or bank), department of the hospital and the day(s) of employment.

Cost of strike cover.120523.docx

1. How many permanent staff are employed by the Radiography/Imaging department (Radiographers & Sonographers, not Radiologists)?
2. How many permanent vacancies are currently open/unfilled within the Radiography/Imaging department (Radiographers & Sonographers, not Radiologists)?
3. How many agency staff/locums are currently being used across the Radiography/Imaging department (Radiographers & Sonographers, not Radiologists)?
4. For agency staff/locums, what is the split in numbers between radiographers and sonographers?
5. How many bank temps are being used across the Radiography/Imaging department?
6. During the 2017-2018 financial year, how much did the Radiography/Imaging department spend on temporary agency staff?
7. During the 2018-2019 financial year, how much did the Radiography/Imaging department spend on temporary agency staff?
8. During the 2018-2019 financial year, how much did the Radiography/Imaging department spend on temporary bank staff?
9. During the 2018-2019 financial year, how much did the Radiography/Imaging department spend on permanent finders/introduction fees through recruitment agencies?
10. Does the Radiography/Imaging department have a dedicated breast screening unit?
11. Please provide me with the following contact names within the authority:
a) The name of the senior manager (Radiology Services Manager / Imaging Services Manager) with overall responsibility for the Radiography/Imaging department.
b) The name of the head of temporary staffing.

Download response Diagnostic radiology staff details. 260919

1. Does your organization use a Direct Engagement scheme?
2. If so, who provides it? And when did you start using it?
3. Did you take external legal advice before entering into it and, if so, from whom did you take external legal advice?
4. What has your total locum/temporary staffing spend since you started using the scheme? If you started using the scheme before April 2017 please also state the total locum/temporary staffing spend since April 2017.
5. How does the third party direct engagement facilitator save you money on the agency spend? Please answer in short point form
6. How much has been paid to the third party direct engagement facilitator thus far?
7. Was this payment calculated as a percentage of the savings generated by employing the services of the third party direct engagement facilitator? If so, what percentage is this?

Download response Engagement of locum staff using third parties. 181718

All questions are shown as received by the Trust.
1) Since the beginning of the calendar year 2023, how much has the trust spent on external management/business consultants, including commitments that cover the rest of the calendar year?
2) Since the beginning the calendar year 2023, how much has the trust spent fees to recruitment agencies, including commitments that cover the rest of the calendar of the calendar year?

External management, business consultants and recruitment agency fees.060224.docx

1. A list of all the areas across the Trust that use external temporary staff.
2. The monthly and annual cost of having these staff supplied, averages are fine if exact data is unavailable.
3. The types of staff that are supplied.
4. Whether these staff are supplied via an approved NHS Framework, if not what is the nature of the contract or agreement in place.

Download response External temporary staff. 220321

Question 1 – For the timescale from the 1st April 2023 until 30th April 2023, details of the lowest, highest and average fee paid to agencies providing HCA’s for band 5, 6 and 7.

Question 2 – For the single week of the 16th July 2023 until 22nd July 2023, details only of the average fee paid to agencies providing HCA’s for band 5, 6 and 7.

HCA agency fees.180823.docx

1) How many interim appointments were made at your organisation in the (i) 2017-18 and (ii) 2018-19 financial years where the daily rate you paid to the supplier was £500-per-day or more?
Please note that by ‘interim appointment’ I’m referring to an individual on a fixed-term contract, hired to work in management.
2) For each such appointment, please provide me with (i) whether the appointment started in either the 2017-18 financial year or the 2018-19 financial year, (ii) the job title, (iii) whether the position was full or part-time, (iv) the name of the supplier, (v) the daily rate paid to the supplier, (vi) the total amount budgeted for and (vii) the length of the fixed-term contract on which they were hired.

Download response Interim Appointments. 100120

1. In the last 12 months, how many visa applications did the hospital process for medical staff?
Please break down into specialties where possible (e.g. medicine, surgery, anaesthetics etc.)
2. If this information is not readily available could you tell me how many were processed for medicine only?
3. How many permanent vacancies in medicines has the trust had unfilled in the last 12 months?
4. From these vacancies how many were SHO’s? (this includes FY1, FY2, ST1, ST2, CT1, CT2, StR Lower, Clinical fellow, Trust grade, RMO)
5. From these vacancies how many were Specialty Doctors? (Staff Grade)
6. From these vacancies how many were Consultants?
7. How many permanent vacancies do you currently have in medicine?
8. In the last 12 months through which agencies have you recruited doctors across any speciality on either a permanent or fixed term contract?
9. Which agencies were successful in recruiting doctors from overseas for the trust on any type of contract?
10. Across all grades what number of medical agency locum staff did the trust employ across the dates 31/03/2018 to 31/06/2018?
11. How much did the trust spend on medical agency locum staff over the 2017/2018 financial year?
12. Does the trust utilize a medical recruitment framework for international doctors?
13. Who is the dedicated contact in your organisation who liaises with agencies for the purposes of international medical recruitment?
14. Please provide names and contact details for the following posts within the trust:
– Medical Director
– All Clinical Directors within Mental Health
– Head of HR
– Head of Medical Staffing
– Head of Procurement

Download response International recruitment and agency spend. 091019

A) 2017/18
B) 2018/19
1. Did your organisation use an external consultant for any of the following functions?
a. Human Resources
b. Legal Services
c. Leadership and organisational development
d. Board reviews
e. Mediation
f. Regulatory body inspection support
2. What were the names of the consultants used?
3. What was the expenditure with each consultant?

Download response Legal and HR consultants. 030919

1) Please could you confirm the names of the top 5 locum agencies you have the most spend with within AHP/HSS there at the trust from the calendar year of 2021?
2. Please could you state the utilisation rate for each agency that has been achieved? This should amount to the total value of AHP locum spend supplied by each agency during the 2021 calendar year as a percentage of total AHP locum spend in the same period.
3) Please can you breakdown the total spend on AHP/HSS agency staff during the calendar year of 2021?
4) Please can break down the total spend on AHP/HSS agency staffing during the calendar year 2021 for the specialisms below:
AHP
Sonographers
Radiographers
Radiotherapists
Clinical Physiologists
Physiotherapists
Occupational Therapists
Speech and Language Therapists
Audiologists
Dieticians
Podiatrists
Clinical Psychologists
Theatre Practitioners
HSS
Biomedical Scientists
Mortuary/Pathology Technicians
Pharmacy Services Staff
Orthoptists & Optometrists

Locum agencies.010622.docx

1. How many agencies are used to supply Locum agency doctors?
2. Of these agencies, how many are off framework?
3. What is your highest capped commission rates for each grade?
4. When is your PSL up for renewal?
5. Which Framework does your trust use for Locum Doctors?
6. How many Locum Bookings are paid over the framework or capped rates at your trust in the last 12 months?
7. Please confirm what percentage of bookings over the last 6 months have been within the NHSI agency caps (an approximation based on NHSI data submissions is fine)
8. Please confirm which provider manages your direct engagement process, the fee for the service and the date on which this contract expires
9. Is your bank managed by an external bank provider (e.g., NHS Professionals, Bank Partners) or in-house? Please confirm who is the external bank provider and when the contract expires if relevant
10. Please confirm what percentage of bookings are processed with a VAT savings by your direct engagement (DE) provider
11. Please confirm % of locums working non-Direct Engagement and % outside IR35
12. What is the grade & speciality of all locums paid outside IR35?
13. Please confirm which services in the hospital are currently utilising insourcing contacts, who is supplying the insourcing service and when the contract is up for renewal.
14. Does your Trust utilise a payment portal to process Locum Doctors Pay?
15. What grade & speciality is your highest paid Locum agency doctor, what is their speciality and their hourly charge?
16. What grade & speciality is your highest paid bank doctor, what is their speciality and their hourly charge?
17. Please outline you spend per agency, broken down by grade and speciality of doctor over the past 12 months?
18. Please outline spend per doctors’ specialty, broken down by grade and speciality of doctor over the past 12 months from your internal Bank?
19. What grade & speciality is your highest paid Locum agency doctor, what is their speciality and their hourly charge?
20. Please confirm the name, job title and email of the head of department & manager for the following services:
• General Surgery
• Urology Service
• Trauma and Orthopaedic Service
• Ear, Nose and Throat Service
• Ophthalmology Service
• Neurology Service
• Cardiology Service
• Cancer Services
• Endocrinology Service
• Respiratory Medicine
• Dermatology Service
• Gastroenterology
• Acute Medicine
• Geriatrics
• Stroke Medicine
• Palliative Care
• Radiology
• Anaesthetics
• Maxillofacial Surgery
• Pathology Services
Locum agency doctors.230823.docx

1. Please could you provide me a breakdown of the locum agency doctor spend for the last financial year? Please break this down in to specialty and grades
2. Please could you provide me a breakdown of the permanent doctor vacancies across the trust? Please break this down into specialty and grades
3. Please could you confirm how many agency locums are currently in post on long term agency contracts? In the last 6 months and year
4. Please could you provide how much the trust has paid to agencies for introductory fees?
5. Please provide details of any overseas recruitment campaigns that the trust has taken part in for the recruitment of doctors?

Download response Locum agency Doctors. 270619

I would like you to send me the locum agency spend for the trust for Nurses in acute settings as well as the community, including but not limited to general, ITU, Mental Health. I would like to know the spend for from January 2020 to date, also including the amount of locums that this refers to per month, broken down on a monthly basis. In the breakdown if you could please include the agencies that provide the locums also broken down numerically.

Download response Locum agency spend for the trust for Nurses. 081020

How much has your trust spent on locum doctors each year from 2014-15, 2015-16, 2016-17, 2017-18, 2018-19, respectively?

How much has your trust spent on agency nurses, during the years listed above?

What was the highest amount the trust had to pay a locum doctor for a shift during the years stated above?

What was the highest amount the trust had to pay an agency nurse for a shift during the years stated above?

Download response Locum doctors and agency nurses. 210519

All questions are shown as received by the Trust.
how much was spent on locum and agency doctors during the walkouts held by both consultants and junior doctors over the past 12 months.
Please provide answers for each timeframe and separate each one clearly in your response.
These timeframes are:
(A) Junior doctor strike – 13, 14 and 15 March 2023
(B) Junior doctor strike – 11, 12, 13, 14 and 15 April
(C) Junior doctor strike – 14, 15, 16 and 17 June
(D) Junior doctor strike – 13, 14, 15, 16, 17 and 18 July
(E) Junior doctor strike – 11, 12, 13, 14 and 15 August
(F) Consultant strike – 20 and 21 July
(G) Consultant strike – 24, 25 and 26 August

For each given timeframe could you please provide the following information.
1. How many staff walked out as a result of industrial action over each period and what percentage of your junior doctor/consultant staff did this equate to. IE – 150 junior doctor staff walked out during 13, 14 and 15 March dates out of 200 junior doctor staff would be 75%.
2. How much did the trust spend on locum/agency workers during each period specifically as a result of industrial action. If this specific figure is not held, please provide the locum and agency spend for the previous year for each relevant timeframe. IE 13, 14 and 15 March 2023 vs 13, 14 and 15 March 2022.
3. Did the Trust allow doctors who were taking part in industrial action to take on locum shifts at the same trust during strike periods when they were not scheduled to work?
4. If the answer to the above question was yes, (a) How many doctors did this during each period and (b) How much did the Trust spend on paying its own doctors for these shifts during each period?

Locum shifts during industrial action.311023.docx

All questions are shown as received by the Trust.
We seek to request that your trust shares any FOI responses where your organisation(s) indicated an adverse event due to an Electronic Patient Record System issue.

Adverse event due to an Electronic Patient Record System issue.100624.docx

All questions are shown as received by the Trust.
Under the FOI Act I would like to request the amount of times nurses working for the trust were a) assaulted and b) sexually assaulted in each of the last three years (2021, 2022 and 2023).

Assaults on nursing staff.250624.docx

All questions are shown as received by the Trust.
1. Please state what percentage of your total discharges from the Acute Medical Unit are discharged home/to usual place of residence without support
2. For those patients, what was the average length of stay in the Acute Medical Unit?
3. Please state what percentage of all admitted patients from A&E waited more than 12 hours from decision to admit to actual admission (12hr+ trolley waits)
4. Please state what percentage of cancelled elective operations for non-clinical reasons were due to:
a. unavailable ward beds: b. unavailable surgeon
c. unavailable anaesthetist: d. unavailable theatre staff

Acute Medical Unit, A&E waits and cancelled elective operations.250624.docx

1. How many of the following scheduled procedures/appointments were cancelled by the Trust:
i) Elective operations
ii) Appointments made via urgent cancer referrals
iii) Mammograms
iv) Organ transplant operations
v) Optical appointments/procedures
During the following periods:
i) 2019-2020
ii) 2020-to date
NB. I do not require the reasons for the cancellations.
2. How many of the following scheduled procedures/appointments were pushed back by the Trust:
i) Elective operations
ii) Appointments made via urgent cancer referrals
iii) Mammograms
iv) Organ transplant operations
v) Optical appointments/procedures
NB. I do not require the reasons behind the delay/re-scheduling.
For the following time frames:
i) Up to one month
ii) Up to three months
iii) Up to six months
iv) Up to a year
v) Indefinitely
During the following periods:
i) 2019-2020
ii) 2020-to date

Download response Cancelled appointments and procedures. 091220

1. How many cancer operations have been cancelled by your NHS Trust in each of the past four financial years:
a. 2022/23
b. 2021/22
c. 2020/21
d. 2019/20
2. Please could you provide a breakdown for the reasons these operations were cancelled e.g. lack of staff, lack of beds, or equipment issues, again broken down by the financial years:
a. 2022/23
b. 2021/22
c. 2020/21
d. 2019/20

Cancelled cancer operations.061223.docx

I would like to know how many cancer operations have been cancelled by your NHS Trust since March 1st 2020?

Download response Cancelled cancer operations. 220920

All questions are shown as received by the Trust.
1. How many cancer operations have been cancelled by your NHS Trust in each of the past four financial years:
a. 2022/23
b. 2021/22
c. 2020/21
d. 2019/20
2. The highest number of times a patient’s operation has been cancelled at your NHS Trust since the start of 2022.
3. Please could you provide a breakdown for the reasons these operations were cancelled e.g. lack of staff, lack of beds, or equipment issues.
a. 2022/23
b. 2021/22
c. 2020/21
d. 2019/20

Cancelled Cancer operations.290224.docx

The total number of children’s operations cancelled for non-clinical reasons, broken down by the cause of the cancellation, for example due to lack of beds, operating theatre capacity, staffing issues, and equipment failures. Please provide this information for each of the past three financial years 2017/18, 2018/19, 2019/20). In the total number of operations, broken down by cancellation reason, please include:

· Elective children’s operations cancelled at the last minute. For the purposes of this request, last minute means on the day the patient was due to arrive, after the patient has arrived in hospital or on the day of the operation or surgery.

· Cancelled urgent children’s operations.

For the purposes of this FOI, Children will be defined as under 18’s.

Download response Cancelled children’s operations. 131020

You asked: All questions are shown as received by the Trust.
1. The number of children (under 18s) who have an operation cancelled or delayed at your trust for non-clinical reasons, in each of the past five calendar years (2022, 2021, 2020, 2019, 2018).
2. For each of these years, please could you provide figures broken down by the reason behind the cancellation or delay, e.g. lack of staff, lack of bed capacity, or lack of equipment.
3. Please could you provide figures on the five longest waits for an operation currently faced by under-18s at your trust, e.g. 118 days, 116 days, 113 days. For each of these waits, please could you provide a summary of the surgical procedure in question, e.g. heart surgery.

Cancelled children’s operations.140323.docx

Question 1
How many booked elective invasive procedures (this includes but is not limited to procedures being performed in operating theatres, interventional radiology or other radiology suites, cardiac catheter labs, endoscopy and any other site not mentioned involving an invasive procedure, whether under local anaesthetic, general anaesthetic, spinal or epidural anaesthetic, peripheral nerve block, or sedation) did your trust cancel in the calendar years:
a. 2017
b. 2018
c. 2019
d. 2020
e. 2021
Question 2
How many booked elective invasive procedures (this includes but is not limited to procedures being performed in operating theatres, interventional radiology or other radiology suites, cardiac catheter labs, endoscopy and any other site not mentioned involving an invasive procedure, whether under local anaesthetic, general anaesthetic, spinal or epidural anaesthetic, peripheral nerve block, or sedation) did your trust cancel at the date of this request in this calendar year?

Cancelled elective procedures.270722.docx

I would like to request the total number of operations cancelled for non-clinical reasons, broken down by the cause of the cancellation, for example due to lack of beds, operating theatre capacity, staffing issues, and equipment failures.

Please provide this information for each of the past five financial years (i.e. years running from April to March – 2013/14, 2014/15, 2015/16, 2016/17, 2017/18).

In the total number of operations, broken down by cancellation reason, please include:
1. Elective operations cancelled at the last minute. For the purposes of this request, last minute means on the day the patient was due to arrive, after the patient has arrived in hospital or on the day of the operation or surgery.
2. Cancelled urgent operations.
If the data is collected by the trust, please also provide a separate total for each year for all operations cancelled for non-clinical reasons, regardless of how soon before the scheduled operation time the cancellation occurred.

Download response Cancelled operations. 011018

a) How many elective operations were cancelled for a non-clinical reason at the Trust in 2021/22, broken down by reason for cancellation?
b) Of the total elective operations cancelled for a non-clinical reason at the Trust in 2021/22, how many were:
i. urgent surgery
ii. paediatric surgery
iii. surgical oncology

Cancelled operations.021222.docx

All questions are shown as received by the Trust.
Please can you provide me with information on medical equipment at your Trust.
The number of procedures that were cancelled by your NHS Trust due to issues with defective diagnostic equipment in each of the calendar years
a) 2019, b) 2020, c) 2021, d) 2022, e) 2023

Cancelled operations.050624.docx

a) How many operations in total has your Trust cancelled from 1 March 2020 – 1 March 2021 and can you give a breakdown of reasons for the cancellations? How many were urgent operations?
b) How many operations in total has your Trust cancelled from 1 March 2019 – 28 February 2020 and can you give a breakdown of reasons for the cancellations? How many were urgent operations?
c) How many operations in total has your trust cancelled for Under 16s from 1 March 2020 – 1 March 2021 and can you give a breakdown of reasons for the cancellations? How many were urgent operations?
d) How many operations in total has your trust cancelled for Under 16s from 1 March 2019 – 28 February 2020 and can you give a breakdown of reasons for the cancellations? How many were urgent operations?

Download response Cancelled operations. 070721

All questions are shown as received by the Trust.
1. Please could you provide me with information for each of the financial years 2023/24, 2022/23
2. How many elective operations were cancelled last minute for non clinical reasons?
3. How many of those patients were not treated within 28 days of the last minute elective cancellation?
4. How many patients had their elective operation cancelled last minute on more than 5 occasions?
5. How many patients had their elective operation cancelled last minute on more than 10 occasions?
6. In the financial years above – what was the highest number of occasions that a patient had an elective operation cancelled at the last minute?

Cancelled operations.080424.docx

1. Please can you tell me the number of last minute elective operations cancelled for non clinical reasons at your trust or board for each month of 2020 and 2021 to date.
2. Please can you tell me the number of urgent operations cancelled for non-medical reasons during each month.
If giving the full data requested would be likely to exceed the costs cap, please provide data for the most recent month and then as many months as possible working backwards until the limit is reached.
3. If possible, please let me know how many of the cancelled elective operations had still not been carried out 28 days later.
4. If possible, please let me know how many of the cancelled urgent operations had still not been carried out 28 days later.

Download response Cancelled operations. 131021.docx

1. The number of people who have had an operation cancelled or delayed at your trust for non-clinical reasons, in each of the past five calendar years (2022, 2021, 2020, 2019, 2018).
2. For each of these years, please could you provide figures broken down by the reason behind the cancellation or delay, e.g. lack of staff, lack of bed capacity, or lack of equipment.
3. Please could you provide figures on the five longest waits for an operation currently faced by under-18s at your trust, e.g. 110 days, 98 days, 200 days. For each of these waits, please could you provide a summary of the surgical procedure in question, e.g. heart surgery.

Cancelled operations.140323.docx

1. The number of elective operations scheduled. I would like this information for January 2022 to end of December 2022 broken down by week i.e. the total number of elective operations that were planned for Week 1, January 2022, Week 2 etc.
2. The number of elective operations performed. January 2022 to end of December 2022 broken down by week i.e. the total number of elective operations that were planned for Week 1, January 2022, Week 2, etc
3. The number of elective operations cancelled at the “last minute”, as defined by the NHS when providing data on cancelled elective operations. I would like this information for January 2022 to end of December 2022 broken down by week i.e. the total number of elective operations planned for Week 1, January 2022, Week 2 etc.
4. The total number of elective operations cancelled, regardless of how long cancellations were made before scheduled operation times, if this information is also collected. I would like this information for January 2022 to the end of December 2022 broken down by week i.e. the total number of elective operations planned for Week 1, January 2022, Week 2 etc.

Cancelled operations.2. 140323.docx

All questions are shown as received by the Trust.
How many elective operations were cancelled for a non-clinical reason at the Trust in 2021/22, broken down by reason for cancellation?

Cancelled operations 2021-2022.110624.docx

All questions are shown as received by the Trust.
a) How many elective operations were cancelled for a non-clinical reason at the Trust in 2022/23, broken down by reason for cancellation?

Cancelled operations 2022-2023.110624.docx

All questions are shown as received by the Trust.
a) How many elective operations were cancelled for a non-clinical reason at the Trust in 2023/24, broken down by reason for cancellation?

Cancelled operations 2023-2024.110624.docx

1. Please can you provide figures on the total number of patients who have had their operation cancelled for a second time. I would like these figures broken down by year for each of the past five years:
a. 2022,
b. 2021,
c. 2020,
d. 2019,
e. 2018.
For context, I am looking for incidents where the surgery was cancelled for non-clinical reasons (i.e. staff shortages, equipment problems, lack of theatre capacity) and also not at the request of the patient.
2. In addition, please can you provide the largest number of times that a single patient has had their operation cancelled for non-clinical reasons, over the past five years.
a. Please could you name the operation in question (e.g. hip replacement),
b. The year that the last cancellation took place (e.g. 2022).

Cancelled operations.280923.docx

The total number of operations cancelled for non-clinical reasons, broken down by the cause of the cancellation, for example due to lack of beds, operating theatre capacity, staffing issues, and equipment failures. Please provide this information for each of the past three financial years (2016/17, 2017/18, 2018/19). In the total number of operations, broken down by cancellation reason, please include:
• Elective operations cancelled at the last minute. For the purposes of this request, last minute means on the day the patient was due to arrive, after the patient has arrived in hospital or on the day of the operation or surgery.
• Cancelled urgent operations.

Download response Cancelled operations for non-clinical reasons. 050919

I would like to request the total number of operations cancelled for non-clinical reasons, broken down by the cause of the cancellation, for example due to lack of beds, operating theatre capacity, staffing issues, and equipment failures, in 2018/19 (financial year, April to March).

In the total number of operations, broken down by cancellation reason, please include:
• Elective operations cancelled at the last minute. For the purposes of this request, last minute means on the day the patient was due to arrive, after the patient has arrived in hospital or on the day of the operation or surgery.
• Cancelled urgent operations.
If the data is collected by the trust, please also provide a separate total for each year for all operations cancelled for non-clinical reasons, regardless of how soon before the scheduled operation time the cancellation occurred.

Download response Cancelled operations for non-clinical reasons.2 050919

a) How many adult’s operations were cancelled at your Trust from 1 March 2020 – 31 August 2020?
b) How many adult’s operations were cancelled at your Trust from 1 March 2019 – 31 August 2019?
c) How many children’s operations were cancelled at your Trust from 1 March 2020 – 31 August 2020?
d) How many children’s operations were cancelled at your Trust from 1 March 2019 – 31 August 2019?

Download response Cancelled operations March – September 2019 and 2020. 141020

Please could you provide me with your trust’s loss of income as a result of the cancelled elective or non-urgent surgeries this year? I understand that there are tariffs assigned for every procedure undertaken and that cancelling an operation results in the loss of that revenue.

I would like this data on a monthly basis from January 2018 to the last date for which the data is held.

If you have comparative data for Jan-Dec 2017 (on the monthly basis also), I would also like this. If there is any breakdown of this data (for example, tariffs lost, cost of surgeons not working and so on), could you provide that too?

Download response Loss of income due to cancelled operations. 080119

I have been looking on the MTW website for your “2 week urgent referral policy”. I have not been able to locate this or a leaflet. Would you please be able to email me a copy of this?

Download response 2-week urgent referral policy. 031121.docx

All questions are shown as received by the Trust.
Please see below a Freedom of Information request made by OPEN Health. Please answer the questions with regards to NHS patients, i.e., excluding patients that received treatment as part of clinical trials or private healthcare.
1. Do you treat patients with acute myeloid leukaemia (AML) in your Trust?
If yes, please proceed to Question 3, if no, please answer Question 2
2. Where do patients diagnosed with AML in your Trust receive treatment?
3. Please complete the table below with how many newly diagnosed patients with AML have started first-line treatment with each of the following therapies during the 6-month period October 2023 to March 2024?
• Azacitidine monotherapy
• Low dose cytarabine (LoDAC) monotherapy
• Venetoclax + azacitidine
• Venetoclax + LoDAC
• Ivosidenib
• Intensive chemotherapy-based regimen
o Examples include: cytarabine and daunorubicin, idarubicin, fludarabine, mitoxantrone, etoposide (VP-16), 6-thioguanine (6-TG), methotrexate (MTX) or 6-mercaptopurine (6-MP), gemtuzumab ozogamicin with daunorubicin cytarabine, or FLAG-Ida (fludarabine, cytarabine, granulocyte-colony stimulating factor and idarubicin)
• Best supportive care
• Other
o Do not include prophylactic therapies such as GCSF, anti-fungals, antihistamines, anti-nauseants

Note: this should only include patients with AML who have started first-line treatment during the 6-month window.

Acute myeloid leukaemia (AML).100524.docx

All questions are shown as received by the Trust.
Patients with acute myeloid leukaemia (AML)
1. How many patients with AML, in total, have been treated with the following therapies during the last 6 months, irrespective of start date or line of therapy?
• Azacitidine monotherapy
• Low dose cytarabine (LoDAC) monotherapy
• Venetoclax + azacitidine
• Venetoclax + LoDAC
• Ivosidenib
• Intensive chemotherapy-based regimen
• Other
2. How many newly diagnosed patients with AML have started first-line treatment with the following therapies during the last 6 months?
• Azacitidine monotherapy
• Low dose cytarabine (LoDAC) monotherapy
• Venetoclax + azacitidine
• Venetoclax + LoDAC
• Ivosidenib
• Intensive chemotherapy-based regimen
• Other
3. (a) Of the patients with AML treated with venetoclax (venetoclax + azacitidine or venetoclax + LoDAC) in the last 6 months, how many are approved for treatment via Blueteq?
Patients with chronic lymphocytic leukaemia (CLL)
4. How many patients with CLL have received treatment with venetoclax in the past 6 months (including venetoclax monotherapy, venetoclax + rituximab, venetoclax + obinutuzumab or venetoclax + ibrutinib)?
5. How many patients with CLL who were new to all lines of treatment received venetoclax in the past 6 months (including venetoclax monotherapy, venetoclax + rituximab, venetoclax + obinutuzumab or venetoclax + ibrutinib)?

Acute myeloid leukaemia (AML) and chronic lymphocytic leukaemia (CLL).171123.docx

Please note the questionnaire refers only to Adult Haematology services.
1) Does your Trust have a Clinical Haematology service for Adults?
Yes / No (delete as appropriate)
If No, please return the questionnaire at this stage – there are no further questions that need to be answered.
2) If Yes, please complete the staffing table below:
3) If you have Haematology Clinical Nurse Specialists, please advise on how their jobs are split, for example 1.0WTE Myeloma CNS, 0.8WTE BMT CNS etc.
4) Which of the below haematological services does your Haematology service cover?
5) In the last 3 years, how many ‘New’ patients were seen by your Clinical Haematology Team?
6) If you have a BMT service, how many patients do you treat on average per year?

Adult Haematology services.190522.docx

1) In the past 3 months, how many advanced/metastatic breast cancer patients have the status of;
a) HR+ and HER2+ [Hormone receptor-positive and human epidermal growth factor 2-positive]
b) HR- and HER2+ [Hormone receptor-negative and human epidermal growth factor 2-positive]
2) In the past 3 months, how many breast cancer patients were treated with:
a. Abemaciclib (Verzenios) + aromatase inhibitor *
b. Abemaciclib (Verzenios) + Fulvestrant
c. (Faslodex) Alpelisib (Piqray) + Fulvestrant (Faslodex)
d. Atezolizumab (Tecentriq)**
e. Bevacizumab (Avastin)
f. Eribulin (Halaven)
g. Everolimus (Afinitor) + Exemestane
h. Fulvestrant (Faslodex) as a single agent
i. Gemcitabine + paclitaxel
j. Lapatinib (Tyverb)
k. Neratinib (Nerlynx)
l. Olaparib (Lynparza)
m. Palbociclib (Ibrance) + aromatase inhibitor*
n. Pertuzumab (Perjeta) + trastuzumab + docetaxel
o. Ribociclib (Kisqali) + aromatase inhibitor*
p. Ribociclib (Kisqali) + Fulvestrant (Faslodex)
q. Talazoparib (Talzenna)
r. Trastuzumab + paclitaxel Trastuzumab as a single agent
s. Trastuzumab emtansine (Kadcyla)
t. Trastuzumab Deruxtecan (Enhertu)
u. Tucatinib + Trastuzumab + Capecitabine (Tukysa)
v. Other active systemic anti-cancer therapy ** *aromatase inhibitor e.g. Anastrozole, Exemestane or Letrozole **e.g. docetaxel, vinorelbine or capecitabine as a single agent

Advanced breast cancer.041122.docx

1a. Does your trust treat advanced breast cancer?
1b. If none, where are your patients referred?
2. In the past 3 months, how many advanced breast cancer patients [Stage IV] have the status of;
HR+ and HER2+ [Hormone receptor-positive and human epidermal growth factor 2-positive]
HR+ and HER2- [Hormone receptor-positive and human epidermal growth factor 2-negative]
HR- and HER2+ [Hormone receptor-negative and human epidermal growth factor 2-positive]
HR- and HER2- [Hormone receptor-negative and human epidermal growth factor 2-negative] – Triple negative disease
Not Known
3. In the past 3 months, how many breast cancer patients were treated with:
Abemaciclib (Verzenios) + aromatase inhibitor *
Abemaciclib (Verzenios) + Fulvestrant (Faslodex)
Alpelisib (Piqray) + Fulvestrant (Faslodex)
Atezolizumab (Tecentriq)**
Bevacizumab (Avastin)
Eribulin (Halaven)
Everolimus (Afinitor) + Exemestane
Fulvestrant (Faslodex) as a single agent
Gemcitabine + paclitaxel
Lapatinib (Tyverb)
Neratinib (Nerlynx)
Olaparib (Lynparza)
Palbociclib (Ibrance) + aromatase inhibitor*
Pertuzumab (Perjeta) + trastuzumab + docetaxel
Ribociclib (Kisqali) + aromatase inhibitor*
Ribociclib (Kisqali) + Fulvestrant (Faslodex)
Talazoparib (Talzenna)
Trastuzumab + paclitaxel
Trastuzumab as a single agent
Trastuzumab emtansine (Kadcyla)
Other active systemic anti-cancer therapy **
*aromatase inhibitor e.g. Anastrozole, Exemestane or Letrozole
**e.g. docetaxel, vinorelbine or capecitabine as a single agent

Download response Advanced Breast Cancer. 221019

Q1. How many patients have been diagnosed with advanced hepatocellular carcinoma (Stage 3b and 4) in the last 6 months?
Q2. How many hepatocellular carcinoma patients (any stage) have been treated in the last 6 months with the following treatments:
a. Lenvatinib
b. Sorafenib
c. Regorafenib
d. Atezolizumab + Bevacizumab
Q3. In the last 6 months, how many patients has your trust treated (for any condition) with the following treatments:
a. Avatrombopag
b. Eltrombopag
c. Fostamatinib
d. Romiplostim
Q4. In the last 6 months, how many patients has your trust treated for Immune thrombocytopenia (ICD10 code D69.3) ONLY with the following treatments:
a. Avatrombopag
b. Mycophenolate mofetil
c. Rituximab
d. Surgery (splenectomy)
Q5. Does your trust participate in any clinical trials for the treatment of hepatocellular carcinoma? If so, can you please provide the name of each trial and the number of patients taking part.

Advanced hepatocellular carcinoma (Stage 3b and 4).230522.docx

Which of the radiotherapy locations in the trust deliver the advanced radiotherapy treatment SABR ()?

Download response Advanced radiotherapy treatment SABR (Stereotactic ablative radiotherapy).180920

1. Does your trust use any AI software within radiology? If so could you please specify programme and its application?
2. If you use AI software within radiology – how often do/would you update, upgrade or swap them?
3. What is the decision-making criteria of choosing which AI software to use?
4. Do you make purchasing decision on your own and if not, what are the other stakeholders involved?

Download response AI software within radiology.110821.docx

All questions are shown as received by the Trust.
I should be grateful if you could inform me of the number of ALK-positive lung cancer patients that your Trust is currently treating. Would it be possible to separate out NHS and private patients?

ALK-positive lung cancer.150923.docx

Q1. How many patients were treated (for any condition) in the latest 6-month period with the following drugs:
a. Juluca (rilpivirine/dolutegravir)
b. Dovato (lamivudine/dolutegravir)
c. Triumeq (abacavir/lamivudine/dolutegravir)
d. Tivicay (dolutegravir)
e. Isentress (raltegravir)
f. Biktarvy (TAF/emtricitabine/bictegravir)
g. Genvoya (TAF/emtricitabine/elvitegravir/cobisistat)
h. Symtuza (TAF/emtricitabine/darunavir/cobisistat)
i. Odefsey (TAF/emtricitabine/rilpivirine)
j. Descovy (TAF/emtricitabine)
k. Truvada or generic TDF/emtricitabine
Q2. How many patients received any antiretroviral (ART) therapy for HIV treatment (excluding pre-exposure prophylaxis):
a. for the latest 6-month period
b. for the 6 months from July-December 2019
Q3. How many patients were treated in the latest 6-months period with Truvada or generic TDF/emtricitabine for?
a. HIV treatment
b. Pre-exposure prophylaxis (PrEP)
Q4. How many packs of Truvada or generic TDF/emtricitabine were dispensed in latest 6-month period for?
a. HIV treatment
b. Pre-exposure prophylaxis (PrEP)

Download response Antiretroviral therapies. 140521

1. The number of Autoclaves commissioned and commissioned date.
2. The departments where Autoclaves are used.

Autoclaves.130223.docx

1. How many patients have been treated by your trust (for any medical condition) in the past 6 months with Bevacizumab?
2. Please provide the number of patients treated in the past 6 months with Bevacizumab for the following conditions:
a. Colorectal cancer
b. Breast cancer
c. Renal cell carcinoma
d. Non-small cell lung cancer
e. Ovarian cancer (epithelial, fallopian tube or primary peritoneal)
f. Carcinoma of the cervix

Download response Bevacizumab. 290121

All questions are shown as received by the Trust.
I would be grateful if you could please provide the following information with regards to patients treated with Durvalumab (Imfinzi) and Nivolumab.

Where the specified Nov 23 – March 24 timeframe is not possible to provide, could you please provide the latest 5 months of data you have, and specify which timeframe this covers.

1. How many unique total patients were treated in the last 5 months (Nov 23 – March 24) with Durvalumab for the following indications?
A) Biliary Tract Cancer
B) Non-Small Cell Lung Cancer
2. How many unique total patients were treated in the last 5 months (Nov 23 – March 24) with Nivolumab for early stage (resectable) non-small cell lung cancer (Stages 1 – 3b).
3. How many unique total patients were treated last month (March 24) with Durvalumab for the following indications?
C) Biliary Tract Cancer
D) Non-Small Cell Lung Cancer

4. How many patients received their first treatment in the last 5 months (Nov 23 – March 24) with Durvalumab for the following indications?
E) Biliary Tract Cancer
F) Non-Small Cell Lung Cancer

Biliary Tract and Non-Small Cell Lung Cancer Treatment.240424.docx

All questions are shown as received by the Trust.
1. In the last 12 months, how many individual patients were treated for biliary tract cancer with the following Diagnosis Codes:
A) C22.1 Intrahepatic Bile Duct Cardinoma
B) C23 Malignant Neoplasm of Gallbladder
C) C24 Malignant Neoplasm of unspecified biliary tract (If possible, could this please be further split to C24.0 Extrahepatic bile duct, C24.8 Overlapping lesion of Biliary Tract, C24.9 Biloary Tract, Unspecified).

Could you please also provide a total unique patient number for all of the diagnosis codes above, in case they have been coded multiple times.
2. In the last 12 months, how many patients were treated for Oesophagus Oesophagogastric Junction Cancer? (C16.7)

Biliary tract cancer.281223.docx

1. Does your Trust routinely provide bisphosphonates to postmenopausal women with primary breast cancer to reduce the risk of their cancer spreading to other parts of the body?
2. If your Trust does routinely provide bisphosphonates to reduce the risk of primary breast cancer spreading to other parts of the body, but is not providing them for all postmenopausal women, how is eligibility defined? For example, women at increased risk of recurrence.
3. If your Trust does routinely provide bisphosphonates for postmenopausal women to reduce the risk of primary breast cancer spreading to other parts of the body, which bisphosphonates do you prescribe? For example, zoledronic acid, ibandronic acid, sodium clodronate.
4. If your Trust does not routinely provide bisphosphonates for postmenopausal women to reduce the risk of primary breast cancer spreading to other parts of the body, what are your reasons for not doing so?

Download response Bisphosphonates. 160818

All questions are shown as received by the Trust.
In the past three months, how many patients have been treated for Bladder cancer with the below:
a) Avelumab
b) Atezolizumab
c) Carboplatin with Gemcitabine
d) Carboplatin single or in any other combination
e) Cisplatin with Gemcitabine
f) Cisplatin single or in any other combination
g) Nivolumab
h) Pembrolizumab
i) Any other systemic anti-cancer therapy
j) Palliative care only

Bladder cancer.081223.docx

1. How do you obtain blood collection tubes for liquid biopsies on cancer patients?
2. From what suppliers do you obtain these products?
3. Were these products purchased through a tender or framework? If so, which one? Please provide details including the name, reference and where this was published.
4. Are you under contract with your current supplier(s) for the above? If so, what is the start and end date of the contract?
5. Can you provide the name and contact details for the person(s) responsible for procuring these products?
6. Can you provide contact details for the department responsible for managing this service?

Download response Blood collection tubes for liquid biopsies. 250521

Please provide details of the type (manufacturer and model), quantity, department, site where they are located and age of all Blood Gas Analysers listed on your trust’s asset register (or equivalent).

Blood Gas Analysers.111022.docx

1. Within your health trust how many metastatic breast cancer patients are currently [within the past 6 months] being treated, with any therapy, surgery or palliative care.
2. Within your health trust how many breast cancer patients are currently [within the past 6 months] being treated for bone metastases with the following treatments;
a. disodium pamidronate (Arcadia)
b. ibandronic acid or ibandronate (Bondronat)
c. sodium clodronate (Bonefos, Clasteon, Loron)
d. zoledronic acid or zoledronate (Zometa)
e. denosumab (Xgeva)
3. Within your health trust how many breast cancer patients are currently [within the past 6 months] being treated with adjuvant therapy with the following treatments;
a. disodium pamidronate (Aredia)
b. ibandronic acid or ibandronate (Bondronat)
c. sodium clodronate (Bonefos, Clasteon, Loron)
d. zoledronic acid or zoledronate (Zometa)
4. Within your health trust how many metastatic lung cancer patients are currently [within the past 6 months] being treated with any therapy, surgery or palliative care.
5. Within your health trust how many lung cancer patients are currently [within the past 6 months] being treated for bone metastases with the following treatments;
a. disodium pamidronate (Aredia)
b. ibandronic acid or ibandronate (Bondronat)
c. sodium clodronate (Bonefos, Clasteon, Loron)
d. zoledronic acid or zoledronate (Zometa)
e. denosumab (Xgeva)
6. Within your health trust how many metastatic renal cell cancer patients are currently [within the past 6 months] being treated with any therapy, surgery or palliative care.
7. Within your health trust how many renal cell carcinoma [RCC] patients are currently [within the past 6 months] being treated for bone metastases with the following treatments;
a. disodium pamidronate (Aredia)
b. ibandronic acid or ibandronate (Bondronat)
c. sodium clodronate (Bonefos, Clasteon, Loron)
d. zoledronic acid or zoledronate (Zometa)
e. denosumab (Xgeva)

Download response Bone Metastases. 240919

1. How many patients have been treated for glioblastoma brain cancer in the last 12 months, in your trust/ health board?
2. Which consultant is the nominated medical lead for the treatment or referral of glioblastoma brain cancer?
3.Does your trust/ health board treat all referred glioblastoma brain cancer cases, or are they referred to different centre’s? If so, which treatment centre(s) are they referred to?

Brain Cancer Treatment.051022.docx

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:
a. Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
b. Abemaciclib + Fulvestrant
c. Alpelisib + Fulvestrant
d. Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
e. Atezolizumab +Nab-paclitaxel/Paclitaxel
f. Capecitabine as a single agent
g. Eribulin as a single agent or in combination
h. Everolimus + Exemestane
i. Fulvestrant as a single agent
j. Lapatinib
k. Neratinib
l. Parp Inhibitors (Olaparib/Talazoparib)
m. Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
n. Palbociclib + Fulvestrant
o. Pembrolizumab
p. Platinum (e.g. carboplatin or cisplatin) as a single agent
q. Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
r. Ribociclib + Fulvestrant
s. Sacituzumab Govitecan
t. Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
u. Taxane and/or Anthracycline in combination
v. Trastuzumab as a single agent or in combination
w. Trastuzumab emtansine
x. Transtuzumab deruxtecan
y. Any other active systemic anti-cancer therapy

Breast cancer.021123.docx

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:
a. Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
b. Abemaciclib + Fulvestrant
c. Alpelisib + Fulvestrant
d. Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
e. Atezolizumab +Nab-paclitaxel/Paclitaxel
f. Capecitabine as a single agent
g. Eribulin as a single agent or in combination
h. Everolimus + Exemestane
i. Fulvestrant as a single agent
j. Lapatinib
k. Neratinib
l. Parp Inhibitors (Olaparib/Talazoparib)
m. Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
n. Palbociclib + Fulvestrant
o. Pembrolizumab
p. Platinum (e.g. carboplatin or cisplatin) as a single agent
q. Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
r. Ribociclib + Fulvestrant
s. Sacituzumab Govitecan
t. Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
u. Taxane and/or Anthracycline in combination
v. Trastuzumab as a single agent or in combination
w. Trastuzumab emtansine
x. Transtuzumab deruxtecan
y. Any other active systemic anti-cancer therapy
Q2. Does your trust participate in any clinical trials for the treatment of breast cancer? If so, please provide the name of each trial and the number of patients taking part.

Breast Cancer.030723.docx

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:
a. Abemaciclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)
b. Abemaciclib + Fulvestrant
c. Alpelisib + Fulvestrant
d. Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
e. Atezolizumab + Nab-paclitaxel/Paclitaxel
f. Capecitabine as a single agent
g. Eribulin as a single agent or in combination
h. Everolimus + Exemestane
i. Fulvestrant as a single agent
j. Lapatinib
k. Neratinib
l. Parp Inhibitors (Olaparib/Talazoparib)
m. Palbociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)
n. Palbociclib + Fulvestrant
o. Pembrolizumab
p. Platinum (e.g. carboplatin or cisplatin) as a single agent
q. Ribociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)
r. Ribociclib + Fulvestrant
s. Sacituzumab Govitecan
t. Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
u. Taxane and/or Anthracycline in combination
v. Trastuzumab as a single agent or in combination
w. Trastuzumab emtansine
x. Transtuzumab deruxtecan
y. Any other active systemic anti-cancer therapy

Q2. Of the patients treated for breast cancer with Abemaciclib + Aromatase Inhibitor in the past the 3 months, please provide the number of patients with:
a. early/locally advanced breast cancer (Stages 1 to 3B)
b. advanced/metastatic breast cancer (Stages 3C and 4)

Breast cancer.090323.docx

1. In the past 3 months, how many Breast Cancer patients (any stage) were treated with:
a. Abemaciclib monotherapy
b. Aromatase inhibitor monotherapy (e.g. anastrazole, exemestane, letrozole)
c. Tamoxifen monotherapy
d. Abemaciclib + Tamoxifen
e. Abemaciclib + Tamoxifen + Goserelin
f. Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) + Goserelin
g. Aromatase inhibitor + Goserelin
h. Tamoxifen+ Goserelin
2. How many patients have been treated for Triple-Negative Breast Cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:
a. Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
b. Atezolizumab +Nab-paclitaxel/Paclitaxel
c. Pembrolizumab
d. Sacituzumab Govitecan
e. Parp Inhibitors (Olaparib/Talazoparib)
f. Eribulin as a single agent or in combination
g. Capecitabine as a single agent
h. Platinum (e.g. carboplatin or cisplatin) as a single agent
i. Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
j. Taxane and/or Anthracycline in combination
k. Any other active systemic anti-cancer therapy

Breast cancer.090922.docx

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of June 2023 and end of August 2023?
Please provide data for the latest 3-month period, if Jun to Aug is not available yet
1.1 Abemaciclib (Verzenios)
1.2 Alpelisib (Piqray)
1.3 Fulvestrant (fulvestrant or Faslodex)
1.4 Palbociclib (Ibrance)
1.5 Ribociclib (Kisqali)
Q2. How many patients received abemaciclib (Verzenios) for early breast cancer in the 3 months between the start of June 2023 and end of August 2023?
Please provide data for the latest 3-month period, if Jun to Aug is not available yet
Q3. How many patients received abemaciclib (Verzenios) as adjuvant treatment for early breast cancer in the 3 months between the start of June 2023 and end of August 2023?
Please provide data for the latest 3-month period, if Jun to Aug is not available yet
Q4. How many patients received abemaciclib (Verzenios) with the following treatment intent in the 3 months between the start of June 2023 and end of August 2023?
Please provide data for the latest 3-month period, if Jun to Aug is not available yet
4.1 Curative
4.2 Palliative
4.3 Not known / stated
Q5. How many patients were treated with the following medicines in combination in the 3 months between the start of June 2023 and end of August 2023?
Please provide data for the latest 3-month period, if Jun to Aug is not available yet
5.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)
5.2 Abemaciclib (Verzenios) + an aromatase inhibitor (anastrozole, letrozole or exemestane)
5.3 Abemaciclib (Verzenois) + tamoxifen
5.4 Abemaciclib monotherapy
5.5 Alpelisib (Piqray) + Fulvestrant (fulvestrant or Faslodex)
5.6 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)
5.7 Palbociclib (Ibrance) + an aromatase inhibitor (anastrozole, letrozole or exemestane)
5.8 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)
5.9 Ribociclib (Kisqali) + an aromatase inhibitor (anastrozole, letrozole or exemestane)

Breast Cancer.151223.docx

1. Please confirm or deny if Maidstone and Tunbridge Wells NHS Trust holds information on the number of people diagnosed in Maidstone and Tunbridge Wells NHS Trust with early breast cancer in each year from 2013 to 2018.
If confirm, please release this data.
2. Please confirm or deny if Maidstone and Tunbridge Wells NHS Trust holds information on the number of people diagnosed in Maidstone and Tunbridge Wells NHS Trust with early breast cancer that were offered tumour profiling tests to guide adjuvant chemotherapy decisions, in each year from 2013 to 2018. If confirm, please release this data.
3. Please confirm or deny if Maidstone and Tunbridge Wells NHS Trust holds information on the number of people diagnosed in Maidstone and Tunbridge Wells NHS Trust with early breast cancer that were tested with tumour profiling tests to guide adjuvant chemotherapy decisions, in each year from 2013 to 2018. If confirm, please release this data.
4. Please confirm or deny if Maidstone and Tunbridge Wells NHS Trust holds information on the number of people diagnosed in Maidstone and Tunbridge Wells NHS Trust with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative and lymph node (LN)-negative (including micrometastatic disease) early breast cancer in each year from 2013 to 2018. If confirm, please release this data.
5. Please confirm or deny if Maidstone and Tunbridge Wells NHS Trust holds information on the numbers of people diagnosed in Maidstone and Tunbridge Wells NHS Trust with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative and lymph node (LN)-negative (including micrometastatic disease) early breast cancer that were offered tumour profiling tests to guide adjuvant chemotherapy decisions in each year from 2013 to 2018. If confirm, please release this data.
6. Please confirm or deny if Maidstone and Tunbridge Wells NHS Trust holds information on the number of people diagnosed in Maidstone and Tunbridge Wells NHS Trust with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative and lymph node (LN)-negative (including micrometastatic disease) early breast cancer that were tested with tumour profiling tests to guide adjuvant chemotherapy decisions in each year from 2013 to 2018. If confirm, please release this data.

Download response Breast cancer. 181019

1. In the past 3 months, how many Breast Cancer patients (at any stage) were treated with:
a. Abemaciclib monotherapy
b. Aromatase inhibitor monotherapy (e.g. anastrazole, exemestane, letrozole)
c. Tamoxifen monotherapy
d. Abemaciclib + Tamoxifen
2. In the past 3 months, how many early/locally advanced Breast Cancer (Stages 1 to 3B) patients were treated with:
a. Abemaciclib + Aromatase inhibitor (e.g. anastrazole, exemestane, letrozole)
b. Taxane and/or Anthracycline (monotherapy or in combination)
c. Any other active systemic anti cancer therapy
3. How many patients have been treated for Triple Negative Breast Cancer (any stage) in the past 3 months with the following systemic anti cancer therapies:
a. Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
b. Atezolizumab +Nab-paclitaxel/Paclitaxel
c. Pembrolizumab
d. Sacituzumab Govitecan
e. Parp Inhibitors (Olaparib/Talazoparib)
f. Eribulin as a single agent or in combination
g. Capecitabine as a single agent
h. Platinum (e.g. carboplatin or cisplatin) as a single agent
i. Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
j. Taxane and/or Anthracycline in combination
k. Any other active systemic anti-cancer therapy

Breast Cancer.181122.docx

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the systemic anti-cancer therapies listed below?
a. Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) as a single agent
b. Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
c. Abemaciclib + Fulvestrant
d. Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
e. Atezolizumab +Nab-paclitaxel/Paclitaxel
f. Capecitabine as a single agent
g. Carboplatin or Cisplatin as a single agent
h. Eribulin as a single agent or in combination
i. Everolimus + Exemestane
j. Fluorouracil
k. Fulvestrant as a single agent
l. Goserelin
m. Lapatinib
n. Neratinib
o. Olaparib
p. Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
q. Palbociclib + Fulvestrant
r. Pertuzumab + Trastuzumab + Docetaxel
s. Platinum (e.g. carboplatin or cisplatin) as a single agent
t. Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
u. Ribociclib + Fulvestrant
v. Talazoparib
w. Tamoxifen
x. Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
y. Transtuzumab as a single agent
z. Trastuzumab emtansine
aa. Transtuzumab deruxtecan
bb. Any other active systemic anti-cancer therapy

Q2. In the past 3 months, how many early/locally advanced (Stages I to IIIc) breast cancer patients were treated with an Aromatase Inhibitor (anastrozole, exemestane, Letrozole) as a single agent?

Download response Breast cancer. 251021.docx

Breast Cancer.

You asked: All questions are shown as received by the Trust.
1) In the past 3 months, how many advanced/metastatic breast cancer patients have the status of;
a) HR+ and HER2+ [Hormone receptor-positive and human epidermal growth factor 2-positive]
b) HR- and HER2+ [Hormone receptor-negative and human epidermal growth factor 2-positive]
c) The total number of Metastatic breast cancer patients of any type.

2) In the past 3 months, how many metastatic breast cancer patients were treated with:
a) Trastuzumab + Pertuzumab + paclitaxel
b) Trastuzumab + paclitaxel Trastuzumab as a single agent
c) Trastuzumab emtansine
d) Trastuzumab Deruxtecan
e) Tucatinib + Trastuzumab + Capecitabine

Breast Cancer.270224.docx

All questions are shown as received by the Trust.
Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:
a. Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
b. Abemaciclib + Fulvestrant
c. Alpelisib + Fulvestrant
d. Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
e. Atezolizumab +Nab-paclitaxel/Paclitaxel
f. Capecitabine as a single agent
g. Eribulin as a single agent or in combination
h. Everolimus + Exemestane
i. Fulvestrant as a single agent
j. Lapatinib
k. Neratinib
l. Parp Inhibitors (Olaparib/Talazoparib)
m. Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
n. Palbociclib + Fulvestrant
o. Pembrolizumab
p. Platinum (e.g. carboplatin or cisplatin) as a single agent
q. Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
r. Ribociclib + Fulvestrant
s. Sacituzumab Govitecan
t. Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
u. Taxane and/or Anthracycline in combination
v. Trastuzumab as a single agent or in combination
w. Trastuzumab emtansine
x. Transtuzumab deruxtecan
y. Any other active systemic anti-cancer therapy
Q2. Does your trust participate in any clinical trials for breast cancer? If so, please provide the name of each trial, and the number of patients taking part.

Breast cancer.280224.docx

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the latest three months for which you have data?
Name of medicine
1.1 Abemaciclib (Verzenios)
1.2 Alpelisib (Piqray)
1.3 Anastrozole (anastrozole or Arimidex)
1.4 Exemestane (exemestane or Aromasin)
1.5 Fulvestrant (fulvestrant or Faslodex)
1.6 Letrozole (letrozole or Femara)
1.7 Palbociclib (Ibrance)
1.8 Ribociclib (Kisqali)
Q2. How many patients received abemaciclib (Verzenios) as adjuvant treatment for early breast cancer in the latest three months for which you have data?
If you do not have data on early breast cancer, please state how many patients received abemaciclib (Verzenios) as adjuvant treatment.
Q3. How many patients received abemaciclib in combination with an aromatase inhibitor (anastrozole or exemestane or letrozole) for early breast cancer and locally advanced or metastatic breast cancer in the latest three months for which you have data?
3.1 Abemaciclib + aromatase inhibitor (anastrozole or exemestane or letrozole)
3.2 Abemaciclib + aromatase inhibitor (anastrozole or exemestane or letrozole)
Q4. How many patients received Olaparib (Lynparza) as adjuvant treatment for early breast cancer in the latest three months for which you have data?
If you do not have data on early breast cancer, please state how many patients received Olaparib (Lynparza) as adjuvant treatment.
Q5. How many patients were treated with the following medicines in combination in the latest three months for which you have data?
Name of combination
4.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)
4.2 Abemaciclib (Verzenios) + Anastrozole (anastrozole or Arimidex)
4.3 Abemaciclib (Verzenios) + Exemestane (exemestane or Aromasin)
4.4 Abemaciclib (Verzenios) + Letrozole (letrozole or Femara)
4.7 Alpelisib (Piqray) + Fulvestrant (fulvestrant or Faslodex)
4.8 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)
4.9 Palbociclib (Ibrance) + Anastrozole (anastrozole or Arimidex)
4.10 Palbociclib (Ibrance) + Exemestane (exemestane or Aromasin)
4.11 Palbociclib (Ibrance) + Letrozole (letrozole or Femara)
4.12 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)
4.13 Ribociclib (Kisqali) + Anastrozole (anastrozole or Arimidex)
4.14 Ribociclib (Kisqali) + Exemestane (exemestane or Aromasin)
4.15 Ribociclib (Kisqali) + Letrozole (letrozole or Femara)
Q5. How many patients were treated with Olaparib (Lynparza) as monotherapy for locally advanced or metastatic breast cancer in the latest three months for which you have data?
Q6. Which of these protocols does your Trust follow when issuing prescriptions for aromatase inhibitors (anastrozole or exemestane or letrozole) prescribed in combination with CDK4/6 inhibitors (abemaciclib or palbociclib or ribociclib)?
6.1 Aromatase inhibitors and CDK4/6 inhibitors are issued together To Take Out at the hospital
6.2 Aromatase inhibitors and CDK4/6 inhibitors are issued separately. The CDK4/6 inhibitors (abemaciclib or palbociclib or ribociclib) are issued To Take Out at the hospital. The aromatase inhibitors (anastrozole or exemestane or letrozole) are issued as an FP10 to the patient or a request is sent to the GP to issue in the community
6.3 Both protocols above

Breast Cancer.310323.docx

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:
a. Abemaciclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)
b. Abemaciclib + Fulvestrant
c. Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
d. Atezolizumab +Nab-paclitaxel/Paclitaxel
e. Capecitabine as a single agent
f. Eribulin as a single agent or in combination
g. Everolimus + Exemestane
h. Fulvestrant as a single agent
i. Lapatinib
j. Neratinib
k. Parp Inhibitors (Olaparib/Talazoparib)
l. Palbociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)
m. Palbociclib + Fulvestrant
n. Pembrolizumab
o. Platinum (e.g. carboplatin or cisplatin) as a single agent
p. Ribociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)
q. Ribociclib + Fulvestrant
r. Sacituzumab Govitecan
s. Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
t. Taxane and/or Anthracycline in combination
u. Trastuzumab as a single agent or in combination
v. Trastuzumab emtansine
w. Transtuzumab deruxtecan
x. Any other active systemic anti-cancer therapy
Q2. In the past 3 months, how many early/locally advanced breast cancer (Stages 1 to 3B) patients were treated with:
a. Abemaciclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)
b. Taxane and/or Anthracycline (monotherapy or in combination)
c. Any other active systemic anti-cancer therapy

Breast cancer treatment.110722.docx

1. Within your health trust how many patients are currently [within the past 3 months] being treated with the following for breast cancer?
Abemaciclib + aromatase inhibitor *
Abemaciclib + Fulvestrant
Alpelisib + Fulvestrant
Atezolizumab
Bevacizumab
Eribulin
Everolimus + Exemestane
Fulvestrant as a single agent
Gemcitabine + paclitaxel
Lapatinib
Neratinib
Olaparib
Palbociclib + aromatase inhibitor*
Pertuzumab + trastuzumab + docetaxel
Ribociclib + aromatase inhibitor*
Ribociclib + Fulvestrant
Talazoparib
Herceptin SC
Herceptin IV
Transtuzumab biosimilar SC
Transtuzumab biosimilar IV
Trastuzumab emtansine
Other active systemic anti-cancer therapy **
*aromatase inhibitor e.g. Anastrozole, Exemestane or Letrozole
**e.g. docetaxel, vinorelbine or capecitabine as a single agent

2. How many patients are being treated for
2a Neo-adjuvant breast cancer;
Transtuzumab total SC
Transtuzumab total IV
2.b Adjuvant breast cancer;
Transtuzumab total SC
Transtuzumab total IV

Download response Breast Cancer treatments.241219

1. In November and December 2019 how many requests/bookings for radical radiotherapy to the breast or chestwall were received by the radiotherapy department?
2. For those patients requested/booked in November and December 2019, how many commenced treatment?
3. Of those who received treatment what was the average length of time between the request/booking being made and the patient receiving treatment?
4. What is your average length of time for all radical radiotherapy requests/bookings to starting treatment?

Download response Breast radiotherapy access. 170120

Breast Screening – (Asymptomatic)
1. Does the trust have a dedicated breast screening service/unit (Asymptomatic mammograms) – This could be separate from the main x-ray department?
2. If so, what is the name of the service?
3. Is this run in a static unit or on breast screening vans (Or Both)? How many vans does the service run? How many static sites does the service run?
4. How many ladies are scanned/screened on average, per day on each van/static unit?
5. Does the service scan on a 5 day or 7 day week?
6. Who has the overall responsibility for the breast screening service?
7. Please provide an organisational chart for the team/department with overall responsibility for the breast screening service

Symptomatic Mammography & Breast Clinics
1. Which department has the responsibility for symptomatic mammograms / Symptomatic Breast Lists/Clinics? Does this come under the breast screening unit or the main radiography department of the trust?
2. How many ladies are assessed on average per day in the symptomatic breast clinic?
3. Does the service scan on a 5 day or 7 day week?
4. Who has the overall responsibility for the symptomatic breast clinics?
5. Please provide an organisational chart for the team/department with overall responsibility for the symptomatic breast clinics

Download response Breast Screening & Breast Clinics. 031219

Please can you answer the following questions regarding the Mobile C-arm medical imaging equipment used within the Trust?
Please can you provide the following information for each piece of Mobile C-arm medical imaging equipment? (Please complete the attached spreadsheet)
a. Manufacturer
b. Model
c. Type (Image Intensifier, Flat Panel Detector)
d. Generator Power
e. Location – Hospital Name
f. Location – Department
g. Method of Finance at Procurement
h. Initial cost of Equipment
i. Annual Maintenance cost
j. Acquisition Date
k. Planned Replacement Date

Download response C-Arm provision. 250220

1. How many cancer operations have been cancelled by your NHS Trust in each of the past four financial years:
a. 2022/23
b. 2021/22
c. 2020/21
d. 2019/20
2. Please could you provide a breakdown for the reasons these operations were cancelled e.g. lack of staff, lack of beds, or equipment issues, again broken down by the financial years:
a. 2022/23
b. 2021/22
c. 2020/21
d. 2019/20

Cancelled cancer operations.061223.docx

I would like to know how many cancer operations have been cancelled by your NHS Trust since March 1st 2020?

Download response Cancelled cancer operations. 220920

All questions are shown as received by the Trust.
1. How many cancer operations have been cancelled by your NHS Trust in each of the past four financial years:
a. 2022/23
b. 2021/22
c. 2020/21
d. 2019/20
2. The highest number of times a patient’s operation has been cancelled at your NHS Trust since the start of 2022.
3. Please could you provide a breakdown for the reasons these operations were cancelled e.g. lack of staff, lack of beds, or equipment issues.
a. 2022/23
b. 2021/22
c. 2020/21
d. 2019/20

Cancelled Cancer operations.290224.docx

All questions are shown as received by the Trust.
1. The number of (a) first consultant appointments after an urgent referral, (b) first definitive cancer treatments, and (c) subsequent cancer treatments, that were cancelled or rescheduled by your trust in financial year 2022/23:
(i) once
(b) twice
(c) three times or more
2. The most amount of times the date was changed on a single one of the above cancer appointments by your trust in FY 2022/23.

Cancer appointments.081223.docx

1) How many PALS enquiries and official complaints your Trust has received from patients concerned about
a) the impact of the coronavirus pandemic and your Trust’s response on their or their family member’s access to cancer treatment
b) and access to cancer testing – including tests to find out whether their or their family member’s cancer has spread, returned or occurred for the first time
2) For the five most recent PALS enquiries/official complaints received, please provide me with
a) a summary of the complaint (e.g. a patient with stage 4 lung and breast cancer has contacted PALS to complain about their chemotherapy being postponed for a month)
b) the exact wording of the complaint, with redactions to remove potentially identifying information
c) what action the Trust took in response

Download response Cancer complaints. 021121.docx

Could you please tell me between 1st March 2020 and the date of this email (31st July 2020):
1) How many PALS enquiries and official complaints your Trust has received from patients concerned about
a) the impact of the coronavirus pandemic and your Trust’s response on their access to cancer treatment
b) and access to cancer testing – including tests to find out whether their cancer has spread, returned or occurred for the first time
NOTE: I suggest you search for these complaints by using the keywords ‘cancer treatment’, ‘chemotherapy’, ‘cancer testing’, ‘coronavirus’, ‘COVID-19’ and other relevant terms.
2) For the five most recent PALS enquiries/official complaints received, please provide me with
a) a summary of the complaint (e.g. a patient with stage 4 lung and breast cancer has contacted PALS to complain about their chemotherapy being indefinitely suspended)
b) the exact wording of the complaint, with redactions to remove potentially identifying information
c) what action the Trust took in response

Download response Cancer complaints. 170820

All questions are shown as received by the Trust.
1. How many fatalities have been due to cancer wrong diagnosis or failure/delay diagnosis in the last three years (Between 2021-up to and including any data held for 2024)?

For example: The number of incidents where the Primary Cause is ‘Wrong Diagnosis’ or ‘Failure/Delay Diagnosis’ and where both injury codes ‘Cancer’ and ‘Fatality’ are recorded?

Cancer diagnosis.190424.docx

All questions are shown as received by the Trust.
The number of patients diagnosed with cancer, broken down between 2018 and 2023, where:
o The source of referral for the cancer diagnosis was listed as ‘Following A&E Attendance’.
o Attendances at A&E where the presenting complaint indicated that the patient was already known to have cancer or was undergoing cancer treatment were excluded.

Cancer diagnosis via A&E.190424.docx

1. How many patients are currently on your trust’s waiting list for a cancer diagnostic test?
2. How many patients were on your trust’s waiting list for a cancer diagnostic test 12 months ago?
3. What is the longest time a patient has had to wait for a cancer diagnostic test in the last 12 months?
4. How many cancer diagnostic tests have been cancelled by your trust for non-clinical reasons in the last 12 months?
5. What is the highest number of times a cancer diagnostic test for one patient has been cancelled by your trust for non-clinical reasons in the last 12 months?

Cancer diagnostic tests.021123.docx

All questions are shown as received by the Trust.
“The total amount of your Trusts budget in pounds-sterling (£) that is allocated for all cancer funding in each of the financial years a) 2023-2024, b) 2023-2022, c) 2022-2021, d) 2021-2020, e) 2020-2019
The percentage of your Trusts total budget that is allocated for all cancer funding in each of the financial years a) 2023-2024, b) 2023-2022, c) 2022-2021, d) 2021-2020, e) 2020-2019”

Cancer funding.140324.docx

All questions are shown as received by the Trust.
1. The number of people at your trust currently receiving treatment for cancer?
2. The number of people at your trust currently waiting to receive treatment for cancer?
3. How long has the person who has waited the longest been waiting?
4. The number of people waiting to start cancer treatment, as measured from the date of urgent referral, who have waited longer than:
a. 62 days,
b. 3 months,
c. 4 months
d. 6 months,
e. 12 months.
5. The single longest wait to start cancer treatment, as measured from the date of the urgent referral, for each of the last three years?

Cancer – Longest Wait.310823.docx

1. How many patients on the cancer pathway started treatment within the 62 days and over 62 days, from urgent GP referral to starting treatment in each month of 2020 and 2021.
2. How many patients referred under the 2 weeks wait pathway were seen within 14 days in each month of 2020 and 2021.
3. How many patients started cancer treatment in each month of:
a. 2019
b. 2020
c. 2021

Download response Cancer pathway and treatment. 270821.docx

Please send me:
1. The total number of cancer patients receiving treatment within 62 days.
2. The total number of cancer patients waiting more than 104 days for treatment.

Download response Cancer patients. 240920

What percentage of cancer referrals received an appointment within 12 weeks of the original referral from a GP, for each month in 2019 and for each month in 2020.

Download response Cancer referrals.280521

1) What support do you offer for the family members of patients being treated for cancer within your NHS trust? (Support can include anything that would contribute to the emotional well-being of an individual, such as support groups, counselling or advice).
2) Does your NHS Trust provide any tailored support specifically for young people (under 25s) who have family members being treated for cancer?
3) If so, please could you provide details.
4) Are services actively offered to patients’ family members, or do they have to approach the Trust themselves to request support?

Download response Cancer Services. 110221

1. Over all how many Cancer trackers are employed by your Trust (WTE)?
2. Over all how many cancer MDT co-ordinators are employed by your Trust (WTE)?
3. Please provide the split of cancer tracker WTE by each tumour site of responsibility
a. Lung
b. Breast
c. Head & Neck
d. Lower GI
e. Upper GI
f. Gynaelogical
g. Children’s
h. Acute leukaemia
i. Haematological malignancies (excluding acute leukaemia)
j. Testicular
k. Urological
4. Please provide the split of cancer MDT co-coordinators WTE by each tumour site of responsibility
a. Lung
b. Breast
c. Head & Neck
d. Lower GI
e. Upper GI
f. Gynaelogical
g. Children’s
h. Acute leukaemia
i. Haematological malignancies (excluding acute leukaemia)
j. Testicular
k. Urological
5. What cancer PAS system is used by your organisation? I.e. Somerset, Infoflex other. If other please specify.

Cancer services.180522.docx

I wonder if you could get a complete copy including finance of the Trusts Cancer Policy.
On another issue, we are trying to get hold of copies of the two trusts Radiotherapy policy.

Download response Cancer Services and Radiotherapy policies. 090620

All questions are shown as received by the Trust.
1) Over the last 6 months, how many patients were treated with a combination of Dabrafenib + Trametinib for the following diseases:
A) Metastatic Melanoma
B) Adjuvant Melanoma
C) BRAF mutated Lung Cancer

2) Over the last 6 months, how many patients were treated with a combination of Encorafenib (Braftovi) + Binimetnib (Mektovi) for the following diseases:
A) Metastatic Melanoma
B) Colorectal Cancer
C) Any other indications

Cancer Treatment.101023.docx

1 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Non-small cell Lung Cancer (NSCLC) with the following
Paclitaxel
Gemcitabine
Osimertinib
Carboplatin and Pemetrexed
Cisplatin and Pemetrexed
Pembrolizumab monotherapy
Pembrolizumab in combination
Atezolizumab
Nivolumab
Other active systemic anti-cancer therapy
2a – Does your Health Trust participate in any ongoing clinical trails for the treatment of Metastatic Non Small Cell Lung cancer patients ?
2b – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials ?
3 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Colorectal Cancer (CRC) with the following:
Cetuximab not in combination with FOLFIRIE or FOLOX
Cetuximab in combination with FOLFIRI
Cetuximab in combination with FOLFOX
Panitumumab not in combination with FOLFIRI or FOLFOX
Panitumumab in combination with FOLFIRI
Panitumumab in combination with FOLFOX
Nivolumab
Aflibercept
Bevacizumab
Ramucirumab
Regorafenib
Sorafenib
Other active systemic anti-cancer therapy (eg 5FU, CAPIRI, CAPOX, FOLFIRI, FOLFOX, Oxaliplatin, Irinotecan, Tegafur or Uracil + 5FU)
3a – Does your Health Trust participate in any ongoing clinical trials for the treatment of Colorectal cancer patients ?
3b – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials ?
4 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Head and Neck Cancer (Squamous Cell Carcinoma) ?
4a – If your Trust is able to split these patients, how many are locally advanced and how many are recurrent and or metastatic Head and Neck Cancer patients ?
Locally advanced
Recurrent metastatic
Unable to split
4b – Of the Head and Neck cancer patients please split by their current drug treatment (if you are unable to split by locally advanced and recurrent please state the total)
Carboplatin (only or in combination with 5-FU)
Cisplatin (only or in combination with 5-FU)
Cetuximab with / without chemotherapy
Cetuximab with radiotherapy
Pembrolizumab monotherapy
Pembrolizumab with chemotherapy
Nivolumab
Docetaxel (only or in combination with 5-FU)
Fluorouracil (5-FU)
Radiotherapy only
Other
4c – Does your Health Trust participate in any ongoing clinical trials for the treatment of Head and Neck cancer patients ?
4d – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials ?
5 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Urothelial Carcinoma UCC) with the following:
Cisplatin single agent
Cisplatin in combination with another agent
Carboplatin single agent
Carboplatin in combination with another agent
Nivolumab
Pembrolizumab
Atezolizumab
Other active systemic anti-cancer therapy
5a – Does your Health Trust participate in any ongoing clinical trials for the treatment of Metastatic Urothelial Carcinoma patients ?
5b – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials ?

Download response Cancer treatment. 181019

1 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Non-small cell Lung Cancer (NSCLC) with the following
Paclitaxel
Gemcitabine
Osimertinib
Carboplatin and Pemetrexed
Cisplatin and Pemetrexed
Pembrolizumab monotherapy
Pembrolizumab in combination
Atezolizumab
Nivolumab
Other active systemic anti-cancer therapy
2a – Does your Health Trust participate in any ongoing clinical trails for the treatment of Metastatic Non Small Cell Lung cancer patients ?
2b – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials ?
3 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Colorectal Cancer (CRC) with the following:
Cetuximab not in combination with FOLFIRIE or FOLOX
Cetuximab in combination with FOLFIRI
Cetuximab in combination with FOLFOX
Panitumumab not in combination with FOLFIRI or FOLFOX
Panitumumab in combination with FOLFIRI
Panitumumab in combination with FOLFOX
Nivolumab
Aflibercept
Bevacizumab
Ramucirumab
Regorafenib
Sorafenib
Other active systemic anti-cancer therapy (e.g. 5FU, CAPIRI, CAPOX, FOLFIRI, FOLFOX, Oxaliplatin, Irinotecan, Tegafur or Uracil + 5FU)
3a – Does your Health Trust participate in any ongoing clinical trials for the treatment of Colorectal cancer patients ?
3b – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials ?
4 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Head and Neck Cancer (Squamous Cell Carcinoma) ?
4a – If your Trust is able to split these patients, how many are locally advanced and how many are recurrent and or metastatic Head and Neck Cancer patients ?
Locally advanced
Recurrent metastatic
Unable to split
4b – Of the Head and Neck cancer patients please split by their current drug treatment (if you are unable to split by locally advanced and recurrent please state the total)
Carboplatin (only or in combination with 5-FU)
Cisplatin (only or in combination with 5-FU)
Cetuximab with / without chemotherapy
Cetuximab with radiotherapy
Pembrolizumab monotherapy
Pembrolizumab with chemotherapy
Nivolumab
Docetaxel (only or in combination with 5-FU)
Fluorouracil (5-FU)
Radiotherapy only
Other
4c – Does your Health Trust participate in any ongoing clinical trials for the treatment of Head and Neck cancer patients ?
4d – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials ?
5 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Urothelial Carcinoma UCC) with the following:
Cisplatin single agent
Cisplatin in combination with another agent
Carboplatin single agent
Carboplatin in combination with another agent
Nivolumab
Pembrolizumab
Atezolizumab
Other active systemic anti-cancer therapy
5a – Does your Health Trust participate in any ongoing clinical trials for the treatment of Metastatic Urothelial Carcinoma patients ?
5b – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials ?

Download response Cancer treatment. 181019

You asked:
1. In the past 3 months, how many mNSCLC patients were treated with?
Afatinib
Atezolizumab
Becacizumab
Ceritinib
Crizotinib
Erlotinib
Gefitinib
Nitendaninb
Nivolumab
Pembrolizumab
Pemetrexed
Ramucirumab
Metastatic hepatocellular carcinoma
2. In the past three months, how many patients were treated with?
Bevacizumab
Cisplatin
Doxorubicin
Everolimus
Lapatinib
Levantinib
Regorafenib
Sorafenib
Sunitinib
TACE
Other active systemic anti-cancer therapy
Metastatic Thyroid Cancer
3. In the past three months, how many patients were treated with?
Axitinib
Cabozantinib
Levantinib
Pazopanib
Sorafenib
Sunitinib
Vandetanib
Others

Download response Cancer treatment. 291118

All questions are shown as received by the Trust.
1) In the past 6 months, what was the number of patients treated with a combination of Dabrafenib + Trametinib for the following conditions:
A) Metastatic Melanoma
B) Adjuvant Melanoma
C) BRAF mutated Lung Cancer
2) In the past 6 months, what was the number of patients treated with a combination of Encorafenib (Braftovi) + Binimetnib (Mektovi) for the following conditions:
A) Metastatic Melanoma
B) Colorectal Cancer

Cancer treatment using specified products.250624.docx

1a – How many melanoma patients undergoing treatment are BRAF+?
1b – In the past 3 months, how many melanoma patients were treated with the following:
Bevacizumab
Cobimetinib
Dabrafenib
Dabrafenib AND trametinib
Dacarbazine
Encorafenib AND binimetinib
Ipilimumab
Ipilimumab AND Nivolumab
Nivolumab
Pembrolizumab
Trametinib
Vemurafenib
Vemurafenib AND Cobimetinib
Other active systemic anti-cancer therapy
Palliative care
1c – In the past 3 months how many patients were seen who had stage III resectable melanoma
1d – Of all stage III patients seen, how many received a complete resection?
2 – In the past 3 months, how many Squamous Cell Non-small cell lung cancer (SqNSCLC) patients were treated with:
Afatinib
Atezolizumab monotherapy
Bevacizumab
Docetaxel monotherapy
Durvalumab
Erlotinib
Gemcitabine
Necitumumab
Nivolumab
Paclitaxel
Pembrolizumab monotherapy
Pembrolizumab chemo in combination
Pemetrexed
Ramucirumab
Vinorelbine and cisplatin / carboplatin
Other active systemic anti-cancer therapy [please state]
Palliative care only
3 – In the past 3 months, how many Non Squamous Cell Non-small cell lung cancer (Non SqNSCLC) patients were treated with:
Afatinib
Alectinib
Atezolizumab mono
Atezolizumab + bevacizumab + carboplatin + paclitaxel
Bevacizumab
Brigatinib
Ceritinib
Crizotinib
Dacomitinib
Docetaxel monotherapy
Erlotinib
Gefitinib
Nintedanib with docetaxel
Nivolumab
Osimertinib
Paclitaxel
Pembrolizumab monotherapy
Pembrolizumab chemo in combination
Pemetrexed with carboplatin
Pemetrexed with cisplatin
Ramucirumab
Other active systemic anti-cancer therapy [please state]
Palliative care only

Download response Cancer Treatments. 040320

1. Within your health trust, how many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the following agents?
a. Carboplatin (monotherapy or in combination with 5-FU)
b. Cisplatin (monotherapy or in combination with 5-FU)
c. Cetuximab with/without chemotherapy
d. Cetuximab with radiotherapy
e. Pembrolizumab monotherapy
f. Pembrolizumab with chemotherapy
g. Nivolumab
h. Docetaxel (monotherapy or in combination with 5-FU)
i. Fluorouracil (5FU)
j. Radiotherapy only
k. Other
2. For the patients treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the therapies listed in the first question, please provide:
a. Total number of head and neck cancer patients
b. Number of locally advanced head and neck cancer patients
c. Number of recurrent and/or metastatic head and neck cancer patients
3. Within your health trust, how many patients have been treated in the past 3 months with the following agents for colorectal cancer [CRC]?
a. Aflibercept
b. Bevacizumab
c. Capecitabine
d. CAPIRI
e. CAPOX (XELOX)
f. Cetuximab in combination with FOLFIRI
g. Cetuximab in combination with FOLFOX
h. Cetuximab not in combination with FOLFIRI or FOLFOX
i. Irinotecan only
j. FOLFIRI
k. FOLFOX
l. Fluorouracil (5FU) only
m. Oxaliplatin only
n. Panitumumab in combination with FOLFIRI
o. Panitumumab in combination with FOLFOX
p. Panitumumab not in combination with FOLFIRI or FOLFOX
q. Pembrolizumab
r. Nivolumab
s. Raltitrexed
t. Ramucirumab
u. Regorafenib
v. Sorafenib
w. Other SACT

Download response Cancer treatments. 051121.docx

1. Does your trust treat adult multiple myeloma [MM] ? – if you refer your multiple myeloma patients to another centre, please state which.
2. If yes, then how many multiple myeloma patients, have been treated in the past 6 months with the following;
· Bortezomib [Velcade]
· Carfilzomib [Kyprolis]
· Ixazomib [Ninlaro]
· Lenalidomide [Revlimid]
· Daratumumab [Darzalex]
· Melphalan, prednisolone and thalidomide (known as MPT)
· Cyclophosphamide, thalidomide and dexamethasone (known as CTD)
· Pomalidomide [Imnovid]
3. Over the past 6 months [latest possible], how many chronic lymphocytic leukaemia (CLL) patients have you treated?
If possible, how many CLL patients treated were new to therapy in the past 3 months?
4. How many chronic lymphocytic leukaemia patients, have been treated in the past 6 months with the following;
· Fludarabine (Fludara), cyclophosphamide (Cytoxan), and rituximab (known as FCR)
· Bendamustine and rituximab (known as BR)
· Ibrutinib [Imbruvica]
· Chlorambucil
· Venetoclax
· Obinutuzumab
· Idelalisib
· Fludarabine and rituximab (known as FR)
· High-dose prednisone and rituximab
· Pentostatin (Nipent), cyclophosphamide, and rituximab (known as PCR)
· Alemtuzumab (Campath) with rituximab

Download response Cancer treatments. 210920

1. Within your health trust how many patients have been treated in the past 6 months for head and neck cancer (Squamous cell carcinoma)?
2. Of these patients how many are locally advanced and how many are recurrent and/or metastatic head and neck cancer patients?
Locally advanced
Recurrent metastatic
Unknown
3. Within your health trust how many patients have been treated in the past 6 months for head and neck cancer (Squamous cell carcinoma) with the following agents?
Carboplatin (only or in combination with 5-FU)
Cisplatin (only or in combination with 5-FU)
Cetuximab with/without chemotherapy
Cetuximab with radiotherapy
Pembrolizumab monotherapy
Pembrolizumab with chemotherapy
Nivolumab
Docetaxel (only or in combination with 5-FU)
Fluorouracil (5FU)
Radiotherapy only
Other
Does your health trust participate in any ongoing clinical trials for the treatment of head and neck cancer patients, if so how many patients are currently taking part in clinical trials / what is the name/s of the trials?
4. Within your health trust how many patients have been treated in the past 6 months with the following agent for colorectal cancer [CRC];
Aflibercept
Bevacizumab
Capecitabine
CAPIRI
CAPOX
Cetuximab not in combination with FOLFIRI or FOLFOX
Cetuximab in combination with FOLFIRI
Cetuximab in combination with FOLFOX
Irinotecan
FOLFIRI
FOLFOX
Oxaliplatin
Panitumumab not in combination with FOLFIRI or FOLFOX
Panitumumab in combination with FOLFIRI
Panitumumab in combination with FOLFOX
Nivolumab
Raltitrexed
Ramucirumab
Regorafenib
Sorafenib
5FU only
Tegafur Uracil + 5FU
Trifluridine–tipiracil
XELOX
Other
5. Within your health trust how many patients have been treated in the past 6 months with the following agent for Renal Cell Carcinoma :
Sunitinib
Avelumab + Axitinib
Axinitib
Cabozantinib
Everolimus
Lenvantinib + Everolimus
Nivolumab
Nivolumab + Ipilimumab
Pazopanib
Pembrolizumab + Axitinib
Sunitinib
Temsirolimus
Tivozanib
6. Does your health trust participate in any ongoing clinical trials for the treatment of renal cell cancer patients, if so how many patients are currently taking part in clinical trials / what is the name/s of the trials?

Download response Cancer treatments. 220120

1 – Within your Health Trust how many patients are currently (within the past 3 months) being treated with the following treatments for Kidney Carcinoma (Renal Cell – RCC);
If you do not treat, where do you refer these patients?
2 – Within your Health Trust how many patients are currently (within the past 3 months) being treated with the following treatments for Melanoma?
If you do not treat, where do you refer these patients?
2a – In the past 3 months, how many Melanoma patients were BRAF+?
3 – Within your Health Trust how many patients are currently (within the past 3 months) being treated with the following treatments for Liver Cancer (Hepatic Cell – HCC);
If you do not treat, where do you refer these patients?
4 – Within your Health Trust how many patients are currently (within the past 3 months) being treated with the following treatments for Thyroid Cancer;
If you do not treat, where do you refer these patients?

Download response Cancer treatments. 241019

1. In the past 3 months, how many metastatic melanoma patients were treated by your Trust?
a. Dabrafenib
b. Dabrafenib + Trametinib
c. Densoumab
d. Encorafenib + Binimetinib
e. Ipilimumab
f. Ipilimumab + Nivolumab
g. Nivolumab
h. Pembrolizumab
i. Trametinib
j. Vemurafenib
k. Vemurafenib + Cobimetinib
l. Other active systemic anti-cancer therapy
Palliative care only
2. Within your health trust how many patients are currently [within the past 3 months] being treated for metastatic Non-small-cell lung cancer (NSCLC) with the following:
a. Afatinib
b. Atezolizumab monotherapy or combination
c. Brigatinib
d. Ceretinib
e. Crizotinib
f. Docetaxel monotherapy or combination
g. Erlotinib
h. Gefitinib
i. Gemcitabine
j. Nitendanib + docetaxel
k. Nivolumab
l. Osimertinib
m. Paclitaxel
n. Pembrolizumab monotherapy
o. Pembrolizumab chemo in combination
p. Pembrolizumab monotherapy
q. Pemetrexed monotherapy or combination
r. Ramucirumab
s. Vinorelbine monotherapy or combination
t. Other active systemic anti-cancer therapy
u. Palliative care only
3. Out of the metastatic NSCLC patients currently [within the past 3 months] being treated, are you able to provide the number of patients being treated for Squamous Cell Non-small-cell lung cancer (SqNSCLC ) with the following products?
a. Afatinib
b. Atezolizumab monotherapy or combination
c. Brigatinib
d. Ceretinib
e. Crizotinib
f. Docetaxel monotherapy or combination
g. Erlotinib
h. Gefitinib
i. Gemcitabine
j. Nitendanib + docetaxel
k. Nivolumab
l. Osimertinib
m. Paclitaxel
n. Pembrolizumab monotherapy
o. Pembrolizumab chemo in combination
p. Pembrolizumab monotherapy
q. Pemetrexed monotherapy or combination
r. Ramucirumab
s. Vinorelbine mono or combination
t. Other active systemic anti-cancer therapy
u. Palliative care only

Download response Cancer treatments. 260620

All questions are shown as received by the Trust.
1) in the past 6 months, how many patients were treated with a combination of both Encorafenib (Braftovi) + Binimetnib (Mektovi) for the following diseases:

A) Metastatic Melanoma
B) Colorectal Cancer
C) Any other indications

2) In the past 6 months, how many patients were treated with a combination of Dabrafenib + Trametinib for the following diseases:
A) Metastatic Melanoma
B) Adjuvant Melanoma
C) BRAF mutated Lung Cancer

Cancer treatments.270224.docx

All questions are shown as received by the Trust.
I writing to request, under the Freedom of Information Act, the number of cancer treatments started at each cancer stage in each of the last five years in your trust.

Cancer treatments.270923.docx

1. Within your health trust how many patients have been treated in the past 6 months for head and neck cancer (Squamous cell carcinoma)?
2. Of these patients how many are locally advanced, recurrent, metastatic and unresectable head and neck cancer patients?
a. Locally advanced
b. Recurrent
c. Metastatic
d. Unresectable
e. Unknown
3. Within your health trust how many patients have been treated in the past 6 months for head and neck cancer (Squamous cell carcinoma) with the following agents?
a. Carboplatin (only or in combination with 5-FU)
b. Cisplatin (only or in combination with 5-FU)
c. Cetuximab with/without chemotherapy
d. Cetuximab with radiotherapy
e. Pembrolizumab monotherapy
f. Pembrolizumab with chemotherapy
g. Nivolumab
h. Docetaxel (only or in combination with 5-FU)
i. Fluorouracil (5FU)
j. Radiotherapy only
k. Other
3b. Does your health trust participate in any ongoing clinical trials for the treatment of head and neck cancer patients, if so how many patients are currently taking part in clinical trials / what is the name/s of the trials?
4. Within your health trust how many patients have been treated in the past 6 months with the following agent for colorectal cancer [CRC];
a. Aflibercept
b. Bevacizumab
c. Capecitabine
d. CAPIRI
e. CAPOX
f. Cetuximab not in combination with FOLFIRI or FOLFOX
g. Cetuximab in combination with FOLFIRI
h. Cetuximab in combination with FOLFOX
i. Irinotecan
j. FOLFIRI
k. FOLFOX
l. Oxaliplatin
m. Panitumumab not in combination with FOLFIRI or FOLFOX
n. Panitumumab in combination with FOLFIRI
o. Panitumumab in combination with FOLFOX
p. Nivolumab
q. Raltitrexed
r. Ramucirumab
s. Regorafenib
t. Sorafenib
u. 5FU only
v. Tegafur Uracil + 5FU
w. Trifluridine–tipiracil
x. XELOX
y. Other
5. Within your health trust how many patients have been treated in the past 6 months with the following agent for Renal Cell Carcinoma:
a. Sunitinib
b. Avelumab + Axitinib
c. Axinitib
d. Cabozantinib
e. Everolimus
f. Lenvantinib + Everolimus
g. Nivolumab
h. Nivolumab + Ipilimumab
i. Pazopanib
j. Pembrolizumab + Axitinib
k. Sunitinib
l. Temsirolimus
m. Tivozanib
5b. Does your health trust participate in any ongoing clinical trials for the treatment of renal cell cancer patients, if so how many patients are currently taking part in clinical trials / what is the name/s of the trials?

Download response Cancer treatments. 291020

Please can you let me know what your success rate in meeting the cancer two week wait referral is? What % of patients referred are actually seen within the two weeks?

Cancer two week wait referral.110822.docx

1. How many individuals diagnosed in the last 5 years with prostate cancer?
2. How many deaths attributable to prostate cancer in the last 5 years?
3. How many individuals diagnosed in the last 5 years with breast cancer?
4. How many deaths attributable to breast cancer in the last 5 years?
5. How many individuals diagnosed with brain cancer in the last 5 years?
6. Of those diagnosed with brain cancer how many with GBM4?
7. How many deaths attributable to brain cancer in the last 5 years?
8. Of those deaths how many due to GBM4?
9. How many children diagnosed with brain cancer in the last 5 years?
10. How many child deaths attributable to brain cancer in the last 5 years?
Download response Cancers. 050718

Q1. Does your trust provide SACT (systemic anti-cancer therapy) treatments for the following conditions?
a. Cervical cancer
b. Endometrial cancer
In case you do not provide SACT treatments for either of the above conditions, which other trust do you refer patients to for these treatments?
Q2. How many patients were treated for cervical cancer in the past 6 months with the following treatments:
a. Paclitaxel in combination with Platinum and/or Bevacizumab
b. Pembrolizumab in combination with Platinum and/or Bevacizumab
c. Platinum standalone or in combination with Bevacizumab
d. Toptecan in combination with Platinum and/or Bevacizumab
e. Any other SACT
Q3. How many patients were treated for endometrial cancer in the past 6 months with the following treatments:
a. Dostarlimab
b. Hormone therapy (Progesterone or Letrozole)
c. Pembrolizumab in combination with Lenvatinib
d. Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)
e. Any other SACT
Q4. How many endometrial cancer patients received the following therapies as 1st Line treatment in the past 6 months:
a. Hormone therapy (Progesterone or Letrozole)
b. Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)
c. Any other SACT
Q5. Does your trust participate in any clinical trials for the treatment of cervical cancer? If so, can you please provide the name of each trial and the number of patients taking part.
Q6. Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part.

Cervical cancer and Endometrial cancer.171022.docx

We are seeking information for both general advice relevant to all chemotherapies and anything specific to carboplatin.
As part of this guidance and information we are seeking data including but not limited to:
1. The % and number of patients having the kidney function tests before chemo has begun and after it has begun, with associated outcomes, including mortality rates, split by chemo cycle stage undertaken.
2. The % and number of patients whose GFR tests taken prior to chemo starting, have indicated their kidneys were not functioning sufficiently to enable progression of chemotherapy.
3. It would then be helpful to understand which of those patients guided chemo cannot be progressed, did not progress and those that did (going against doctors wishes if that is possible to do?) and their outcomes.
It needs to reflect a time pre covid that is representative of more ‘normal’ time in treatment of cancers patients and also post pandemic peak when hospitals have been ramping up recovery.
We’d therefore be looking at two periods of data 1) 12 rolling months, February 2018 to Feb 2019 and then 5 months May 2021 to September 2021.
In addition to our questions below we’d like:
4. The specific data on number of patients during those periods who did not have a kidney function test prior to the first chemo cycle e.g total patients given chemo and not given chemo and the numbers of those that had gfr test before and those that did not.
5. For those patients that did not, also confirm of any subsequent kidney failure experienced and at what stage of chemo it was experienced.
6. To make a fair comparison, we’d welcome data of those who experienced kidney failure from chemo and at what stage chemo this happened – who undertook a gfr test prior and whose kidneys were deemed fit enough to withstand chemo treatment.

Chemotherapies and anything specific to carboplatin. 170322.docx

A list of the current medical imaging equipment held by the Trust across all hospital sites, providing the following information:
Q1: What is your overall spend on medical imaging products and services for the current year?
Q2: How much do you spend on each modality requested below for the current year:
a) Computed Tomography (CT)
b) Magnetic Resonance Imaging (MRI)
c) Ultrasound
d) Fluoroscopy
e) Mammography
f) Nuclear
g) Mobile X-ray
h) Static X-ray
Q3: A list of the current equipment held by the Trust across all hospital sites for each of the following:
a) Supplier
b) Product
c) Contract start date
d) Contract expiry date
e) Number of devices
f) Age of product
Example Response: 3 x Siemens Acuson SC2000, Initial cost £ 29,000, Contract start date 10/02/2022 Contract end date 10/02/2026, 6 years old
Q4: Annual cost of maintenance of equipment
Q5: What percentage of your imaging equipment has an element of Artificial Intelligence?

Clinical Imaging Equipment. 150322.docx

1. Do you insource clinical services and if so, which ones?
2. Do you have any current contracts in place with a company for these insourced services, and if so which services?
3. How much have you spent on insourcing clinical services per annum for the past 3 years?
4. Do you outsource clinical services and if so, which ones?
5. Do you have any current contracts in place with a company for these outsourced services, and if so which services?
6. How much have you spent on outsourcing clinical services per annum for the past 3 years?

Download response Clinical Insourcing and Outsourcing. 111121.docx

All questions are shown as received by the Trust.
Name of person completing out this form:
Full name of the hospital or NHS Trust (specify):
Your role at the hospital:
Your involvement in oncology clinical trials:
Is your hospital/ NHS Trust a Cancer Unit, Cancer Centre or Centre of Excellence in Cancer Care?
1.Ia What tumour groups do you treat with systemic anti-cancer therapy at your centre?
1.Ib Since 2010, for what tumour groups has your organisation had clinical trials involving systemic anti-cancer therapy? Select all that apply.
1.Ic In TOTAL, how many clinical trials (interventional Phase 0 – III) involving novel or novel combination or novel way of administering systemic anti-cancer therapies for solid cancers did you have in the Oncology department on 31 Dec in each year (provide a snapshot number) since 2010?
1.Id Of the total number of clinical trials you reported in 1.Ic, how many were solely funded by the NHS and NIHR (thus excluding trials funded by charity, government research councils like MRC, academic institutions and commercial companies)?
1.Ie Of the total number of clinical trials you reported in 1.Ic, how many were PHASE 1 trials?
1.If Of the total number of clinical trials you reported in 1.Ic, how many were PHASE 2 trials?
1.Ig Of the total number of clinical trials you reported in 1.Ic, how many were PHASE 3 trials?
1.Ih On a separate note, how many Phase IV trials did you conduct in each year at your hospital/ Trust?
1.Ii Of the total number of clinical trials you reported in 1.Ic, how many involved another procedure such as surgery or radiotherapy in combination with the trialled systemic anti-cancer therapy within the trial?
1.Ij Provide the total number of adult patients enrolled in phase I – III solid-cancer systemic anti-cancer therapy trials on 31 Dec of each year at your hospital/ Trust:
1.Ik In each year, how many new Phase I – III clinical trials did you open for recruitment?
2.I Post-BREXIT, what regulatory changes have had the greatest impact on the initiation of oncology trials at your centre?
2.II Post-BREXIT, what regulatory changes have had the greatest impact on the conduct/ continuation of oncology trials at your centre?
2.IIIa Post-BREXIT, have you observed any specific challenges related to regulatory compliance for initiating new oncology trials at your centre?
2.IIIb If yes, please specify the regulatory challenges encountered:
2.IVa Have there been any notable changes in the regulatory reporting requirements for ongoing oncology trials post-BREXIT?
2.IVb If yes, please elaborate on the changes and their impact on trial conduct:
2.Va Have there been any changes in the timeline for regulatory approvals post-BREXIT for initiating new oncology trials?
2.Vb If yes, please specify the nature of delays and their impact on trial initiation:
2.VI How has the communication and coordination with regulatory authorities changed post-BREXIT in the context of oncology trials?
2.VIa Have there been any new documentation or compliance requirements introduced post-BREXIT for ongoing oncology trials?
2.VIb If yes, please provide examples of the additional documentation or compliance measures introduced:
2.VII How has the training and education of clinical trial staff in your centre been impacted by regulatory changes post-BREXIT?
2.VIIIa Have there been any changes in the requirements for informed consent processes for oncology trials post-BREXIT?
2.VIIIb If yes, please specify the nature of changes and their impact on the informed consent process:
2.IX How has the interpretation and implementation of Good Clinical Practice (GCP) guidelines evolved post-BREXIT in your centre?
2.Xa Where staff updated or educated on regulatory changes post- BREXIT?
2.Xb If yes, explain how:
2.Xc If no, explain why not:
3.I In each year, how many Phase 0 – IV clinical trials did you have to discontinue due to a lack of funding? Comment on the funding sources affected:
3.II Name all organisations, including your own, that sponsored and/or funded solid- cancer systemic-anticancer therapy trials at your centre in each year:
3.III How has the funding landscape for oncology pharmaceutical trials at your centre changed post-BREXIT?
3.IV If there has been a change, please describe the main factors contributing to the shift in funding availability:
3.V How has the change in funding impacted the continuity of ongoing oncology pharmaceutical trials at your centre?
3.VI Are there specific types of trials more affected by funding challenges (e.g., Phase 1, investigator-initiated trials, certain types of systemic anti-cancer drugs, combination therapies, for certain tumour groups)?
3.VII How has the uncertainty surrounding BREXIT impacted the willingness of funding organisations to support oncology trials?
3.VIII Answering on behalf of your organisation, are there any specific policy changes that would enhance funding opportunities for oncology trials post-BREXIT?
3.IXa Have you explored alternative funding sources or strategies to mitigate potential funding challenges post-BREXIT?
3.IXb If yes, please share details of any successful strategies or approaches implemented:
3.X To what extent have patient advocacy groups played a role in supporting or influencing funding for oncology trials post-BREXIT in or for your organisation?
3.XIa Have there been any changes in the criteria or preferences of funding organisations when considering proposals for oncology trials post-BREXIT?
3.XIb If yes, please elaborate on the key changes in criteria or preferences:
4.I Comment on collaborative challenges that affected or caused disruptions in the initiation or running of solid-cancer systemic anti- cancer therapy drugs:
4.IIa Have there been challenges in maintaining international collaborations for oncology trials post-BREXIT?
4.IIb If yes, please identify the main collaborative challenges faced:
4.IIIa Have changes in regulatory requirements impacted international partnerships in oncology trials?
4.IIIb If yes, please elaborate on the specific regulatory aspects causing challenges:
4.IVa In your experience, have collaborative challenges affected the timeline and efficiency of oncology trials?
4.IVb If yes, please provide examples or instances where collaboration challenges led to disruptions in trial initiation or conduct:
4.Va At your current NHS hospital, have there been challenges in aligning international ethical standards and practices for oncology trials post-BREXIT?
4.Vb If yes, please elaborate on the specific ethical challenges faced and their impact on collaborative efforts:
4.VI How has the exchange of trial-related data and information with international partners been affected post-BREXIT?
4.VIIa In your organisation’s experience, have there been any challenges related to differences in patient populations across international sites in oncology trials?
4.VIIb If yes, please provide examples or instances where differences in patient populations posed challenges to collaborative efforts?
4.VIII How has the exchange of expertise and specialised resources with international collaborators been affected post-BREXIT?
4.IX From your organisation’s perspective, what strategies or initiatives could enhance international collaboration in oncology trials in the post-BREXIT era?
5.Ia Have you become aware of or experienced any challenges related to the alignment of data privacy and protection regulations in international oncology trials post-BREXIT?
5.Ib If yes, please elaborate on the specific challenges faced and any measures

Clinical Trials in Oncology.210324.docx

1. The total number of colonoscopies undertaken in Maidstone and Tunbridge Wells NHS Trust for the period
i) April 2019-March 2020
ii) April 2020-March 2021.
2. The total number of people diagnosed with colorectal cancer (or other clearly defined indications) within Maidstone and Tunbridge Wells NHS Trust for the period
i) April 2019-March 2020
ii) April 2020-March 2021.
3. The average adenoma detection rate (ADR) and post-colonoscopy colorectal cancer rate (PCCRC) for Maidstone and Tunbridge Wells NHS Trust for the period
i) April 2019-March 2020
ii) April 2020-March 2021
4. The total number of cancers detected, against cancer stage (e.g. 1,2,3 or 4), against colonoscopies performed in the prior three years within Maidstone and Tunbridge Wells NHS Trust in the period
i) April 2019-March 2020
ii) April 2020-March 2021

Colonoscopies and colorectal cancer. 160322.docx

In the past 3 months, how many patients have been treated for Colorectal Cancer [CRC] with the following regimens? If possible, please also provide the split of metastatic vs non-metastatic patients for each regimen.
Regimens
a. Capecitabine
b. CAPIRI
c. CAPOX
d. Cetuximab with FOLFIRI
e. Cetuximab with FOLFOX
f. Cetuximab as a single agent
g. Cetuximab with Encorafenib
h. Irinotecan as a single agent
i. FOLFIRI
j. FOLFOX
k. Fluorouracil (5FU) as a single agent
l. Oxaliplatin as a single agent
m. Nivolumab with Ipilimumab
n. Panitumumab with FOLFIRI
o. Panitumumab with FOLFOX
p. Panitumumab as a single agent
q. Pembrolizumab
r. Any other systemic anti-cancer therapy
s. Palliative care only

Colorectal Cancer.041223.docx

Name of organisation (NHS Trust):
Please list the acute hospital site/s within the Trust:
PLEASE ANSWER THE FOLLOWING QUESTIONS FOR EACH ACUTE HOSPITAL SITE LISTED ABOVE
HOSPITAL AND SERVICES
1. The hospital would be described as a:
District general
Teaching hospital
2. Total number of inpatient beds at this hospital:
3. Does the hospital provide colorectal cancer services
4. Is the hospital a specialist colorectal cancer care centre
5. How many dietitians are employed in the hospital (please answer in FTE units):
6. How many dietitians are commissioned to provide dietetic services in each cancer type (please answer in FTE units. Where no time is commissioned, please enter 0):
7. a. Is there any band 5, general dietetic cover for colorectal cancer care
b. If yes, how many dietitians are commissioned (please answer in FTE units):
8. If there is dietetic time commissioned for colorectal cancer care at the hospital, does this include outpatient or community follow up after discharge?
9. If dietetic time is commissioned for colorectal cancer care, where does the funding come from?

Download response Colorectal Cancer. 280520

1. Within your health trust how many patients have been treated in the past 6 months for head and neck cancer (Squamous cell carcinoma)?
2. Of these patients how many are locally advanced, recurrent, metastatic and unresectable head and neck cancer patients?
Locally advanced
Recurrent
Metastatic
Unresectable
Unknown
3. Within your health trust how many patients have been treated in the past 6 months for head and neck cancer (Squamous cell carcinoma) with the following agents?
Carboplatin (only or in combination with 5-FU)
Cisplatin (only or in combination with 5-FU)
Cetuximab with/without chemotherapy
Cetuximab with radiotherapy
Pembrolizumab monotherapy
Pembrolizumab with chemotherapy
Nivolumab
Docetaxel (only or in combination with 5-FU)
Fluorouracil (5FU)
Radiotherapy only
Other
4. Does your health trust participate in any ongoing clinical trials for the treatment of head and neck cancer patients, if so how many patients are currently taking part in clinical trials / what is the name/s of the trials?
5. Within your health trust how many patients have been treated in the past 6 months with the following agent for colorectal cancer [CRC];
Aflibercept
Bevacizumab
Capecitabine
CAPIRI
CAPOX
Cetuximab not in combination with FOLFIRI or FOLFOX
Cetuximab in combination with FOLFIRI
Cetuximab in combination with FOLFOX
Irinotecan
FOLFIRI
FOLFOX
Oxaliplatin
Panitumumab not in combination with FOLFIRI or FOLFOX
Panitumumab in combination with FOLFIRI
Panitumumab in combination with FOLFOX
Nivolumab
Raltitrexed
Ramucirumab
Regorafenib
Sorafenib
5FU only
Tegafur Uracil + 5FU
Trifluridine–tipiracil
XELOX
Other
6. Within your health trust how many patients have been treated in the past 6 months with the following agent for Renal Cell Carcinoma :
Sunitinib
Avelumab + Axitinib
Axinitib
Cabozantinib
Everolimus
Lenvantinib + Everolimus
Nivolumab
Nivolumab + Ipilimumab
Pazopanib
Pembrolizumab + Axitinib
Sunitinib
Temsirolimus
Tivozanib
7. Does your health trust participate in any ongoing clinical trials for the treatment of renal cell cancer patients, if so how many patients are currently taking part in clinical trials / what is the name/s of the trials?

Download response Colorectal cancer [CRC]. 091220

Q1. Within your health trust, how many patients have been treated in the past 3 months with the following agents for colorectal cancer [CRC]?
a. Aflibercept
b. Bevacizumab
c. Capecitabine
d. CAPIRI
e. CAPOX (XELOX)
f. Cetuximab in combination with FOLFIRI
g. Cetuximab in combination with FOLFOX
h. Cetuximab not in combination with FOLFIRI or FOLFOX
i. Irinotecan only
j. FOLFIRI
k. FOLFOX
l. Fluorouracil (5FU) only
m. Oxaliplatin only
n. Panitumumab in combination with FOLFIRI
o. Panitumumab in combination with FOLFOX
p. Panitumumab not in combination with FOLFIRI or FOLFOX
q. Pembrolizumab
r. Nivolumab
s. Raltitrexed
t. Ramucirumab
u. Regorafenib
v. Sorafenib
w. Other SACT
Q2. In the last 3 months, how many patients has your trust treated (for any condition) with the following treatments
a. Avatrombopag
b. Eltrombopag
c. Fostamatinib
d. Romiplostim
Q3. In the last 3 months, how many patients has your trust treated for Immune thrombocytopenia (ICD10 code D69.3)?
Q4. In the last 3 months, how many patients has your trust treated for Immune thrombocytopenia (ICD10 code D69.3) ONLY with the following treatments:
a. Avatrombopag
b. Mycophenolate mofetil
c. Rituximab
d. Surgery (splenectomy)

Colorectal cancer [CRC].160922.docx

All questions are shown as received by the Trust.
In the past 3 months, how many patients have been treated for Colorectal Cancer [CRC] with the following regimens? If possible, please also provide the split of metastatic vs non-metastatic patients for each regimen.
Regimens
Capecitabine
CAPIRI
CAPOX
Cetuximab with FOLFIRI
Cetuximab with FOLFOX
Cetuximab as a single agent
Cetuximab with Encorafenib
Irinotecan as a single agent
FOLFIRI
FOLFOX
Fluorouracil (5FU) as a single agent
Oxaliplatin as a single agent
Nivolumab with Ipilimumab
Panitumumab with FOLFIRI
Panitumumab with FOLFOX
Panitumumab as a single agent
Pembrolizumab
Any other systemic anti-cancer therapy
Palliative care only

Colorectal Cancer [CRC].180324.docx

I was wondering if you’d be able to share with me a copy of the letter and information leaflet that you send out to patients who receive a colposcopy appointment.

Download response Colposcopy appointments. 140421

Please could you provide me with a copy of the business case for the Trust’s Community Diagnostic Centre project, including the capital budget for the entire project.

Community Diagnostic Centre.080922.docx

I am writing to obtain information, under the Freedom of Information Act, about your Trust’s funding of Complementary and Alternative Medicine (CAM) services they provided.
To outline my query as clearly as possible, I am requesting:
1. How much the Trust has spent on CAM services for the following financial years:
a. 2019-20
b. 2020-21
c. 2021-22
This includes salaries for those employed to carry out these services, costs of medicine, equipment and any additional costs involved.
2. A list of all services provided under CAM.

Complementary and Alternative Medicine (CAM) services.101022.docx

1. What percentage of consultations were carried out in April 2021 via:
a. Phone
b. Video
c. Face-to-face
2. Did you carry out any patient satisfaction survey on each of the channels in April 2021:
a. Phone
b. Video
c. Face-to-Face
3. Did you introduce digital services (either as new services or expanding into new departments) as a response to the pandemic?
Yes (highlight below):
a. Telephone consultations
b. Video consultations
c. Online appointment booking/management
d. E-prescription services
4. Who are your suppliers for:
a. Telephone consultations
b. Video consultations
c. Online appointment booking/management
d. E-prescription services
5. What are the most common barriers to technology use within your trust?
a. The service requires face-to-face interactions
b. The staff member is unable to use the technology
c. The patient is unable to use the technology
d. Lack of funding
e. Other (please explain)
6. Are you collecting patient feedback following interactions with the digital services you offer?
a. Yes – feedback obtained for all services
b. Feedback obtained for some services:
c. Telephone consultations
d. Video consultations
e. Online appointment booking/management
f. E-prescription services
g. No – we are not collecting this feedback
h. If no – do you plan to introduce this feedback data collection in the next six months? yes/no
i. If yes, how do you collect feedback?
7. Did you stop your FFT during the pandemic when the requirement to submit data was paused?
a. If yes, why?
b. If no, why?
8. Will you be deploying PIFU?
9. Will you be collecting feedback on PIFU?
10. Who is your FFT supplier?
11. If the FFT contract is outsourced, when was the contract initiated?
12. When does the FFT contract with your current supplier end?
13. What is the expected value of this contract (£)?

Download response Consultations. 240521

1) How many Coronary CT angiography scans were performed in the trust in the financial year 2011-12?
2) How many Coronary CT angiography scans were performed in the trust in the financial year 2012-13?
3) How many Coronary CT angiography scans were performed in the trust in the financial year 2013-14?
4) How many Coronary CT angiography scans were performed in the trust in the financial year 2014-15?
5) How many Coronary CT angiography scans were performed in the trust in the financial year 2015-16?

Download response Coronary CT angiography scans. 270918

All questions are shown as received by the Trust.
I kindly request that you provide the number of CT and MRI machines, categorised based on ownership (owned or rented) for the years 2019, 2020, 2021, 2022, and 2023, along with details regarding the age of the owned machinery for the year 2023 only.

CT and MRI machines.310124.docx

1) How many of each of the following machines do you have in use:
i) CT
ii) MRI
iii) X-ray
2) How many of each of the following machines are you using that are older than ten years old:
i) CT
ii) MRI
iii) X-ray
3) How old is your oldest in-use machine for each of:
i) CT
ii) MRI
iii) X-ray
4) How many of each of the following machines have you purchased in the past year:
i) CT
ii) MRI
iii) X-ray
5) How much did you spend repairing CT, MRI and X-ray machines in each of the past three years?

CT and MRI machines.311022.docx

1) The number of CT scanners in your Trust, where relevant please provide a number for each hospital.
2) The number of MRI scanners in your Trust, where relevant please provide a number for each hospital.
3) The number of ultrasound scanners in your Trust, where relevant please provide a number for each hospital.
4) The number of x-ray machines in your Trust, where relevant please provide a number for each hospital.
5) For each of the items 1-4, please also provide the number of machines that are more than 10 years old and if available the year that the machine was purchased.

Download response CT, MRI and Ultrasound Scanners and X-Ray machines. 170921.docx

Tab 1:
MES Contract
1. Supplier
2. Contract Start Date
3. Contract End Date
4. Initial Cost
5. Interest rates (%)
6. Consumables included?
7. Accessories included?
8. Maintenance included?
Tab 2:
Clinical Imaging Asset Details
1. Local Identifier
2. Modality
3. Equipment detail
4. Asset name
5. Manufacturer
6. Age
7. First in Service
8. Planned replacement date
9. Replacement schedule
10. Ownership structure
11. How is the ownership accounted for?
12. Capital purchase cost
13. Maintenance type (drop-down list)
14. Maintenance provider
15. Maintenance Service Contract Start Date
16. Maintenance Service Contract End Date
17. Maintenance Cost
Tab 3:
Clinical Imaging Accessories
1. Local Identifier
2. Modality
3. Equipment detail
4. Asset name
5. Manufacturer
6. Age
7. First in Service
8. Planned replacement date
9. Replacement schedule
10. Ownership structure
11. How is the ownership accounted for?
12. Capital purchase cost
13. Maintenance type (drop-down list)
14. Maintenance provider
15. Maintenance Service Contract Start Date
16. Maintenance Service Contract End Date
17. Maintenance Cost

CT, MRI, Nuclear Medicine and Ultrasound clinical imaging equipment.130324.docx

We are looking to produce a map of the CTCL (cutaneous T cell lymphoma) treatment centres in the UK.
To help with this, please could you provide the following:
1. Which centre/s in your NHS Trust offer treatment for CTCL, if any
2. The type of CTCL treatment these centres offer (TSEB or ECP)
3. A contact phone number for referrals for each centre

CTCL (cutaneous T cell lymphoma) treatment centres. 110322.docx

1. How many patients with cutaneous squamous cell carcinoma have you treated?
2. How many adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma have you treated?
3. Of these how many are not candidates for curative surgery or curative radiation?
4. In the past 3 months, how many adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation have you treated with the following;
Libtayo (cemiplimab)
Non curative surgery only
Non curative surgery + chemotherapy*
Non curative surgery + radiotherapy
Non curative surgery + chemotherapy* + radiotherapy
Chemotherapy* only
Chemotherapy* + radiotherapy
Non curative radiotherapy only
No treatment
Palliative Care / Best Supportive care
Other [please state]
*chemotherapy such as cisplatin, doxorubicin, 5-fluorouracil (5-FU), capecitabine, topotecan, or etoposide
5. Does your trust treat adult multiple myeloma [MM]? – if you refer your multiple myeloma patients to another centre, please state which.
6. If yes, then how many multiple myeloma patients, have been treated in the past 6 months with the following;
Bortezomib [Velcade]
Carfilzomib [Kyprolis]
Ixazomib [Ninlaro]
Lenalidomide [Revlimid]
Daratumumab [Darzalex]
Melphalan, prednisolone and thalidomide (known as MPT)
Cyclophosphamide, thalidomide and dexamethasone (known as CTD)
Pomalidomide [Imnovid]
7. Over the past 6 months [latest possible], how many chronic lymphocytic leukaemia (CLL) patients have you treated?
If possible how many CLL patients treated were new to therapy in the past 3 months?
8 How many chronic lymphocytic leukaemia patients, have been treated in the past 6 months with the following;
Fludarabine (Fludara), cyclophosphamide (Cytoxan), and rituximab (known as FCR)
Bendamustine and rituximab (known as BR)
Ibrutinib [Imbruvica]
Chlorambucil
Venetoclax
Obinutuzumab
Idelalisib
Fludarabine and rituximab (known as FR)
High-dose prednisone and rituximab
Pentostatin (Nipent), cyclophosphamide, and rituximab (known as PCR)
Alemtuzumab (Campath) with rituximab

Download response Cutaneous Squamous Cell Carcinoma. 270220

Question 1 – How many adult patients with Cutaneous Squamous Cell Carcinoma have you seen / treated (example Surgery, Radiotherapy, Chemotherapy or combinations of these) in the last 6 months?
Question 2 – How many adult patients with locally advanced (patients with Perineural invasion and local Lymphovascular or Bone involvement) or Metastatic Cutaneous Squamous Cell Carcinoma (patients with both local and distant Nodal involvement, as well as any other organ involvement) have you seen / treated (example Surgery, Radiotherapy, Chemotherapy or combinations of these) in the last 6 months?
Question 3 – Of these how many are not candidates for Curative surgery or Curative Radiation? *
Question 4 – In the past 6 months, how many adult patients with locally advanced or metastatic Cutaneous Squamous Cell Carcinoma have you treated with the following:
Question 5 – Are you participating in any clinical trials for Cutaneous Squamous Cell Carcinoma (CSCC)?
If yes, please state which?
*Example of factors to consider when deciding if locally advanced patients are suitable candidates for surgery: Disease recurrence after two or more surgical procedures and the treating clinicians expected that curative resection would be unlikely
CSCC in a anatomically challenging location where surgery would result in substantial complications or deformity or dysfunction significant local invasion that precludes complete resection
* Example of factors to consider when deciding if locally advanced patients are suitable candidates for radiation:
CSCC in a anatomically challenging location where radiation would be associated with unacceptable toxicity risk in context of the patients overall condition
Clinical judgement that tumour might not respond to RT
Factors / conditions contradicting for RT
Prior treatment with RT for CSCC, and further RT would exceed the threshold of acceptable cumulative does
** Chemotherapy such as Cisplatin, Doxorubicin, 5-Fluorouracil (5-FU), Capecitabine, Topotecan, Methotrexate or Etoposide

Download response Cutaneous Squamous Cell Carcinoma. 271119

1. The number of da Vinci surgical robots in use throughout your trust and the number of each model (e.g. Si, X, Xi, SP)
2. The number of yearly procedures carried out using da Vinci systems with a breakdown by procedure type for the last 5 years
3. A breakdown of the cost per procedure using da Vinci systems including instrumentation, servicing, disposable accessories, sterilisation costs, depreciation and other costs incurred
4. The upfront cost of da Vinci system instruments per surgery or on a per instrument basis
5. Historical number/rate of occurrence of incidences where cross infection has resulted from improper sterilisation and the number of associated adverse events
6. The rate of surgical site infections associated with procedures where a da Vinci system has been used.

Download response Da vinchi surgical robots. 100419

Please answer these questions relating to the usage of Dabrafenib + Trametinib in cancer treatment.
A) Over the previous 6 months, how many patients for the following diseases have been treated with a combination of Dabrafenib + Trametinib:
i) Metastatic Melanoma
ii) Adjuvant Melanoma
iii) BRAF mutated Lung Cancer

Dabrafenib + Trametinib.050722.docx

A) Over the previous 6 months, how many patients for the following diseases have been treated with a combination of Dabrafenib + Trametinib:
i) Metastatic Melanoma
ii) Adjuvant Melanoma
iii) BRAF mutated Lung Cancer

Dabrafenib + Trametinib.110423.docx

Please can you answer the following questions regarding the Dental X-Ray equipment used within the Trust?
1. Please can you provide the following information for each piece of Dental X-Ray equipment within the Trust or associated sites? (Please complete the attached spreadsheet)
a. Manufacturer
b. Model
c. Location – Hospital Name or Site Name
d. Department equipment is primarily used in
e. Method of Finance at Procurement (Trust/Lease/MES/Charity/PFI)
f. Initial cost of Equipment
g. Annual Maintenance cost
h. Acquisition Date
i. Planned Replacement Date

2. Please can you provide the following information for each Cone Beam CT Imaging equipment within the Trust or associated sites? (Please complete the attached spreadsheet)
a. Manufacturer
b. Model
c. Location – Hospital Name or Site Name
d. Department equipment is primarily used in
e. Method of Finance at Procurement (Trust/Lease/MES/Charity/PFI)
f. Initial cost of Equipment
g. Annual Maintenance cost
h. Acquisition Date
i. Planned Replacement Date

Download response Dental X-Ray equipment. 210519

Please could you provide the figures for diagnoses of cancer within your hospital from January 2010 to date.
Please could you present these figures in a yearly format.

Diagnoses of cancer. 020822.docx

All questions are shown as received by the Trust.
1. How much has your trust spent on new diagnostic equipment in each of the past three financial years, e.g. x ray machines, CT scanners, MRIs etc?
2. How much has your trust spent on maintaining and repairing old equipment in the past three financial years?
3. How many diagnostic machines did you purchase in the last financial year?

Diagnostic equipment spend.251023.docx

Q1. Does your trust treat patients with Diffuse Large B Cell Lymphoma (DLBCL)? If not, then which trust do you refer DLBCL patients to?
Q2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL)?
Q3. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:
a. R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)
b. R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)
c. Other immuno-chemotherapy
d. Other chemotherapy
e. Stem cell transplant or bone marrow transplant (autologous or allogeneic)
f. Pola-BR (polatuzumab vedotin with rituximab and bendamustine) – any line of treatment
g. Pola-BR (polatuzumab vedotin with rituximab and bendamustine) – third-line treatment only
h. Tisagenlecleucel
i. Axicabtegene ciloleucel
j. Lisocabtagene maraleucel
Q4. In the last 6 months, how many Diffuse Large B Cell Lymphoma (DLBCL) patients have you referred to other trusts for:
a. Stem cell transplant or bone marrow transplant (autologous or allogeneic)
b. CAR-T therapy (Tisagenlecleucel, Axicabtegene ciloleucel, Lisocabtagene maraleucel)
Q5. Do you participate in any active clinical trials for Diffuse Large B-Cell Lymphoma (DLBCL)? If so, can you please provide the name of each trial along with the number of patients taking part?

Diffuse Large B Cell Lymphoma (DLBCL).270722.docx

Infrastructure:
1) Do you outsource your DXA scans? If Yes- please state the organisation providing this service and forward this FOI to your provider for completion (please continue to complete for any of the elements of the DXA pathway that are provided by your Trust/board)
2) In January 2023 how many DXA scanning machines did you have at your trust/board for clinical use?
a. n. Operational
b. n. not in use
c. n. accessible outside of Trust
3) What is the average weekly capacity for clinical scans? (N. of scans per week)
4) What was your average DNA rate over the last 3 months? (n. DNA/total n. scans booked)
5) What age range do you include in your clinical scans? Please tick all that apply
a. <20 years b. 20-40 years c. 40-60 years d. 60-75 years e. 75-80 years f. >80 years
6) What is the duration of your routine DXA appointment:
a. 15 minutes or less
b. 16-25 minutes
c. 26-30 minutes
d. >30 minutes
7) What was the average wait for clinical patients from referral to scan in January 2023?
a. <2 weeks (move to Q9) b. 2-6 weeks (move to Q9) c. 6-13 weeks d. >13 weeks
8) What are your perceived barriers to delivering DXA scans within 6 weeks from referral? Please tick all that apply
a. Scanner capacity (DXA equipment)
b. Clinical capacity (operator)
c. Other- please state
9) What was the average time from the scan to the report being available to the referrer in January 2023?
a. <3 weeks (move to Q11) b. 4-6 week c. 6-13 weeks d. >13 weeks
10) What are your perceived barriers to referrers receiving DXA scan reports within 3 weeks from scan? Please tick all that apply
a. Clerical- internal
b. Clinical- internal
c. Factors external to this service (please state)
d. Other (please state)
11) What hospital department is responsible for delivery of DXA scans:
a. Radiology
b. Medical physics
c. Nuclear medicine
d. Rheumatology
e. Other- please state
12) Which DXA examinations are included in routine protocols for the clinical service? Please tick all that apply
a. Lumbar spine
b. Proximal femur
c. Long femur (AFF assessment)
d. Total body
e. Vertebral fracture assessment (VFA)
f. Peripheral/forearm
13) What access facilities do you have available? Please tick all that apply
a. Overhead hoist
b. Portable hoist
c. Wheelchair transfers
d. Bed/trolley transfers
e. Changing room
f. Assistance for transfers
g. Other- please state
Workforce:
1)
i) What professional groups perform DXA scan measurements at your centre? (DXA operators)
a. Radiographer
b. DXA technician
c. Assistant practitioner
d. Clinical scientist
e. Nurse
f. Medical Dr- please state specialism
g. Other- please state
h. Unknown]
ii) Please indicate WTE for each group selected
2) What DXA-specific training (outside of professional training) have the DXA operators performing scans had?
a. In house
b. Manufacturers applications training
c. Recognized/accredited national training programme (please state the name of the training programme/provider)
d. Other- please state
e. Unknown
3) What professional groups report your DXA scans at your centre? ()
a. Radiographer – internal
b. Radiographer – external
c. DXA technician – internal
d. DXA technician – external
e. Assistant practitioner – internal
f. Assistant practitioner – external
g. Clinical scientist – internal
h. Clinical scientist – external
i. Nurse -internal
j. Nurse – external
k. Medical Dr – internal – please state specialism(s)
l. Medical Dr – external – please state specialism(s)
m. Other- please state
n. Reporting is outsourced
o. Unknown
4) What training (outside of professional training) have those reporting DXA scans had- specifically in DXA reporting?
a. In house
b. Manufacturers applications training
c. Recognized/accredited national training programme (please state the name of the training programme/provider)
d. Other- please state
e. Unknown
5) What professional group provides clinical leadership for your service?
a. Radiographer
b. DXA technician
c. Assistant practitioner
d. Clinical scientist
e. Nurse
f. Medical Dr- please state specialism(s)
g. Other- please state
h. Unknown
6) Please indicate how many (WTE) clinical vacancies in your DXA service do you have in January 2023? (Free text)
Quality:
1) Is your service accredited as part of a national programme?
a. ISAS
b. IOS
c. Other- please state
d. None
e. Unknown
2) What clinical audits do you routinely undertake? Please tick all that apply
a. DXA scan technique
b. Reporting (double reporting)
c. Reporting (clinical review)
d. Scanner QA review
e. Other- please state
f. Unknown
3) What IR(ME)R audits do you routinely undertake? Please tick all that apply
a. Patient pregnancy
b. DXA dose audit
c. Referrer entitlement
d. Scan justification
e. Other- please state
f. Unknown
4) What clinical protocols do you have in place? Please tick all that apply
a. Scan site
b. Scan mode
c. Reference data selection
d. Patient positioning
e. Scan analysis
f. Interpretation- T&Z-scores
g. Reporting
h. Other- please state
i. Unknown
5) Which of the following are routinely included in the DXA report issued to the PRIMARY CARE referrer? Please tick all that apply
A. Admin. details
i. Date of assessment
ii. Patient ID and demographics
iii. Reason for referral
iv. Reporter’s ID
B. BMD results for each measurement site
i. T score (after peak bone mass)
ii. Z score
iii. Rate of change for serial measurements
C. Comment on reliability of measurements
i. BMD results
ii. Documentation of excluded measurements eg. vertebrae
iii. Statistical significance of rate of change
iv. Clinical significance of rate of change
D. WHO diagnostic category (for adults after peak bone mass)
E. Results of additional investigations performed at DXA appointment
i. VFA
ii. X-ray or other imaging
iii. Laboratory tests
F. Summary of clinical risk factors for fracture
G. Summary of fracture history
H. Clinical interpretation to quantify absolute fracture risk
i. FRAX+BMD
ii. FRAX + TBS
iii. FRAX+BMD plus comment on additional adjustment
iv. Statement on level of risk based on clinical judgement (eg. low/moderate/high)
I. Management advice
i. Reference to national guideline (NICE/NOGG/ROS)
ii. Reference to local management guideline
iii. Individualised advice
J. Recommendations on:
i. Need for onward referral eg. falls assessment or additional investigation
ii. Timing of future scan
6) Which of the following are routinely included in the DXA report issued to the SECONDARY CARE referrer? Please tick all that apply
A. Admin. details
i. Date of assessment
ii. Patient ID and demographics
iii. Reason for referral
iv. Reporter’s ID
B. BMD results for each measurement site
i. T score (after peak bone mass)
ii. Z score
iii. Rate of change for serial measurements
C. Comment on reliability of measurements
i. BMD results
ii. Documentation of excluded measurements eg. vertebrae
iii. Statistical significance of rate of change
iv. Clinical significance of rate of change
D. WHO diagnostic category (for adults after peak bone mass)
E. Results of additional investigations performed at DXA appointment
i. VFA
ii. X-ray or other imaging
iii. Laboratory tests
F. Summary of clinical risk factors for fracture
G. Summary of fracture history
H. Clinical interpretation to quantify absolute fracture risk
i. FRAX+BMD
ii. FRAX + TBS
iii. FRAX+BMD plus comment on additional adjustment
iv. Statement on level of risk based on clinical judgement (eg. low/moderate/high)
I. Management advice
i. Reference to national guideline
ii. Reference to local management guideline
iii. Individualised advice
J. Recommendations on:
i. Need for onward referral eg. falls assessment or additional investigation
ii. Timing of future scan
K. The secondary care report is the same as the primary care report

DXA Facilities Audit.020323.docx

Q1. I am researching the usage of Pembrolizumab for the treatment of Melanoma. How many patients have you treated with Pembrolizumab in the three months from October to December 2022 for:
a. Melanoma – any stage
b. Melanoma – Stage IIb/IIc
c. Melanoma – Stage III
d. Melanoma – Metastatic
Q2. How many Stage IIb/IIc melanoma patients were on a “Watch and Wait” strategy in the three months from October to December 2022? These would be patients where a decision has been made to wait before commencing any treatment.

Early Melanoma.020323.docx

Information request in respect to Elastomeric Infusion Devices

Please could you kindly advise which departments and healthcare professionals within your Trust use elastomeric infusion devices?

Information request in respect of Elastomeric Infusion Devices

1. Please could you also advise if you purchase E.I.D and if so:
a. What brand(s) do you purchase?
b. What quantities do you purchase on an annual basis?
c. Who are the main clinicians responsible within your Trust for the prescribing and administration of elastomeric devices?
d. What medicines do you fill the devices with?
e. Do you fill elastomeric devices in your pharmacy aseptic unit if you have one?
2. Please could you also advise if you purchase pre-filled elastomeric devices from a commercial compounder and if so:
a. What drugs are provided pre-filled?
b. What quantities do you purchase on an annual basis?

Download response Elastomeric Infusion Devices (E.I.D) 020320

All questions are shown as received by the Trust.
1. Which hospitals in your Trust open elective theatres at the weekend? (please list the name of the hospital followed by a Y/N as to whether elective theatres are open at the weekend)
2. How many of the following scans has your Trust carried out in the last year, broken down by daily activity?
a. CT Scans
b. MRI Scans
c. X Rays

Elective theatres and scans.300124.docx

1. Does your trust provide SACT (systemic anti-cancer therapy) treatments for endometrial cancer? If not, which other trust do you refer endometrial cancer patients to for SACT treatments?
2. How many patients were treated for endometrial cancer in the past 6 months with the following treatments:
a. Dostarlimab
b. Hormone therapy (Progesterone or Letrozole)
c. Pembrolizumab monotherapy
d. Pembrolizumab in combination with Lenvatinib
e. Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)
f. Any other SACT
3. How many endometrial cancer patients received the following therapies as 1st Line treatment in the past 6 months:
a. Hormone therapy (Progesterone or Letrozole)
b. Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)
c. Any other SACT
4. Of the patients treated for endometrial cancer in the past 6 months with any SACT regimen, how many patients had high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR)?
5. Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part.

Endometrial Cancer.020623.docx

1. Please state what software/ systems the Trust utilises for managing medical equipment/ devices in order to be compliant with MHRA Guidance (see URL below) from the list below. If not listed, please specify:
a. EMAT
b. F2
c. RAM
d. e-Quip
e. Other – please specify
2. Please state the name and contact for the person responsible for ensuring compliance with the MHRA guidance quoted above.

Ensuring MHRA Compliance.190422.docx

Could you please tell me, do you have such services as ‘Flushing and locking of intravenous catheters’ in your clinic?

Flushing and locking of intravenous catheters.010722.docx

1. Fundus Camera
a. How many devices do you have and which model?
b. When were these devices installed?
c. When are these due to be replaced?
d. Is there a replacement budget allocated?
e. Do you have a service contract? When does it expire?
2. Optical Biometer
a. How many devices do you have and which model?
b. When were these devices installed?
c. When are these due to be replaced?
d. Is there a replacement budget allocated?
e. Do you have a service contract? When does it expire?
3. Capsular Tension Ring
a. Which Brand do you use?
b. How many did you use in 2019?

Download response Fundus and Optical Biometer. 220421

1 The manufacturer & model name of each gamma camera (Nuclear Medicine imaging system) installed in your Trust
2 The hospital name where each system is installed
3 The date that the current service/maintenance contract on each gamma camera started
4 The date that the current service/maintenance contract on each gamma camera expires

Gamma camera (Nuclear Medicine imaging system). 080422.docx

Q1. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:
a. CAPOX (Capecitabine with Oxaliplatin)
b. FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)
c. Lonsurf (Trifluridine – tipiracil)
d. Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
e. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
f. Any other systemic anti-cancer therapy
g. Palliative care only
Q2. How many patients were treated in the past 3 months for Oesophageal cancer (any stage) with:
a. Nivolumab monotherapy or combination with Ipilimumab
b. Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)
c. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)
d. Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)
e. Any other systemic anti-cancer therapy
f. Palliative care only
Q3. How many patients were treated in the past 3 months for ovarian cancer (any stage) with:
a. Paclitaxel in combination with a platinum-based compound
b. Platinum-based therapy alone (cisplatin or carboplatin)
c. Bevacizumab in combination with paclitaxel and carboplatin
d. Olaparib
e. Olaparib + Bevacizumab
f. Niraparib
g. Rucaparib
Q4. If data for HRD (homologous recombination deficiency) testing is available, please provide how many HRD positive ovarian cancer patients were treated in the last 3 months with:
a. Olaparib
b. Olaparib + Bevacizumab
c. Niraparib
d. Other treatments
Q5. Does your trust participate in any clinical trials for the treatment of ovarian cancer? If so, please provide the name of each trial along with the number of patients taking part.

Gastric Oesophageal cancer and Ovarian cancer.161123.docx

1. How many general anaesthetics were administered by your NHS Trust in 2018, 2017, 2016 and 2015?
2. How many patients died as a result of general anaesthesia in 2018, 2017, 2016 and 2015?
3. How many patients were given a general anaesthetic for the purpose of carrying out a diagnostic scan/test (MRI, CT etc.) in 2018, 2017, 2016 and 2015?
4. How many patients died as a result of being given a general anaesthetic for the purpose of carrying out a diagnostic scan/test (MRI, CT etc.) in 2018, 2017, 2016 and 2015?
5. How many patients were given a general anaesthetic for the purpose of carrying out an MRI scan in 2018, 2017, 2016 and 2015?
6. How many patients died as a result of being given a general anaesthetic for the purpose of carrying out an MRI scan in 2018, 2017, 2016 and 2015?
7. How many patients were given any other form of sedation for the purpose of carrying out a diagnostic scan/test (MRI, CT etc.) in 2018, 2017, 2016 and 2015?
8. How many patients were given any other form of sedation for the purpose of carrying out an MRI scan in 2018, 2017, 2016 and 2015?
9. How many diagnostic scans/tests (MRI, CT etc.) were aborted at your NHS Trust in 2018, 2017, 2016 and 2015 as a result of patients failing to attend the appointment or the process being stopped mid-way.
10. How many MRI scans were aborted at your NHS Trust in 2018, 2017, 2016 and 2015 as a result of patients failing to attend the appointment or the process being stopped mid-way.

Download response General Anaesthetics. 180319

1. Please can you tell me if the Trust sends NHS Patients to GenesisCare for Cancer treatment?
2. Does the Trust send private patients to GenesisCare for cancer treatment?
3. How many Maidstone & Tunbridge Wells NHS Trust patients were treated by GenesisCare in 2018 and 2019? Please break the numbers down into NHS and private.
4. How long is the Trusts contract with GenesisCare?

Download response Genesiscare. 270919

a. For the period 1st January 2018 to 31st December 2018 (or the most recent 12 month period available), the number of patients diagnosed with genetic haemochromatosis (GH) under your care.
b. For the period 1st January 2018 to 31st December 2018 (or the most recent 12 month period available), the average time in days from first referral from primary care to the patient’s first appointment within your trust.
c. A copy of the protocol and/or patient pathway applicable to the care of people with genetic haemochromatosis.
d. The date that your protocol/patient pathway for genetic haemochromatosis was last reviewed or revised.
e. A copy of your clinical protocol(s) for therapeutic venesection.
f. The date that your protocol(s) for therapeutic venesection were last reviewed or revised.

Download response Genetic Haemochromatosis. 190320

I am researching the use of certain types of drugs used in haematology. Could you please provide the number of patients treated (for any disease in the past 3 months with:
1. Aragam
2. Berinert
3. Cinryze
4. Cutaquig
5. Cuvitru
6. Firazyr
7. Flebogamma DIF
8. Gammagard
9. Gammanorm
10. Gammaplex
11. Gamunex
12. Hizentra
13. Hyqvia
14. Intratect
15. Iqymune
16. Kiovig
17. Octagam
18. Orladeyo
19. Panzyga
20. Privigen
21. Ruconest
22. Subgam
23. Takhzyro

Haematology.281222.docx

1. Please can you tell me how many of the following two devices – MCS+ 9000 Mobile Platelet Collection System and/or MCS+ 8150 Multicomponent Collection System both from a company called Haemonetics – the trust has used over the last 10 years and how many of these devices are currently in operation.

2. Please provide a figure for each device and each year over the last 10 years. If possible, please also state how many patients have had this device used on them.

Download response Haemonetics. 311019

Please can you tell me how many deaths have been reviewed by the trust or reported to a coroner in the past 10 calendar years where the hospital used a Haemonetics plasma device (any model number) on the patient before they died.

Where the death was investigated please can you send me the report (redacted to remove personal details if necessary) and include the age, gender and diagnosis of the patient. If the death was reported to the coroner please include a copy of their report.

Download response Haemonetics plasma device. 220120

1. How many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the following agents:
a. Carboplatin (monotherapy or in combination with 5-FU)
b. Cisplatin (monotherapy or in combination with 5-FU)
c. Cetuximab with/without chemotherapy
d. Cetuximab with radiotherapy
e. Pembrolizumab monotherapy
f. Pembrolizumab with chemotherapy
g. Nivolumab
h. Docetaxel (monotherapy or in combination with 5-FU)
i. Fluorouracil (5FU)
j. Radiotherapy only
k. Other
2. For the patients treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the therapies listed in the first question, please provide:
a. Total number of head and neck cancer patients
b. Number of locally advanced head and neck cancer patients
c. Number of unresectable recurrent and/or metastatic head and neck cancer patients
3. How many Urothelial cancer patients have been treated in the past 3 months with the following agents:
a. Avelumab
b. Atezolizumab
c. Carboplatin with Gemcitabine
d. Carboplatin single or in any other combination
e. Cisplatin with Gemcitabine
f. Cisplatin single or in any other combination
g. Nivolumab
h. Pembrolizumab
i. Any other regimen including Paclitaxel
j. Any other chemotherapy regimen
k. Other active systemic anti-cancer therapy [please state]
l. Palliative care only
4. Does your trust participate in any ongoing clinical trials for the treatment of head and neck cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

Head and neck and urothelial cancer.030822.docx

1. Within your health trust, how many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma)? Of these patients, how many are locally advanced, recurrent and/or metastatic?
a. Total squamous cell carcinoma
b. Locally advanced
c. Recurrent and/or metastatic
2. For the metastatic head and neck cancer patients treated in the past 3 months, could you specify (if possible) how many received first-line treatment versus second-line treatment?
3. Within your health trust, how many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the following agents?
a. Carboplatin (monotherapy or in combination with 5-FU)
b. Cisplatin (monotherapy or in combination with 5-FU)
c. Cetuximab with/without chemotherapy
d. Cetuximab with radiotherapy
e. Pembrolizumab monotherapy
f. Pembrolizumab with chemotherapy
g. Nivolumab
h. Docetaxel (monotherapy or in combination with 5-FU)
i. Fluorouracil (5FU)
j. Radiotherapy only
k. Other
4. Within your health trust, how many patients have been treated in the past 3 months with the following agents for renal cell carcinoma:
a. Sunitinib
b. Avelumab + Axitinib
c. Axinitib
d. Cabozantinib
e. Everolimus
f. Lenvantinib + Everolimus
g. Nivolumab
h. Nivolumab + Ipilimumab
i. Pazopanib
j. Pembrolizumab + Axitinib
k. Sunitinib
l. Temsirolimus
m. Tivozanib
n. Other
5. Does your trust participate in any ongoing clinical trials for the treatment of head and neck cancer? If so, can you please provide the name of each trial along with the number of patients taking part?
6. Does your trust participate in any ongoing clinical trials for the treatment of renal cell carcinoma? If so, can you please provide the name of each trial along with the number of patients taking part?

Download response Head and neck cancer (squamous cell carcinoma). 301120

1. How many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the following agents:
a. Carboplatin (monotherapy or in combination with 5-FU)
b. Cisplatin (monotherapy or in combination with 5-FU)
c. Cetuximab with/without chemotherapy
d. Cetuximab with radiotherapy
e. Pembrolizumab monotherapy
f. Pembrolizumab with chemotherapy
g. Nivolumab
h. Docetaxel (monotherapy or in combination with 5-FU)
i. Fluorouracil (5FU)
j. Radiotherapy only
k. Other
2. For the patients treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the therapies listed in the first question, please provide:
a. Total number of head and neck cancer patients
b. Number of locally advanced head and neck cancer patients
c. Number of recurrent and/or metastatic head and neck cancer patients
3. How many Urothelial cancer patients have been treated in the past 3 months with the following agents:
a. Atezolizumab
b. Carboplatin with Gemcitabine
c. Carboplatin single or in any other combination
d. Cisplatin with Gemcitabine
e. Cisplatin single or in any other combination
f. Nivolumab
g. Pembrolizumab
h. Any other regimen including Paclitaxel
i. Any other chemotherapy regimen
j. Other active systemic anti-cancer therapy [please state]
k. Palliative care only
4. Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

Head and Neck cancer (squamous cell carcinoma) and Urothelial cancer. 140422.docx

1. How many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the following agents:
a. Carboplatin (monotherapy or in combination with 5-FU)
b. Cisplatin (monotherapy or in combination with 5-FU)
c. Cetuximab with/without chemotherapy
d. Cetuximab with radiotherapy
e. Pembrolizumab monotherapy
f. Pembrolizumab with chemotherapy
g. Nivolumab
h. Docetaxel (monotherapy or in combination with 5-FU)
i. Fluorouracil (5FU)
j. Radiotherapy only
k. Other
2. For the patients treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the therapies listed in the first question, please provide:
a. Total number of head and neck cancer patients
b. Number of locally advanced head and neck cancer patients
c. Number of unresectable recurrent and/or metastatic head and neck cancer patients
3. How many Urothelial cancer patients have been treated in the past 3 months with the following agents:
a. Avelumab
b. Atezolizumab
c. Carboplatin with Gemcitabine
d. Carboplatin single or in any other combination
e. Cisplatin with Gemcitabine
f. Cisplatin single or in any other combination
g. Nivolumab
h. Pembrolizumab
i. Any other regimen including Paclitaxel
j. Any other chemotherapy regimen
k. Other active systemic anti-cancer therapy [please state]
l. Palliative care only
4. Does your trust participate in any ongoing clinical trials for the treatment of head and neck cancer? If so, can you please provide the name of each trial along with the number of patients taking part?
5. Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

Head & neck and urothelial cancer.281122.docx

We are researching the incidence and treatment of Head & Neck Cancer (H&N), Renal Cancer (RCC) and Colorectal Cancer (CRC). Could you please answer the following questions for patients treated by your trust?
1. Within your health trust, how many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the following agents?
a. Carboplatin (monotherapy or in combination with 5-FU)
b. Cisplatin (monotherapy or in combination with 5-FU)
c. Cetuximab with/without chemotherapy
d. Cetuximab with radiotherapy
e. Pembrolizumab monotherapy
f. Pembrolizumab with chemotherapy
g. Nivolumab
h. Docetaxel (monotherapy or in combination with 5-FU)
i. Fluorouracil (5FU)
j. Radiotherapy only
k. Other
2. Within your health trust, how many patients have been treated in the past 3 months with the following agents for renal cell carcinoma :
a. Sunitinib
b. Avelumab + Axitinib
c. Axinitib
d. Cabozantinib
e. Everolimus
f. Lenvantinib + Everolimus
g. Nivolumab
h. Nivolumab + Ipilimumab
i. Pazopanib
j. Pembrolizumab + Axitinib
k. Sunitinib
l. Temsirolimus
m. Tivozanib
n. Other
3. Within your health trust, how many patients have been treated in the past 3 months with the following agents for colorectal cancer [CRC]?
a. Aflibercept
b. Bevacizumab
c. Cetuximab monotherapy
d. Cetuximab in combination with FOLFOX or FOLFIRI
e. Panitumumab monotherapy
f. Panitumumab in combination with FOLFOX or FOLFIRI
g. Nivolumab
h. Ramucirumab
i. Regorafenib
j. Sorafenib

Download response Head & Neck Cancer (H&N), Renal Cancer (RCC) and Colorectal Cancer (CRC). 050321

1. Could you detail the quantity of helium that has been purchased each year for the last 5 years?
2. What are the main uses for helium within the Trust?
3. Could you outline the various grades/types of helium purchased?
4. What has the cost of helium been for each of those 5 years?
5. Who are your suppliers of helium and can you provide a copy of the supply contracts?
6. Can you detail your procurement process for obtaining helium and send any tender documents relating to helium?

Helium consumption.271022.docx

All questions are shown as received by the Trust.
1. The number of patients that are currently on the waiting list for this operation at this hospital?
2. What is the average waiting time for the operation from referral to the actual date of the operation.
3. Do the hospitals arrange for NHS patients to undergo this operation at a private hospitals?

HoLEP (Holmium Laser Enucleation of the Prostate) procedure.290524.docx

1. What proportion of emergency department images (x-ray, CT, MRI) were reported within the four-hour target* in December 2018 and December 2019, categorised by each examination?
2. What proportion of inpatient images (x-ray, CT, MRI) were reported within the 24-hour target**, in December 2018 and December 2019, categorised by each examination.
3. How many radiology examinations (CT, MRI, x-ray) did your organisation conduct in 2018, 2019 and the first six months of 2020. Please can you provide the total number for each examination category for each year?
4. Did you have a backlog of unreported radiology examinations (CT, MRI, x-ray) in 2018, 2019 and the first six months of 2020? Please can you provide the average number of unreported images for each examination category for each year?

Download response Imaging. 041120

1. How many CT scanners do you have in your Trust?
2. How many of these CT scanners are over 10 years old?
3. How many MRI scanners do you have in your Trust?
4. How many of these MRI scanners are over 10 years old?
5. Is your Trust a member of an imaging or pathology network/alliance?
6. Has your Trust been working in partnership with a community health setting offering diagnostics services (i.e. a dedicated diagnostic service not part of a Trust or GP practice, such as a community diagnostic hub)?
7. What proportion of your pathology diagnostic equipment is over 10 years old?
8. What are the daily running and ongoing maintenance costs of the cardiorespiratory diagnostic facilities in your Trust?
9. What were the installation costs of the cardiorespiratory diagnostic facilities in your Trust?
10. What proportion of your genomics equipment is over 10 years old?
11. Is your Trust working in collaboration with a genomics laboratory hub?
12. If the answer to (11) was ‘Yes’, what proportion of total genomics diagnostic procedures that your Trust is responsible for are allocated to the genomics hub?

Download response Imaging. 210421 

1. How many CDs does your department produce per annum for the distribution of patient images?*
2. How many CDs does your department produce per annum for interested 3rd parties such as insurance companies or solicitors?*
3. What is the cost of CD production for patient images, e.g. materials for your department per annum?*
4. What are the time/resource costs associated with CD production for patient images for your department per annum?*
5. What are the costs of postage/couriering of CDs of patient images for your department, per annum?*
6. Please provide a breakdown of total costs of CDs for patient images to other hospitals for your department, per annum?*
7. Please provide a breakdown of total costs of CDs to patients for your department, per annum?*
8. Please provide a breakdown of total costs of CDs to interested 3rd parties for your department such as insurance companies or solicitors, per annum?*
9. Are the CDs dispatched from your department that contain patient data consistently encrypted / password protected?*
10. Can you provide information on the number of CDs that are lost or misplaced before they reach the intended recipient?*

*If you use a centralised administration team to administer imaging for your department please include this information to the above questions.
Please provide these answers for the following departments:
• Radiology
• Cardiology
• Medical illustration
• Theatres
• Endoscopy
• Colposcopy
• Diabetic Retinopathy
• Medical Photography
• Dermatology
• Podiatary

Download response Imaging. 270918

1. How many patients are currently awaiting an appointment for imaging studies/scans that have been requested? And how many are awaiting the results of scans that are yet to be assessed?
1a. Please can you specify how many of these are on a cancer pathway.
1b. Please also specify the date your records go up to.
1c. Please can you also provide the data for how many were waiting during the same time period last year.
2. How many two-week wait cancer referrals had to wait longer than 14 days for an appointment in May 2020, May 2019, and May 2018? Please break this down by year and specialty receiving referral.
3. How many more scanners are needed to address the shortfall in imaging capacity?

Download response Imaging and Cancer referrals. 240720

1. Please can you provide the following information for each piece of MRI scanners within the Trust or associated sites? (Please complete the attached spreadsheet)
a. Manufacturer
b. Model
c. Tesla – 0.5 to 1.4, 1.5, 3.0, 3.0 +
d. Location – Hospital Name or Site Name
e. Mobile / Static
f. Department equipment is primarily used in
g. Method of Finance at Procurement – Trust/Lease/MES/Charity/PFI
h. Initial cost of Equipment
i. Annual Maintenance cost
j. Acquisition Date
k. Planned Replacement Date
2. Please can you provide the following information for each CT scanners within the Trust or associated sites? (Please complete the attached spreadsheet)
a. Manufacturer
b. Model
c. Slices – 8, 16, 64, 128, 264
d. Location – Hospital Name or Site Name
e. Mobile / Static
f. Department equipment is primarily used in
g. Method of Finance at Procurement – Trust/Lease/MES/Charity/PFI
h. Initial cost of Equipment
i. Annual Maintenance cost
j. Acquisition Date
k. Planned Replacement Date
3. Please can you provide the following information for each Ultrasound scanner within the Trust or associated sites? (Please complete the attached spreadsheet)
a. Manufacturer
b. Model
c. Location – Hospital Name or Site Name
d. Department equipment is primarily used in
e. Method of Finance at Procurement – Trust/Lease/MES/Charity/PFI
f. Initial cost of Equipment
g. Annual Maintenance cost
h. Acquisition Date
i. Planned Replacement Date

Download response Imaging equipment. 230921.docx

Q1. How many patients has your trust treated (for any disease) in the last 6 months (or the latest 6 months data you have available) with the following treatments:
a. Revolade (eltrombopag)
b. Nplate (romiplostim)
c. Doptelet (avatrombopag)
d. Tavlesse (fostamatinib)
Q2. In the last 6 months (or the latest 6 months data you have available), how many patients has your trust treated for immune thrombocytopenia (ITP)?
Q3. Of the patients treated for immune thrombocytopenia (ITP) in the last 6 months (or the latest 6 months data you have available), how many were treated with:
a. rituximab
b. mycophenolate mofetil
c. surgery (splenectomy)
Q4. Does your trust participate in any ongoing clinical trials for immune thrombocytopenia (ITP)? If so, can you please provide the name of each trial along with the number of patients taking part?

Immune thrombocytopenia (ITP).031122.docx

1. Did you suspend your MRI before biopsy service for patients with suspected prostate cancer as a result of the COVID-19 pandemic?
a. Yes
b. No
c. We did not offer MRI before biopsy before the pandemic
2. If yes, have you now resumed MRI before biopsy for patients with suspected prostate cancer?
a. Yes
b. No
c. No, but we refer patients elsewhere (Please state the referral area:)
d. N /A
3. Do you currently use a pre-MRI clinical triage for patients with suspected prostate cancer? By pre-MRI clinical triage, we mean a process, often Clinical Nurse Specialist led, that determines patient suitability for MRI before biopsy
a. Yes
b. No
4. Has your radiology department introduced any new MRI exclusion criteria for patients with suspected prostate cancer as a result of COVID-19?
a. Yes (please specify:)
b. No
c. N/A
5. If yes, do you plan to maintain any of these exclusion criteria once restrictions to limit patients’ COVID-19 risk are lifted?
a. Yes (please specify:)
b. No
c. N/A
6. Did you stop conducting biopsies for patients with suspected prostate cancer as a result of COVID-19 infection risks?
a. Yes
b. No
7. If yes, have you resumed biopsy services for patients with suspected prostate cancer?
a. Yes
b. Yes, but only for a subset of patients (please specify:)
c. No
d. No, but we refer patients elsewhere for prostate biopsy (Please state the referral area:)
8. Do you offer transperineal biopsy under local anaesthetic?
a. Yes
b. No
c. No, but we plan to in future (please specify when if possible:)
9. Following an MRI scan for suspected prostate cancer, what criteria do you use to select patients for biopsy? Please include all that apply:
a. Patients with a PI-RADSs or Likert score of 1 or greater
b. Patients with a PI-RADS or Likert score of 2 or greater
c. Patients with a PI-RADS or Likert score of 3 or greater
d. Patients with a PI-RADS or Likert score of 3 or greater, but only if PI-RADS or Likert score 3 patients have other clinical indications (such as age, ethnicity, PSA density) that make them higher risk
e. Patients with a PI-RADS or Likert score of 4 or greater
f. We do not offer MRI before biopsy
g. We do not currently biopsy patients
10. Did you delay radiotherapy treatment for prostate cancer patients as a result of COVID-19?
a. Yes
b. No
c. Partially (please specify:)
d. N/A (please specify:)
11. If yes, have you cleared your backlog for prostate cancer radiotherapy treatment?
a. Yes
b. No
c. N/A – We did not delay prostate cancer radiotherapy treatment
12. Did you delay radical prostatectomy for prostate cancer patients as a result of COVID-19?
a. Yes
b. No
c. Partially (please specify:)
d. N/A (please specify:)
13. If yes, have you cleared your radical prostatectomy backlog?
a. Yes
b. No
c. N/A – We did not delay radical prostatectomy for prostate cancer patients
14. To address your backlog did or are you using a protocol to risk stratify patients and prioritise patients with high-risk and locally advanced prostate cancer for treatment within 3 months?
a. Yes
b. No
c. No, we did not have a sufficient backlog to require patient prioritisation
15. Does your protocol apply to new patients with high-risk and locally advanced prostate cancer with the intention to radically treat them within 3 months of diagnosis?
a. Yes
b. No
c. N/A – We do not have a protocol for patient prioritisation
16. Do you have prostate cancer Personalised Stratified Follow Up (PSFU) protocols in place?
a. Yes
b. No
c. We are in the process of developing PSFU protocols
17. If Yes, do you have a digital remote monitoring system in place for follow up?
a. Yes (Please specify the name of the system used: e.g My Medical Record, Patient Knows Best)
b. No
18. If no, do you plan to implement a digital remote monitoring system for follow up?
a. Yes – (Please specify the name of the system you plan to implement: e.g My Medical Record, Patient Knows Best)
b. No
19. Which of the following criteria are part of your follow up protocols? (please mark all that apply:)
a. Patients have access to a Support Worker who acts as their key worker for the duration of their follow up care.
b. Patients have access to an online patient service that allows them to check test results, complete assessments, view patient information and message their clinical team.
c. Patients attend a 4-hour supported self-management workshop with a group of 8 to 10 men to develop knowledge, skills and confidence to self-manage their condition
d. Patients do not need to attend routine appointments unless an issue arises.

Download response Impact of COVID-19 on prostate cancer diagnosis, treatment and support. 021020

1. Has your histopathology laboratory outsourced any cases for reporting in the past year?
2. If yes, approximately what percentage of your work is outsourced?
3. Does your histopathology laboratory use any form of digital pathology?
4. Can you name the supplier(s) of your digital pathology solution?
5. If the answer to question 3 is “no”, can you indicate if you are looking to procure a digital pathology solution in the next year?
6. How much funding does the Trust have to implement this?
7. What would you use digital pathology for?
a. Research
b. Training
c. Primary diagnosis
d. Second opinion
e. MDT preparation and review
(Tick all that apply)
8. What LIS does your department currently use?
9. How old is your current LIS?
10. Does your laboratory workflow incorporate a barcoded tracking system?
11. If yes, what tracking system do you use?
12. To reduce the initial capital outlay, would you favour a cost per scan pricing model?
13. Would you consider an insourcing model where the digital pathology solution is tailored to your needs with scanners placed on site and images stored and streamed to your consultant workforce for reporting on your LIS?
14. Would you use an outsourcing model where your slides are sent offsite for scanning and cases reported by an external consultant team with reports returned direct to your LIS?
15. Would you prefer to purchase your own scanners and IMS and work directly with a partner provider to handle, store, and report your own images?

Implementation of digital pathology in Histopathology. 240222.docx

IMRT Radiotherapy Machines
Could you please advise whether we are using the above modern machines in the Kent and Canterbury Hospital (K&C) and Maidstone?

Download response IMRT Radiotherapy Machines. 121119

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:
a. Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) as a single agent
b. Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
c. Abemaciclib + Fulvestrant
d. Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
e. Atezolizumab +Nab-paclitaxel/Paclitaxel
f. Capecitabine as a single agent
g. Carboplatin or Cisplatin as a single agent
h. Eribulin as a single agent or in combination
i. Everolimus + Exemestane
j. Fulvestrant as a single agent
k. Lapatinib
l. Neratinib
m. Parp Inhibitors (Olaparib/Talazoparib)
n. Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
o. Palbociclib + Fulvestrant
p. Pembrolizumab
q. Pertuzumab + Trastuzumab + Docetaxel
r. Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
s. Ribociclib + Fulvestrant
t. Sacituzumab Govitecan
u. Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
v. Trastuzumab as a single agent or in combination
w. Trastuzumab emtansine
x. Transtuzumab deruxtecan
y. Vinorelbine as a single agent
z. Any other active systemic anti-cancer therapy
Q2. In the past 3 months, how many early/locally advanced (Stages I to IIIc) breast cancer patients were treated with an Aromatase Inhibitor (anastrazole, exemestane, letrozole) as a single agent?

Incidence and treatment of breast cancer.110322.docx

1. How many patients have you treated (using surgery, radiotherapy or any systemic anti-cancer therapy) in the last three months for:
a. Breast cancer (any stage)
b. Early breast cancer (both early-stage and locally advanced, inclusive of stages I-IIIC)
c. Metastatic breast cancer (stage IV)
2. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:
a. Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
b. Abemaciclib + Fulvestrant
c. Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
d. Atezolizumab +Nab-paclitaxel/Paclitaxel
e. Capecitabine as a single agent
f. Carboplatin or Cisplatin as a single agent
g. Eribulin as a single agent or in combination
h. Everolimus + Exemestane
i. Fluorouracil
j. Fulvestrant as a single agent
k. Lapatinib
l. Neratinib
m. Olaparib
n. Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
o. Palbociclib + Fulvestrant
p. Pertuzumab + Trastuzumab + Docetaxel
q. Platinum (e.g. carboplatin or cisplatin) as a single agent
r. Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
s. Ribociclib + Fulvestrant
t. Talazoparib
u. Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
v. Transtuzumab as a single agent or in combination
w. Trastuzumab emtansine
x. Any other active systemic anti-cancer therapy

Download response Incidence and treatment of breast cancer. 110621

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:
a.Abemaciclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)
b. Abemaciclib + Fulvestrant
c. Alpelisib + Fulvestrant
d. Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
e. Atezolizumab +Nab-paclitaxel/Paclitaxel
f. Capecitabine as a single agent
g. Eribulin as a single agent or in combination
h. Everolimus + Exemestane
i. Fulvestrant as a single agent
j. Lapatinib
k. Neratinib
l. Parp Inhibitors (Olaparib/Talazoparib)
m. Palbociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)
n. Palbociclib + Fulvestrant
o. Pembrolizumab
p. Platinum (e.g. carboplatin or cisplatin) as a single agent
q. Ribociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole)
r. Ribociclib + Fulvestrant
s. Sacituzumab Govitecan
t. Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
u. Taxane and/or Anthracycline in combination
v. Trastuzumab as a single agent or in combination
w. Trastuzumab emtansine
x. Transtuzumab deruxtecan
y. Any other active systemic anti-cancer therapy
Q2. Does your trust participate in any clinical trials for breast cancer? If so, can you please provide the name of each trial and the number of patients taking part.

Incidence and treatment of breast cancer.311022.docx

1. Within your health trust, how many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the following agents?
· Carboplatin (monotherapy or in combination with 5-FU)
· Cisplatin (monotherapy or in combination with 5-FU)
· Cetuximab with/without chemotherapy
· Cetuximab with radiotherapy
· Pembrolizumab monotherapy
· Pembrolizumab with chemotherapy
· Nivolumab
· Docetaxel (monotherapy or in combination with 5-FU)
· Fluorouracil (5FU)
· Radiotherapy only
· Other
2. Does your trust participate in any ongoing clinical trials for the treatment of head and neck cancer (squamous cell carcinoma)? If so, can you please provide the name of each trial along with the number of patients taking part?
3. Within your health trust, how many patients have been treated in the past 3 months with the following agents for colorectal cancer [CRC]?
· Aflibercept
· Bevacizumab
· Capecitabine
· CAPIRI
· CAPOX (XELOX)
· Cetuximab in combination with FOLFIRI
· Cetuximab in combination with FOLFOX
· Cetuximab not in combination with FOLFIRI or FOLFOX
· Irinotecan only
· FOLFIRI
· FOLFOX
· Fluorouracil (5FU) only
· Oxaliplatin only
· Panitumumab in combination with FOLFIRI
· Panitumumab in combination with FOLFOX
· Panitumumab not in combination with FOLFIRI or FOLFOX
· Nivolumab
· Raltitrexed
· Ramucirumab
· Regorafenib
· Sorafenib
· Other SACT

Download response Incidence and treatment of different types of cancer.220621

Q1. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:
a. Afatinib
b. Alectinib
c. Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel
d. Atezolizumab monotherapy
e. Bevacizumab
f. Brigatinib
g. Ceritinib
h. Crizotinib
i. Dacomitinib
j. Docetaxel monotherapy
k. Durvalumab
l. Erlotinib
m. Gefitinib
n. Gemcitabine
o. Necitumumab
p. Nintedanib with Docetaxel
q. Nivolumab
r. Osimertinib
s. Paclitaxel
t. Pembrolizumab chemo in combination
u. Pembrolizumab monotherapy
v. Pemetrexed
w. Pemetrexed with Carboplatin
x. Pemetrexed with Cisplatin
y. Ramucirumab
z. Vinorelbine and cisplatin/carboplatin
Q2. Could you please provide the total number of patients with any treatment in the last three months for:
a. Total non-small cell lung cancer (NSCLC)
b. Squamous non-small cell lung cancer (Sq NSCLC)
c. Non-squamous non-small cell lung cancer (Non-Sq NSCLC)

Download response Incidence and treatment of Lung cancer. 091020

Q1. How many patients has your trust treated in the past 3 months for the following conditions:
a. Chronic Lymphocytic Leukaemia (CLL)
b. Mantle Cell Lymphoma (MCL)
c. In case you do not treat either of the above conditions, please tell us which trust or hospital you refer patients to.
Q2. How many Chronic Lymphocytic Leukaemia (CLL) patients have been treated in the past 3 months with the following:
a. BR (bendamustine + rituximab)
b. Calquence (acalabrutinib)
c. FCR (fludarabine + cyclophosphamide + rituximab)
d. Gazyva (obinutuzumab) + chlorambucil
e. Imbruvica (ibrutinib)
f. Venclexta (venetoclax)
g. Venclexta (venetoclax) + Gazyva (obinutuzumab)
h. Venclexta (venetoclax) + rituximab
i. Zydelig (idelalisib) + rituximab
j. Any other systemic anti-cancer therapy
Q3. How many Mantle Cell Lymphoma (MCL) patients have been treated in the past 3 months with the following:
a. BR (bendamustine + rituximab)
b. Imbruvica (ibrutinib)
c. Imbruvica (ibrutinib) + rituximab
d. R-BAC (rituximab, bendamustine and cytarabine)
e. R-CHOP (rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone)
f. Nordic Protocol (rituximab, cyclophosphamide, doxorubicin, vincristine, cytarabine & prednisolone)
g. Velcade (bortezomib) + chemotherapy
h. Any other systemic anti-cancer therapy
i. Stem cell transplant
j. Tecartus (CAR-T) – Autologous anti-CD19-transduced CD3+ cells
Q4. Does your trust currently participate in any ongoing clinical trials for the treatment of Chronic Lymphocytic Leukaemia (CLL)? If so, can you please provide the name of each trial along with the number of patients taking part?
Q5. Does your trust currently participate in any ongoing clinical trials for the treatment of Mantle Cell Lymphoma (MCL)? If so, can you please provide the name of each trial along with the number of patients taking part?

Incidents of Chronic Lymphocytic Leukaemia (CLL) and Mantle Cell Lymphoma (MCL).170622.docx

1. Number and type of interventional radiology (IR) procedures performed by the radiology department (only) per each year in question.
2. Number of interventional radiologists currently in the unit.
3. Number of dedicated interventional Radiology nurses
4. What is the Consultant Interventional Radiology on call rota?
5. Are there interventional Radiology trainees in your units? If yes, how many?
6. Number of Interventional Radiology angiosuites?
7. Is there a day case unit in your radiology department and if so, how many beds?
8. Number of beds in the trust.

Interventional Radiology.031122.docx

For your Trust, please provide, per calendar year for the period January 2006 to December 2018 inclusive, the following information for each admission of Kawasaki Disease – ICD10 diagnosis (primary or secondary) of M303 Mucocutaneous lymph node syndrome:
• Year of each admission
• Month of each admission
• Patient gender
• Patient ethnicity
• Age of patient at diagnosis
• First four items of patient postcode (partial postcode which is non-identifiable)

Download response Kawasaki Disease. 300819

1. Name of Hospital
2. Does the hospital use Lead Aprons? (If NO, then no further information needed) please just enter the hospital name and N in column B of the attached spreadsheet.
3. What brand of Lead Apron is currently used or most recent brand purchased if several in use
4. What is the hospitals annual spend on Lead Aprons? Please provide data for the last 3 complete financial or calendar years if possible
5. How many Lead Aprons are purchased per annum? Please provide data for the last 3 complete financial or calendar years if possible
6. Who is the Key contact person in charge of ordering lead aprons for Radiology Department – Name/Job Title/E-mail/Direct Contact Number/Decision Maker Yes or No (if employee direct contact details can’t be shared please provide a general contact number and e-mail for the Radiology department.)
7. Who is the Key contact person in charge of ordering lead aprons for Cath Lab Department – Name/Job Title/E-mail/Direct Contact Number/Decision Maker Yes or No (if employee direct contact details can’t be shared please provide a general contact number and e-mail for the Cath Lab department.)
8. Who is the Key contact person in charge of ordering lead aprons for Theatre Department – Name/Job Title/E-mail/Direct Contact Number/Decision Maker Yes or No (if employee direct contact details can’t be shared please provide a general contact number and e-mail for the Theatre department.)
9. If the departmental contact is not the decision maker in the buying process please also provide the full contact details (Name/Job Title/E-mail/Direct Contact Number) for a Senior Person in charge of ordering (e.g. Head of Procurement, Service Manager, Clinical Director, Clinical Lead)

Download response Lead aprons. 120221

1. The year of purchase of every LINAC machine in operation at your trust?
2. How many patients received SBRT or SABR at your Trust in 2020 and until the latest available in 2021 and for what indications?
3. How many individual business cases have been raised for new or replacement linear accelerators in 2020 and 2021.

LINAC machines and SBRT or SABR.170322.docx

1. The year of purchase of every LINAC machine in operation at your trust?

2. How many patients received lung SBRT or SABR for oligometastatic disease at your Trust in the most recent year for which data is available? How many of those had been referred from other Trusts?

3. If your Trust does not offer SABR or SBRT for lung or oligometastatic disease, how many patients were referred to another NHS Trust for SBRT or SABR in the most recent year for which data is available? How many of those patients completed their SBRT or SABR treatment at the Trust they had been referred to?

Download response LINAC machines and SBRT or SABR for oligometastatic disease. 020919

1. The year of purchase of every LINAC machine in operation at your trust?

2. How many patients received lung SBRT or SABR for oligometastatic disease at your Trust in the most recent year for which data is available? How many of those had been referred from other Trusts?

3. If your Trust does not offer SABR or SBRT for lung or oligometastatic disease, how many patients were referred to another NHS Trust for SBRT or SABR in the most recent year for which data is available? How many of those patients completed their SBRT or SABR treatment at the Trust they had been referred to?

Download response LINAC machines and SBRT or SABR for oligometastatic disease. 020919

Question 1
Does Maidstone and Tunbridge Wells NHS Trust have any local treatment guidelines/pathways/protocols/algorithms for the treatment of non-small cell lung cancer?
Question 2
Does Maidstone and Tunbridge Wells NHS Trust have protocols for the use of the following targeted drug therapies in the treatment of non-small cell lung cancer?
a. Sotorasib (Lumykras)
b. Entrectinib (Rozlytrek)
c. Larotrectinib (Vitrakvi)
d. Dabrafenib (Tafinlar)
e. Trametinib (Mekinist)
f. Capmatinib (Tabrecta)
g. Tepotinib (Tepmetko)
h. Bevacizumab (Avastin)
i. Ramucirumab (Cyramza)
j. Atezolizumab (Tecentriq)
k. Durvalumab (Imfinzi)
l. Cemiplimab- (Libtayo)
m. Nivolumab (Opdivo)
n. Pembrolizumab (Keytruda)
o. Ipilimumab (Yervoy)
p. Afatinib (Giotrif)
q. Dacomitinib (Vizimpro)
r. Erlotinib (Tarceva)
s. Gefitinib (Iressa)
t. Osimertinib (Tagrisso)
u. Amivantamab (Rybrevant)
v. Mobocertinib (Exkivity)
w. trastuzumab deruxtecan (Enhertu)
x. Alectinib (Alecensa)
y. Brigatinib (Alunbrig)
z. Ceritinib (Zykadia)
aa. Crizotinib (Xalkori)
bb. Lorlatinib (Lorviqua)
cc. Entrectinib (Rozlytrek)
dd. Pralsetinib (Gavreto)
ee. Selpercatinib (Retsevmo)
ff. Nintedanib (Vargatef®)
Question 3
If a local protocol for the use of Sotorasib (Lumykras) for the treatment of non-small cell lung cancer is available please could a copy be provided?
Question 4
Does Maidstone and Tunbridge Wells NHS Trust have any local pathways/protocols/guidelines for the use of molecular biomarker testing in diagnosis/treatment of non-small cell lung cancer?
Question 5
Is Maidstone and Tunbridge Wells NHS Trust part of a Cancer alliance or network, if so which ones?

Local Treatment Guidelines Non-Small Cell Lung Cancer.020823.docx

1. What was the longest a patient at your Trust waited (in weeks/days) for –
a) a first consultant appointment, following a GP urgent referral on the two week wait pathway;
b) being told they have cancer, or cancer being definitively excluded, following a GP urgent referral on the two week wait pathway;
c) a first treatment for cancer, following a GP urgent referral on the two week wait pathway;
d) a diagnostic test or procedure, following a GP urgent referral on the two week wait pathway
In each of the following calendar years – 2018, 2019, 2020, 2021, 2022?

Longest cancer waits.170323.docx

All questions are shown as received by the Trust.
1. The longest wait from an Urgent Suspected Cancer or Breast Symptomatic Referral, or Consultant Upgrade to a First Definitive Treatment for Cancer in the Trust in 2023/24 (so far)?
2. How many patients in your trust are currently waiting longer than 6 months (186 days) from an Urgent Suspected Cancer or Breast Symptomatic Referral, or Consultant Upgrade to a First Definitive Treatment for Cancer?

Longest Cancer Waits.210324.docx

1. Your Trusts longest wait time for a non-urgent X-ray in the past 12 months
2. Your Trusts longest wait time for a CT scan in the past 12 months
3. Your Trusts longest wait time for an MRI in the past 12 months
4. Your Trusts longest wait time for a PET scan in the past 12 months
5. Your Trusts longest wait time for an Ultrasound in the past 12 months
6. Your Trusts longest wait time for an Angiography in the past 12 months
7. Your Trusts longest wait time for an Electrocardiogram scan in the past 12 months
8. Your Trusts longest wait time for an Echocardiogram in the past 12 months

Longest wait time for scans and x-rays.270923.docx

Q1 – How many patients has your Trust treated in the past 3 months for:
a. Non-small cell lung cancer (NSCLC) – any treatment
b. Non-small cell lung cancer (NSCLC) – surgical treatment
c. Non-small cell lung cancer (NSCLC) – radiotherapy
d. Non-small cell lung cancer (NSCLC) – systemic anti-cancer treatment (SACT)
Q2 – How many Non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:
a. ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib)
b. Amivantamab
c. Atezolizumab monotherapy
d. Atezolizumab with chemotherapy
e. Dabrafenib + Trametinib
f. Durvalumab
g. Gemcitabine
h. Nitendanib + Docetaxel
i. Nivolumab
j. Osimertinib
k. Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib)
l. Paclitaxel
m. Pembrolizumab monotherapy
n. Pembrolizumab with chemotherapy
o. Pemetrexed with carboplatin/cisplatin
p. RET Inhibitors (Pralsetinib, Selpercatinib)
q. Sotorasib
r. Tepotinib
s. Vinorelbine monotherapy or combination with Carboplatin/Cisplatin
t. Other active systemic anti-cancer therapy [please state]
u. Palliative care only
Q3 – Of the NSCLC patients treated with Nivolumab in the past 3 months, how many patients received (surgery) or are scheduled to receive surgical treatment after commencement of the treatment with Nivolumab?

Lung cancer.230623.docx

All questions are shown as received by the Trust.
Q1. How many non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:
a. ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib)
b. Amivantamab
c. Atezolizumab Monotherapy
d. Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel
e. Dabrafenib + Trametinib
f. Docetaxel monotherapy or in combination with Carboplatin/Cisplatin
g. Durvalumab
h. Gemcitabine
i. Nitedanib + Docetaxel
j. Nivolumab
k. Osimertinib
l. Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib)
m. Paclitaxel
n. Pembrolizumab Monotherapy
o. Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin)
p. Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin)
q. Pemetrexed + Platinum (Carboplatin/Cisplatin)
r. RET Inhibitors (Pralsetinib, Selpercatinib)
s. Sotorasib
t. Tepotinib
u. Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin
v. Other active systemic anti-cancer therapy
w. Palliative care only
Q2. How many patients were treated for Squamous non-small cell lung cancer (Sq NSCLC) ONLY in the past 3 months with:
a. Atezolizumab monotherapy
b. Durvalumab
c. Gemcitabine
d. Nivolumab
e. Osimertinib
f. Pembrolizumab (Keytruda) Mono
g. Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin)
h. Paclitaxel
i. Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin
j. Other active systemic anti-cancer therapy (SACT)
k. Palliative care only

Lung cancer.250624.docx

Q1. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:
a. Afatinib
b. Alectinib
c. Amivantamab
d. Atezolizumab monotherapy
e. Atezolizumab with chemotherapy
f. Brigatinib
g. Ceritinib
h. Crizotinib
i. Dacomitinib
j. Dabrafenib with Trametinib
k. Durvalumab
l. Erlotinib
m. Gefitinib
n. Lorlatinib
o. Mobocertinib
p. Nintedanib with Docetaxel
q. Nivolumab
r. Osimertinib
s. Pembrolizumab monotherapy
t. Pembrolizumab with chemotherapy
u. Pemetrexed with Carboplatin/Cisplatin
v. Sotorasib
w. Tepotinib
x. Vinorelbine with Carboplatin/Cisplatin
y. Any other active systemic anti-cancer therapy (SACT)
z. Palliative care only
Q2. In the past 3 months, how many patients were treated for Squamous non-small cell lung cancer (Sq NSCLC) ONLY with the following drugs:
a. Atezolizumab monotherapy
b. Atezolizumab with chemotherapy
c. Durvalumab
d. Nivolumab
e. Osimertinib
f. Pembrolizumab (Keytruda) Mono
g. Pembrolizumab (Keytruda) with Chemotherapy
h. Tepotinib
i. Other active systemic anti-cancer therapy (SACT)
j. Palliative care only

Lung cancer.270622.docx

All questions are shown as received by the Trust.
Q1. How many Non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:
a. ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib)
b. Amivantamab
c. Atezolizumab Monotherapy
d. Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel
e. Dabrafenib + Trametinib
f. Docetaxel monotherapy or in combination with Carboplatin/Cisplatin
g. Durvalumab
h. Gemcitabine
i. Nitedanib + Docetaxel
j. Nivolumab
k. Osimertinib
l. Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib)
m. Paclitaxel
n. Pembrolizumab Monotherapy
o. Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin)
p. Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin)
q. Pemetrexed + Platinum (Carboplatin/Cisplatin)
r. RET Inhibitors (Pralsetinib, Selpercatinib)
s. Sotorasib
t. Tepotinib
u. Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin
v. Other active systemic anti-cancer therapy
w. Palliative care only
Q2. Of all the NSCLC patients treated with nivolumab in the past 3 months, how many patients received (surgery) or are scheduled to receive surgical treatment after commencement of the treatment with nivolumab?
Q3. Does your trust/health board participate in any clinical trials for non-small cell lung cancer (NSCLC)? If so, could you please provide the name of each active trial and the number of patients taking part.

Lung cancer.271023.docx

All questions are shown as received by the Trust.
Q1. How many non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:
a. ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib)
b. Amivantamab
c. Atezolizumab Monotherapy
d. Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel
e. Dabrafenib + Trametinib
f. Docetaxel monotherapy or in combination with Carboplatin/Cisplatin
g. Durvalumab
h. Gemcitabine
i. Nitedanib + Docetaxel
j. Nivolumab
k. Osimertinib
l. Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib)
m. Paclitaxel
n. Pembrolizumab Monotherapy
o. Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin)
p. Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin)
q. Pemetrexed + Platinum (Carboplatin/Cisplatin)
r. RET Inhibitors (Pralsetinib, Selpercatinib)
s. Sotorasib
t. Tepotinib
u. Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin
v. Other active systemic anti-cancer therapy
w. Palliative care only
Q2. How many patients were treated for Squamous non-small cell lung cancer (Sq NSCLC) ONLY in the past 3 months with:
a. Atezolizumab monotherapy
b. Durvalumab
c. Gemcitabine
d. Nivolumab
e. Osimertinib
f. Pembrolizumab (Keytruda) Mono
g. Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin)
h. Paclitaxel
i. Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin
j. Other active systemic anti-cancer therapy (SACT)
k. Palliative care only

Lung Cancer.280224.docx

It has come to my attention that there is a disproportionately high number of patients are presenting to Maidstone Respiratory Clinic from people living in Vigo, Gravesend.

I would be grateful if you could provide me with any information you hold on the number of recorded patients you have from Vigo over the past ten years with lung cancer. That would include both incidence and prevalence figures.

Before we commenced extracting any data the Trust highlighted the following to you and asked if you were happy for us to proceed with your request with the following limitations.
• Data will only be as long as the data system has been used, (since 2009)
• Postcodes used have been identified as those listed below, as this is a not an area we can identify any other way from our system.

DA13 0RL
DA13 0SB
DA13 0RR
DA13 0UU
DA13 0SR
DA13 0UT
DA13 0TG
DA13 0ST
DA13 0TD
DA13 0SH
DA13 0TA
DA13 0SF
DA13 0TQ
DA13 0SX
DA13 0RY
DA13 0SP
DA13 0SU
DA13 0SQ
DA13 0RZ
DA13 0SJ
DA13 0TE
DA13 0SY
DA13 0SG
DA13 0SN
DA13 0SL
DA13 0SW

• We cannot give prevalence, and not even incidence really since this is new cases, rather we can give just numbers in those postcodes specified that are on our system, I.e. being treated by the Trust.
• This will be for patients under Maidstone and Tunbridge Wells NHS Trust (MTW) with lung cancer in that postcode area each year, so if they moved in or out, they will appear or disappear (i.e. diagnosis may or may not have been made by MTW depending if they first presented with suspected cancer to us or whether they moved into the area after diagnosis was already made elsewhere).

You confirmed that you were happy to proceed with the listed limitations.

Download response Lung cancer cases in Vigo. 121018

1. Who provides the maintenance and/or repair of the Trust’s surgical power tool inventory? If more than one, please provide all.
2. When is the expiry date of the existing maintenance contract for the Trust’s surgical power tool inventory? If more than one, please provide all.

Maintenance contract for the Trust’s surgical power tool inventory.181022.docx

Could you please provide me with the name, telephone number & email address of whom we need to contact at the Trust to be considered for the maintenance contract on the GE Discovery 670 gamma camera systems when the current contracts expire in March 23?

Maintenance contract on the GE Discovery 670 gamma camera systems.141122.docx

You asked:
• When does the existing maintenance contract(s) expire for the Trust’s flexible endoscope inventory?
• I.e. please provide the expiry date for any contract(s) that cover the maintenance and repair of the Trust’s flexible endoscope inventory.

Download response Maintenance services for flexible endoscopy inventory . 211118

1. What are the contractual performance KPI’s for this contract?
2. Suppliers who applied for inclusion on each framework/contract and were successful & not successful at the PQQ & ITT stages
3. Actual spend on this contract/framework (and any sub lots), from the start of the contract to the current date
4. Start date & duration of framework/contract?
5. Could you please provide a copy of the service/product specification given to all bidders for when this contract was last advertised?
6. Is there an extension clause in the framework(s)/contract(s) and, if so, the duration of the extension?
7. Has a decision been made yet on whether the framework(s)/contract(s) are being either extended or renewed?
8. Who is the senior officer (outside of procurement) responsible for this contract?

Car park management contract.140923.docx

1. Do you currently manage your car parking in-house or do you contract to a third party?
2. If you do employ a parking operator to manage your parking services, who is your current parking provider?
3. What is the exact date your current contract/s terminate?
4. Does the Trust receive the income generated from the hospital parking and notice charges or does the income go to a third party?
5. Please confirm the revenue amount generated from the third-party provider if there is one
6. What are the key challenges that the Trust face with regards to the parking provision?
7. Can you confirm the expenditure on maintenance for the car park equipment for 2019/2020?
8. Overall what was the profit generated by the trust after the cost of maintaining and staffing the car park for 2019/2020?

Download response Car parking. 091220

Based on your latest available data,
1. How many fines have been handed out to members of staff at your Trust over the past five years for issues related to car parking? This could include parking in the wrong area, not having a permit etc.
2. How many staff does your Trust currently have
3. How many of these currently have a car parking permit?
4. How many are on the waiting list to receive a permit?
If possible, please provide data broken down by year by calendar year. Spreadsheet format preferred if possible.

Car parking.110324.docx

All questions are shown as received by the Trust.
1. a list of all of the measurements you record to understand parking demand and availability
2. the data for those measurements for the past 5 years.
3. a copy of the any plans you have in respect of parking improvement

Car parking.140224.docx

Subject to the Freedom of Information Act, I would like to request the following information in the relation to the Trust and associated hospitals.
1. Do you currently manage your car parking in-house or do you contract to a third party?
2. If you do employ a parking operator to manage your parking services, who is your current parking provider?
3. What is the exact date/s your current contract/s terminate?
4. What date do you expect to go to tender?

Download response Car parking. 240119

1. Do hospitals in your area charge patients/visitors to park in their own car park?
2. If so, how much do they charge?
3. Do the hospitals operate their car park under a PFI contract?

Download response Car parking charges. 011118

1. How much money did the trust raise from car parking charges in each of the last two financial years – 2017/18 and 2018/19? Include a breakdown of staff and visitor/patient parking if possible.
2. How much money was raised from parking fines in each of the last two financial years – 2017/18 and 2018/19? Include a breakdown of staff and visitor/patient fines if possible.
3. Have you increased the cost of parking in your car parks during the last financial year – between 2017/18 and 2018/19? Please give a breakdown of how much parking has increased by.
4. Do you charge for disabled parking?
5. Is your car park managed by a private firm? If so, what proportion of revenue created by a) parking income and b) parking fines does the firm take?

Download response Car parking charges. 160519

1. How much money did the trust raise from car parking charges in each of the last two financial years – 2017/18 and 2018/19? Include a breakdown of staff and visitor/patient parking if possible.
2. How much money was raised from parking fines in each of the last two financial years – 2017/18 and 2018/19? Include a breakdown of staff and visitor/patient fines if possible.
3. Have you increased the cost of parking in your car parks during the last financial year – between 2017/18 and 2018/19? Please give a breakdown of how much parking has increased by.
4. Do you charge for disabled parking?
5. Is your car park managed by a private firm? If so, what proportion of revenue created by a) parking income and b) parking fines does the firm take?

Download response Car parking charges. 181019

1. How much money did the trust raise from car parking charges in each of the last two financial years – 2016/17 and 2017/18? Include a breakdown of staff and visitor/patient parking if possible.

2. How much money was raised from parking fines in each of the last two financial years – 2016/17 and 2017/18? Include a breakdown of staff and visitor/patient fines if possible.

3. Have you increased the cost of parking in your car parks during the last financial year – between 2016/17 and 2017/18? Please give a breakdown of how much parking has increased by.

4. Do you charge for disabled parking?

Download response Car parking charges. 280918

Can you please confirm if you planning to extend the current contract with APCOA or extend, if so could you please confirm for how long?

Download response Car parking contract. 051021.docx

1. Could you please advise me if you manage the car parking facilities on your own, or do you employ a private operator/contractor to manage the facilities for you i.e., ANPR, POFs and PCNs etc?
2. If you use a private operator/contractor, can you please advise me who they are and when their existing contract with yourselves expires?

Car parking facilities.180123.docx

1. How much money was generated by your hospital trust through parking charges in the hospital car parks during 2019-20?
2. How many parking fines were issued for parking infringements in your car parks during the year stated above?
3. How many parking fines were written off during the year stated above?

Download response Car parking income. 290620

Car Parking Management Services and Security Services Management for Maidstone & Tunbridge Wells NHS Trust:
https://procontract.due-north.com/Advert?advertId=db2f64cd-fa28-e711-80df-005056b64545

The details we require are:

1. Suppliers who applied for inclusion on each framework/contract and were successful & not successful at the PQQ & ITT stages
2. Actual spend on this contract/framework (and any sub lots), from the start of the contract to the current date
3. Start date & duration of framework
4. Is there an extension clause in the framework(s)/contract(s) and, if so, the duration of the extension?
5. Has a decision been made yet on whether the framework(s)/contract(s) are being either extended or renewed?
6. Who is the senior officer (outside of procurement) responsible for this contract?

Download response Car Parking Management Services and Security Services Management. 150421

1. How many staff members at the trust are declared disabled?
2. How many staff members with a disability use the staff car park?
3. Do the trust charge disabled staff for parking?
4. If yes in Q3 is this charge at a discounted rate compared to a non-disabled staff member?
5. How much is staff car parking for disabled staff and non-disabled staff?

Download response Disabled parking for staff. 030719

All questions are shown as received by the Trust.
1. Financial Revenue and Distribution:
How much revenue was generated from parking fees charged to NHS staff for the last financial year?
a. Of this revenue, what percentage or amount was paid to private parking management companies?
2. Private Companies Profiting:
Can you provide a list of the private parking companies that have benefited from these arrangements within the last financial year?
3. Revenue Breakdown:
Please provide a breakdown of the revenue generated from parking fees and fines, per hospital or area within your trust, for the last financial year.

Financial Details and Operations of Private Parking Arrangements for NHS Staff.050624.docx

1. Do you provide free parking for NHS staff and/or patients?
2. If not, how much do you charge staff to park?
3. how long does it take for staff to be issued a permit when joining your trust?

Free NHS Staff Parking.220722.docx

1. Please state the current fee for parking at the trust for one hour. (If there is no specific fee for one hour, please state the lowest possible time and cost)
2. Please state the fee for parking for one hour in 2018.
3. Please tell me whether the hospital provides free parking for any of the following groups a) cancer patients b) disabled patients c) other patients who are frequent visitors to the trust d) the relatives of patients who are frequent visitors.
4. Please tell me if the hospital provides reduced parking for any of the following groups a) cancer patients b) disabled patients c) patients who are frequent visitors d) the relatives of patients who are frequent visitors 5. If yes to question 4, please provide details.
6. Please state how much the trust collected in parking charges and fines in a) 2018/19 and b) 2017/18.
7. Does the trust hire any private firms to issue parking fines or clamp vehicles?
8. If yes to question 7, please provide the names of these firms

Download response Hospital parking. 190719

1. How many fines have been issued by the hospital for overstaying at Maidstone Hospital and Tunbridge Wells Hospital in Pembury?
2. Can this be broken down year by year from 2018 to 2021 (to date)
– 2018
– 2019
– 2020
– 2021
3. Can you also confirm how much the fines cost, where the money goes to and the outcome of the fines (e.g. paid for, rescinded or other action)

Download response Hospital parking overstaying fines.300621

a) The number of 6-in-1 vaccines offered to be given to babies in the financial years 2017/18, 2016/17, and 2015/16.

b)The number of 6-in-1 vaccines that were refused by parents or guardians of the baby in the financial year 2017/18, 2016/17, and 2015/16.

c) The number of children diagnosed with any of the following in 2017/18 alone, who had not received the 6-in-1 vaccine when they were a baby because their parent or guardian had refused it. If a child was diagnosed with more than one of the below, please provide that information: diphtheria, hepatitis B, Hib, polio, tetanus, or whooping cough

Download response 6-in-1 vaccine. 170718

For every month from 1 January 2019 to 31 May 2021, please answer the following questions:
1 In that month, how many children and young people (CYP) aged 18 and under did you refer to CAMH services after they arrived in your emergency department(s)?
2 In that months, of these CYP in question one, how many were referred to CAMH services for treatment of a suspected or confirmed eating disorder? If helpful, please search against the ICD Code F50.0, which may be included in the referral.
3 In that month, how many CYP were admitted to or treated by your acute hospital trust for the following:
3 a Treatment of an eating disorder, such as refeeding and medical stabilisation? If helpful, please search against the ICD Code F.50, which should cover all relevant eating disorder diagnoses.
3 b Treatment of self-inflicted injury? If helpful, please search against ICD Codes X60 to X69.
3 c Treatment of drug or other toxic substance overdose, whether accidental or intentional? If helpful, please search against ICD Codes X70 to X84.
4 In this month, how many CYP were admitted to your acute trust for compulsory treatment with use of the Mental Health Act?
5 In this month, of those CYP admitted to your acute trust for compulsory treatment with use of the Mental Health Act, how many had an eating disorder diagnosis (ICD Code in the F50 category)?

Download response Acute Trust CYP Healthcare. 050821.docx

1- Number of paediatric patient attended A/E in 2018, Tunbridge wells hospital
2- Number of patient attended paediatric OPD (outpatient department) in 2018, Tunbridge wells hospital

Download response A&E and Outpatient Paediatric attendances. 250419

1. How many babies (i.e.) below the age of 1) were diagnosed with issues of Ankylossia (tongue-tie) in each financial year since 2013/14.
2. Of the babies diagnosed with issues of Ankylossia (tongue-tie) in 2017 how many had a surgical procedure carried out by NHS surgeons to resolve these specific issues, and how long did they wait (on average, in calendar days) for the procedure following diagnosis?
3. In 2017, what was the mean age of babies with such issues when the Ankylossia (tongue-tie) procedure was performed?

Download response Ankylossia (tongue-tie). 270918

Please send me an example of all of the following that are in use:
a) Letter/email reporting low chance combined or quadruple screen results
b) Letter/email reporting high chance combined or quadruple screen results
c) Letter/email reporting low chance NIPT results
d) Letter/email reporting high chance NIPT results
e) Letter/email reporting ‘no result’ NIPT results
f) Letter/email reporting negative QF-PCR/FISH CVS results
g) Letter/email reporting positive QF-PCR/FISH CVS results
h) Letter/email reporting negative full karyotype CVS results
i) Letter/email reporting positive full karyotype CVS results
j) Letter/email reporting negative amniocentesis result
k) Letter/email reporting positive amniocentesis result

Download response Ante natal screening or diagnostic results for Down syndrome. 100519

QUESTION 1
A. How many children are currently waiting to receive a first assessment appointment?
B. What is the average wait time for these children, starting from the point of initial referral?
C. How many of these children have been waiting longer than 13 weeks?
D. What are the longest three wait times for these children?
QUESTION 2
A. How many children are currently waiting to receive a second assessment appointment?
B. What is the average wait time for these children to receive a second appointment, since their first appointment?
C. What are the longest three wait times for these children, since their first appointment?
QUESTION 3
A. How many children are currently waiting to receive a diagnosis (ie. waiting for an assessment outcome to find out whether they do or do not have ASD)?
B. What is the average wait time, since the point of initial referral?
C. What are the longest three wait times for these children, since their initial referral?
QUESTION 4
A. In the year up to 31 March 2022, how many children with suspected autism received a first assessment appointment?
B. What was the average wait time for these children to receive a first assessment appointment, since their initial referral?
C. What were the longest three wait times for these children to receive a first diagnostic appointment, since their initial referral??
QUESTION 5
A. In the year up to 31 March 2022, how many children with suspected autism received a second assessment appointment?
B. What was the average wait time for these children to receive a second diagnostic appointment, since their first appointment?
C. What were the longest three wait times for these children to receive a second assessment appointment, since their first appointment?
QUESTION 6
A. In the year up to 31 March 2022, how many children with suspected autism received an ASD diagnosis?
B. What was the average wait time for these children to receive an ASD diagnosis, since their initial referral?
C. What were the longest three wait times for these children to receive an ASD diagnosis, since their initial referral?
QUESTION 7
A. In the year up to 31 March 2021, how many children with suspected autism received a first assessment appointment?
B. What was the average wait time for these children to receive a first assessment appointment, since their initial referral?
QUESTION 8
A. In the year up to 31 March 2021, how many children with suspected autism received a second assessment appointment?
B. What was the average wait time for these children to receive a second diagnostic appointment, since their first appointment?
QUESTION 9
A. In the year up to 31 March 2021, how many children with suspected autism received an ASD diagnosis?
B. What was the average wait time for these children to receive an ASD diagnosis, since their initial referral?
QUESTION 10
A. In the year up to 31 March 2020, how many children with suspected autism received a first assessment appointment?
B. What was the average wait time for these children to receive a first assessment appointment, since their initial referral?
QUESTION 11
A. In the year up to 31 March 2020, how many children with suspected autism received a second assessment appointment?
B. What was the average wait time for these children to receive a second diagnostic appointment, since their first appointment?
QUESTION 12
A. In the year up to 31 March 2019, how many children with suspected autism received an ASD diagnosis?
B. What was the average wait time for these children to receive an ASD diagnosis, since their initial referral?
QUESTION 13
A. In the year up to 31 March 2020, how many children with suspected autism received an ASD diagnosis?
B. What was the average wait time for these children to receive an ASD diagnosis, since their initial referral?
QUESTION 14
A. In the year up to 31 March 2019, how many children with suspected autism received a first assessment appointment?
B. What was the average wait time for these children to receive a first assessment appointment, since their initial referral?
QUESTION 15
A. In the year up to 31 March 2019, how many children with suspected autism received a second assessment appointment?
B. What was the average wait time for these children to receive a second diagnostic appointment, since their first appointment?

ASD waiting times.230522.docx

Please provide numbers spanning the last 3 years – please segment by year where possible (i.e. 2018, 2019, 2020 – to date) for the following questions:
1. How many children age 7 and under have been admitted/treated for asthmatic symptoms in your Trust in these 3 instances:
a. Have been diagnosed as displaying asthmatic symptoms
b. Have been prescribed home treatment (reliever at home)
c. Have been admitted to A&E / ER for emergency treatment
2. For what number of children aged 7 and under was their admission to A&E/ER/Emergency GP (for asthmatic symptoms) their first instance of having asthmatic symptoms diagnosed and treated (i.e. the first instance of the NHS being made aware of asthmatic symptoms)?
3. How many children age 7 or under have had to be treated due over-medication of prescribed asthma medication?
4. How many children age 7 or under have had to be treated due under-medication of prescribed asthma medication?
5. What number of children age 7 and under are referred to a paediatrician/3rd party to help manage their asthmatic symptoms?
6. Yes/No: Has your trust seen a decline in parents seeking medical help for children aged 7 and under with asthma/asthmatic symptoms since March 2020?

Download response Asthma treatment and care for Children. 240321

You asked:
For each year between 2009 and up-to the end of 2017, how many babies born under your trust were born to drug dependent mothers and once born, were transferred to a drug treatment programme to wean them off their addiction?

Download response Babies born to drug dependent mothers. 151118

1. In the 2018 calendar year were there any babies born at your hospitals where the weight of the baby was 12lbs (5443g) or more? If so please state how many and what their birthweights were.
2. In the 2019 calendar year were there any babies born at your hospitals where the weight of the baby was 12lbs (5443g) or more? If so please state how many and what their birthweights were.
3. In the 2020 calendar year were there any babies born at your hospitals where the weight of the baby was 12lbs (5443g) or more? If so please state how many and what their birthweights were.

Download response Babies over 12lbs (5443g) at birth. 070421

For the time period 1 April 2022 to 31 December 2022, if you do not have figures available for the whole period, please provide the most up-to-date figures and state the period they cover.
LIVE BIRTHS
1. How many live births were there at your hospital Trust in the following periods?
(Please exclude home births from this number and detail them separately in brackets.)
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
STILL BIRTHS
2a. How many stillbirths were there at your hospital Trust in the same periods?
Stillbirth is defined as occurring when a baby is born dead after 24 completed weeks of pregnancy.
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
2b. Of these stillbirths (in answer 2a) how many were Intrapartum stillbirths?
Intrapartum stillbirth is defined as when a baby was thought to be alive at the start of labour but was born, beyond 37 weeks of gestation, with no signs of life.
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
2c. Of the Intrapartum stillbirths (in answer 2b) how many were referred to HSIB?
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
2d. Of the Intrapartum stillbirths referred to HSIB (in answer 2c), how many did HSIB investigate?
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
NEONATAL DEATHS
3a. In the same periods, how many Neonatal deaths were there at your hospital Trust?
Neonatal deaths are defined as a baby that dies within 28 days of birth of any cause or, for the purposes of this process, a baby who dies that has not left hospital since birth.
If a baby was born at your hospital Trust and was transferred to another hospital and died at another hospital Trust, please exclude them from these numbers and specify the number separately in brackets.
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
3b. Of these Neonatal deaths (in answer 3a) how many were ‘early Neonatal deaths’?
Early Neonatal deaths are defined as a baby that dies within the first week of life (0-6 days) of any cause.
If a baby was born at your hospital Trust and was transferred to another hospital and died at another hospital Trust, please exclude them from these numbers and specify the number separately in brackets.
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
4a. Of the Neonatal deaths (in answer 3a) at your hospital Trust, in how many cases was the medical cause identified?
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
4b. Of the Early Neonatal deaths (in answer 3b) at your hospital Trust, in how many cases was the medical cause identified?
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
5a. Of the Neonatal deaths at your hospital Trust, where the medical cause was identified (in answer 4a), how many were referred to the Coroner?
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
5b. Of the Early Neonatal deaths at your hospital Trust, where the medical cause was identified (in answer 4b), how many were referred to the Coroner?
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
6a. Of the Neonatal deaths at your hospital Trust, in how many cases was the medical cause not identified?
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
6b. Of the Early Neonatal deaths at your hospital Trust, in how many cases was the medical cause not identified?
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
7a. Of the Neonatal deaths at your hospital Trust, where the medical cause was not identified, how many were referred to the Coroner?
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
7b. Of the Early Neonatal deaths at your hospital Trust, where the medical cause was not identified, how many were referred to the Coroner?
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
8a. Of the Early Neonatal deaths (in answer 3b) at your hospital Trust, how many were referred to HSIB?
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
8b Of the Early Neonatal deaths referred to HSIB (in answer 8a), how many did HSIB investigate?
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
HYPOXIC ISCHEMIC ENCEPHALOPATHY
9a. Of the Neonatal deaths at your hospital Trust, in how many cases was the cause of death recorded as Hypoxic Ischemic Encephalopathy?
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
9b. Of the Neonatal deaths at your hospital Trust, where the cause of death was recorded as Hypoxic Ischemic Encephalopathy, how many were referred to the coroner?
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
9c. Of the Neonatal deaths at your hospital Trust, where the cause of death was recorded as Hypoxic Ischemic Encephalopathy (in answer 9a), how many were referred to HSIB?
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
9d. Of the Neonatal deaths at your hospital Trust, where the cause of death was recorded as Hypoxic Ischemic Encephalopathy (in answer 9c), how many did HSIB investigate?
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
Please provide a copy of your hospital Trust’s current policy in respect of referring Neonatal deaths to a coroner and advise the date it was last updated.
MATERNAL DEATHS
10a. How many maternal deaths were there at your hospital Trust in the same periods?
Maternal deaths are defined as the death of a woman while pregnant or within 42 days of the end of the pregnancy from any cause related to or aggravated by the pregnancy or its management, and not from accidental or incidental causes. Excludes death by suicide.
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
10b. In how many cases of maternal death was a Neonatal death also recorded?
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
10c. In how many cases of maternal death where a Neonatal death also recorded, was the death an Early Neonatal death?
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?
11. Of the maternal deaths at your hospital Trust (in answer 10a), how many were referred to HSIB?
• 1 April 2019 to 31 March 2020?
• 1 April 2020 to 31 March 2021?
• 1 April 2021 to 31 March 2022?
• 1 April 2022 to 31 December 2022?

Births and deaths.100223.docx

In the 2018 calendar year were there any babies born at your hospitals where the weight of the baby was 12lbs (5443g) or more? If so please state how many and what their birthweights were.

Download response Birthweights. 250419

In the 12 months to date (23.08.18) please confirm the following:
1) Whether the Trust currently is, or has been in the past 12 months, engaged in a contract or written agreement with Bounty UK Limited. If the Trust is currently engaged in a contract please attach a copy of it, making necessary redactions in order to comply with the Act. Please provide the date that the contract began and/ or ended. Please provide an overview of the terms of payment. (i.e. per mother visited / per photo pack purchased).
2) Please confirm how much money has been paid to the Trust by Bounty UK Limited in the past 12 months and how many new mothers are recorded as having been approached by Bounty representatives (if held).
3) Please provide details of the policies the Trust has in place with regards to protecting new mothers (i.e. are representatives allowed on any ward at any time, or do they have restricted access? Are mothers given the option to opt out of being visited?)
4) Please confirm the number of complaints made to the Trust by new parents. If not time prohibitive, please provide details of the complaints.

Download response Bounty. 110219

Q1) Please provide the name of your Trust
Q2) Do you have a contract with Bounty, whose representatives hand out ‘Bounty Packs’ to new mothers on maternity wards?
Q3) If you answered YES to Question 2, how much money did your trust receive from Bounty in the financial years;
Q4) Please explain how the payment from Bounty is calculated (i.e. a pre-agreed figure, or a set payment per child born in your care).
Q5) How many babies were born in your care during the financial years?

Download response Bounty Packs. 110219

Please provide the number of cases where breast milk of a new mother was given to a child who is not her own at all maternity wards in your Trust.

For clarity, I am asking you to please provide the number of instances where a child on a maternity ward was given breast milk from a person who was not their mother.

Please provide annual figures for how many times this happened at your Trust for 2017, 2018, 2019, 2020, 2021, 2022 and so far in 2023.

Please also give the number of times disciplinary action was taken on a member of staff over these instances. Please provide a breakdown of the outcome of any disciplinary action: How many were cautioned, suspended, terminated etc as a direct result of the mistake.

Breast milk.100823.docx

1) How many children received treatment from your local CAMHS in the financial years:
a. 2014/15
b. 2015/16
c. 2016/17
d. 2017/18

2) Please can you breakdown the figures given in answer to Q1a-d by (i) the type of mental health issue that was being treated, and (ii) the ethnicity of the child?

Download response CAMHS. 170818

For each month between (and including) January 2018 and June 2021, please could you tell me the mean average number of days to elapse between a patient being assessed by your CAMHS service and that patient having their first appointment with an appropriate specialist as part of an ongoing treatment plan under CAMHS (as opposed to an appointment with a non-specialist; or supportive care while waiting for therapist availability; or an unscheduled call, letter or other contact that does not qualify as a treatment appointment)?

For each month, please could you specify which specialist or specialists were in attendance at those first treatment appointments, expressed as percentages of the total number of first treatment appointments that month (e.g., 74% of patients had their initial appointment as part of an ongoing treatment plan with a clinical psychologist, 20% with a CBT therapist etc)

Download response CAMHS treatment.160721.docx

The total number of children’s operations cancelled for non-clinical reasons, broken down by the cause of the cancellation, for example due to lack of beds, operating theatre capacity, staffing issues, and equipment failures. Please provide this information for each of the past three financial years 2017/18, 2018/19, 2019/20). In the total number of operations, broken down by cancellation reason, please include:

· Elective children’s operations cancelled at the last minute. For the purposes of this request, last minute means on the day the patient was due to arrive, after the patient has arrived in hospital or on the day of the operation or surgery.

· Cancelled urgent children’s operations.

For the purposes of this FOI, Children will be defined as under 18’s.

Download response Cancelled children’s operations. 131020

What is the name of your acute trust?
(1) Does your trust provide a weight management service for children living with obesity?
Yes ☐ No ☐
If No, you need not answer further.
If yes, what is the name of the service and where delivered:
Who leads this service?
It is a hospital ☐ or community-based☐ clinic
(2) What if any are the criteria for eligibility to attend (for instance BMI >98th percentile)?
None ☐
Eligible if:
(3) Through what mechanism is the service funded?
CCG ☐
NHS England ☐
Research ☐
Charity ☐
Trust Self-Funding ☐
Other ☐
Please specify
(4) Who are the key personnel providing service? Please tick all who apply:
a. Paediatricians ☐
b. Dieticians ☐
c. Psychologists ☐
d. Trained volunteers ☐
e. Hospital or Community based Nursing staff ☐
f. Exercise specialists ☐
g. Social workers ☐
h. CAHMS ☐
i. Youth workers ☐
(5) How many new cases are seen each year?
(6) Over how many weeks is the clinic intervention delivered?
(7) What is the usual follow up period (entry to discharge?)
(8) What final outcomes are collected: Examples: change in BMI, BMI SDS, Self Esteem, Waist Circumference, recruitment, retention.
Please list all.

Download response Childhood obesity services. 160320

1. The number of low secure Children and Adolescent Mental Health Service (CAMHS) and medium secure CAMHS beds within your Authority or Trust and how many of those are currently available for new admissions.
2. The number of low secure CAMHS beds within your Authority or Trust and how many of those are currently available for new admissions.
3. The number of medium secure CAMHS Service beds within your Authority or Trust and how many of those are currently available for new admissions.
4. The number of welfare social care secure beds within your Authority or Trust and how many of those are currently available for new admissions.
5. The number of forensic secure beds within your Authority or Trust and how many of those are currently available for new admissions.
Further, please could you kindly provide details of:
6. The number of young people within your Authority area or Trust area who have been assessed as requiring a CAMHS Tier 4 mental health bed but have not been admitted due to a shortage in resource (we do not require personal details or reasons for the conclusion reached, just numbers).
7. The number of young people within your Authority area or Trust area who have been assessed as requiring a CAMHS low secure mental health bed but have not been admitted due to a shortage in resource.
8. The number of children accommodated within your Authority area or Trust area in unapproved, unregulated settings.

Download response Children and Adolescent Mental Health Service (CAMHS). 051021.docx

1. Number of children attending A&E per month, since Jan 2019 due to a mental health related issue.
2. The top 10 longest stays in A&E of a child who is presenting a mental health issue over the last 12 months.

Children attending A&E due to mental health. 120422.docx

You asked:
Please may you tell me the number of people, under the age of 18, who were treated by the trust for alcohol dependence and/or alcohol misuse in 2012, 2013, 2014, 2015, 2016, 2017, and 2018?

May you please tell me the youngest person you treated for this in 2016, 2017 and 2018?

Download response Children treated for alcohol dependency or misuse. 151118

1. Between 1st April 2018 and 31st March 2019 how many visits to/patients were/are seen at Riverbank Children’s unit? (Volume)
2. Between 1st April 2018 and 31st March 2019 how many individual patients were/are seen at Riverbank Children’s unit? (Reach)
3. How many of these were transferred to Pembury?
4. On a typical day / on average how many patients are transferred from Riverbank to woodlands every day?
5. What are the main reasons for these transfers?
6. On a typical day/ on average many patients transfer each day due to the Riverbank closing time?
7. How often/ on average how many times a week do the staff at Riverbank have to stay past 8.00pm to accommodate patients needs/ transfer to Pembury?
8. Between 1st April 2018 and 31st March 2019 how many visits to/patients were/are seen at Woodlands and hedgehog Children’s unit? (Volume)
9. Between 1st April 2018 and 31st March 2019 how many individual patients were are seen at Woodlands and hedgehog Children’s unit? (Reach)
10. How many of these were transferred from Riverbank?

Download response Children’s Unit. 250919

All questions are shown as received by the Trust.
The purpose of this FOI request is to ascertain your Trust’s approach to screening for and treating congenital cytomegalovirus (cCMV).

The questions have been designed so that they can be answered within the limits (on time, cost, type of information etc.) set out in the Freedom of Information Act and the Information Commissioner’s Guidelines. If it is not possible to provide the exact information requested, please supply the underlying information in narrative form or whichever format you have available.

Definitions of acronyms and terms used in the FOI request:
CMV: cytomegalovirus
cCMV: congenital cytomegalovirus
SNHL: sensorineural hearing loss
‘Practices’ refers to any standard operating procedures or clinical protocols, guidelines, practices or pathways.
‘Information’ refers to any recorded information required to be disclosed in response to requests under the Freedom of Information Act.

If different hospitals or services within your Trust have different Practices or data availability, please provide separate Information or data for each hospital or service (indicating clearly which hospital or service the Information relates to).

Q1. Please provide copies of any Information containing or evidencing Practices used within your Trust whereby newborns who are referred to audiology following their newborn hearing screening test, or newborns/children who demonstrate abnormal hearing at a later stage, are tested for cCMV. Such Practices could include, but are not limited to, early cCMV detection pathways whereby newborns are tested at point of referral to audiology from the newborn hearing screening programme. Please include details about the intended timescales for testing, carrying out tests and returning test results, if this information is recorded.

Q2. If your Trust does employ Practices whereby newborns/children with abnormal hearing are tested for cCMV, please indicate at which stage samples are taken (you may select more than one):
❏ By the newborn hearing screener at the point of referral ❏ By the audiologist at the first appointment after babies have been referred from the newborn hearing screen ❏ By the audiologist at detection of SNHL in a baby referred from the newborn hearing screen ❏ By another healthcare professional (not an audiologist) following detection of SNHL in a baby referred from the newborn hearing screen ❏ At detection of SNHL in older babies and children (i.e. after the newborn hearing screening and testing period) ❏ Unknown ❏ Other, please provide details:

Q3. If your Trust does employ Practices whereby newborns/children with abnormal hearing are tested for cCMV, please indicate what type of sample is taken (you may select more than one):
❏ Saliva swab
❏ Urine
❏ Blood test for the infant
❏ Blood test for the mother
❏ Infant blood spot (Guthrie) card testing ❏ Unknown ❏ Other, please provide details:

Q4. Please provide copies of any Information containing or evidencing Practices used within your Trust whereby children are tested for cCMV as part of investigations of symptoms (in either the mother or child) that are unrelated to hearing. These could include:
Maternal symptoms of CMV (flu-like symptoms) Symptoms of congenital infection identified before or after birth, such as:
• Antenatal abnormalities e.g. on ultrasound scan
• Characteristic rashes caused by cCMV (petechiae or blueberry muffin rash)
• Intrauterine Growth Restriction
• Microcephaly
• Jaundice
• Hepatosplenomegaly
• Neonatal visual signs/symptoms
• Neonatal seizures
Symptoms of congenital infection in older children, such as:
• Neurodevelopmental delays
• Special educational needs and disabilities (e.g. autism, ADHD)
• Cerebral palsy
• Seizures
• Visual or sensory impairment

Q5. Please provide copies of any Information containing or evidencing Practices used within your Trust following a diagnosis of cCMV in a child. This could include, but is not limited to:
• Information about any Practices involving the prescribing of antiviral treatments
• Details of the department(s) that the child would be referred to

Questions 6-9 relate to the provision of data for a specific five-year period. If you do not hold data for this time period, please supply data for any period for which you have available data (preferably a recent five-year period) and specify the beginning and end dates. If the answer to any question is between 1 and 5 (and therefore the true figure cannot be shared in accordance with Section 40 of the Freedom of Information Act), please indicate this by giving the answer “<5”. Please also indicate if the relevant hospitals or services within your Trust have changed during this period.

Q6. Between 1 January 2018 and 31 December 2022, how many children were diagnosed with cCMV within 28 days of birth, within your Trust? This should include children born outside of your Trust who were diagnosed by services within your Trust.

Q7. Of the children who were diagnosed with cCMV within 28 days of birth in this time period (Q6), how many:
a. Previously had a newborn hearing screening test
b. Had been referred to audiology following their newborn hearing screening test
c. Were given antiviral treatment for cCMV following diagnosis

Q8. Between 1 January 2018 and 31 December 2022, how many children were diagnosed with cCMV between 28 days and 18 years of age, within your Trust? This should include children born outside of your Trust who were diagnosed by services within your Trust.

Q9. Of the children who were diagnosed with cCMV between 28 days and 18 years of age in this time period (Q8), how many:
a. Previously had a newborn hearing screening test
b. Had been referred to audiology following their newborn hearing screening test
c. Were given antiviral treatment for cCMV following diagnosis

Congenital cytomegalovirus screening and treatment practices and data.300124.docx

We require sight of the Cooling/Therapeutic hypothermia protocol in the neonatal and/or Special Care Baby Unit at Maidstone & Tunbridge Wells NHS Trust, that was in force in November 2015. We are merely requesting this to provide us with knowledge in accordance with the act.

Download response Cooling-Therapeutic Hypothermia Protocol. 101220

1) Do you allow private stem cell companies to promote their services on your sites, e.g. leaflets?
2) Do you allow representatives from stem cell companies on any of your sites to promote or collect cord blood, e.g. in delivery suites?
3) Does the Trust allow its staff to work for stem cell companies, e.g. collecting umbilical cord blood for private companies?
4) How long (how many minutes) does the Trust consider ‘optimal’ cord clamping?
5) Please supply the following information for each of the individual calendar years: 2015, 2016, 2017, 2018 and 2019 to date:
a) The number of babies born whose umbilical cord blood was collected for banking by a private company.
b) The number of babies born whose umbilical cord blood was collected for banking by the NHS.
c) The income received from stem cell companies.

Download response Cord blood stem cells. 300819

Please provide under the FOI act, the figures for each of the last 5 years (please provide data for each calendar year data 2015-2020)
Please provide the following figures per calendar year:
1. How many live births occurred in your organisation (please break this down to premature and term babies)
2. How many of these live births had cord clamping as being recorded at being at or after one minute? (please break this down to premature and term babies)
3. Please provide the numbers where cord clamping occurred before one minute (please break this down to premature and term babies)
4. How many times this was not documented (please break this down to premature and term babies)
5. Please provide any audits in the last 5 years on cord clamping times.
6. Is it mandatory to record the cord clamping time on any of your systems?

Download response Cord clamping. 011121.docx

1. “Since 01 January 2017, please specify the number of individual cases where the Court has had to intervene in the treatment of a critically ill child, when there has been a difference of opinion between parents and doctors, over the course of treatment for that child?”

Download response Court intervention. 141119

PART 1: ABOUT PAEDIATRIC COMMUNICATION

1. Is there a psychologist dedicated to paediatric wards?
2. Who is in charge to communicate about care and hospitalization practices? (multiple answers)
3. What kind of communication material do you use inside your ward in order to support and enhance the experience of the child and his/her family in hospital, providing information on his/her clinical condition, exams and treatment?
* If you choose “Paper” or “We don’t use communication material” go to PART 3

PART 2: ABOUT THE USE OF TECHNOLOGICAL DEVICES

1. IF YOU USE TECHNOLOGICAL DEVICES, which of the following ones are used in the ward to communicate with and support THE CHILD : (multiple answers)
2. If you use technological devices, which of the following ones are used in the ward to communicate with THE PARENTS: (multiple answers)
3. If you use technological devices, which of the following ones are used in the ward to communicate with THE SIBLINGS: (multiple answers)
4. If you use technological devices, which of the following ones are used in the ward to communicate with THE CHILDREN OF HOSPITALIZED PARENTS: (multiple answers)
5. If you use technological devices to communicate with the child and his family, what do they apply to, CONSIDERING THE CLINICAL CONDITIONS? (multiple answers)
6. If you use technological devices to communicate with the child and his family, what do they apply to, CONSIDERING THE TYPE OF INTERVENTION? (multiple answers)
7. What are the goals of the technological devices you use? (multiple answers)
8. Can you mention some examples of the technological devices you use?
9. Have you published an assessment study on the efficacy of the tool?
10. If your answer was YES, could you please give us references?
* If you use technological devices DON’T answer to PART 3

PART 3: ABOUT THE EVENTUAL USE OF TECHNOLOGICAL DEVICES

1. IF YOU DON’T USE TECHNOLOGICAL DEVICES – Do you think they could be useful tools to improve the quality of communication directed to the child and his family?
2. IF YOUR ANSWER WAS YES – For which clinical conditions? (multiple answers)
3. AND – For which type of intervention? (multiple answers)
4. Which purpose should they set themselves? (up to 3 answers)
5. Why don’t you use technological devices to communicate with the children and their families? (up to 3 answers)

Download response Digital devices inside Paediatric Wards. 081121.docx

We seek information about the evaluation and care given to those with Disorders of Sex Development. In particular, we would like to know more about the number of international referral requests received by your trust from Malta.
We have put together a list of questions, which we would be grateful if you could answer in this order:
1) Since 2015, how many children receiving diagnostic tests and/or treatment for DSDs have been referred to this trust from Malta?
2) Of these children, how many are government-sponsored patients?
a. How many pay privately?
3) Of these referrals, how many have undergone genital surgeries?
4) Which specific DSDs have been referred from Malta? (e.g. Congenital Adrenal Hyperplasia, Androgen Insensitivity Syndrome, Turners Syndrome). If possible, please list them.
5) Are there specific legal or ethical guidelines tailored for Maltese patients?

Disorders of Sex Development in Children. 150222.docx

1. Who provides expert evaluation of gender assignment in newborns with Disorders of Sex Development?

2. Does the trust use a multidisciplinary team that deals with the evaluation and long-term management and needs of patients with Disorders of Sex Development?

3. If yes to question 2, can you provide contact details for the team?

4. What specialties are represented on the multidisciplinary team (e.g. paediatric subspecialists in endocrinology, surgery, and/or urology, psychology/psychiatry, gynaecology, genetics, neonatology, and, if available, social work, nursing, and medical ethics)? Please list them.

5. When dealing with Disorders of Sex Development, what guidelines, if any, do decision makers follow?

6. How many people are referred to this team per year (please give numbers for the last five years)?

Download response Disorders of Sex Development in the UK. 070818

The Royal College of Obstetricians and Gynaecologists ran an initiative called Each Baby Counts aimed at reducing the number of intrapartum stillbirths, early neo-natal deaths and babies born with severe brain injuries. Please provide the total number of notifiable cases reported to the initiative by your organisation and the time period the data relates to, e.g. 1 January 2015 – 31 December 2019.

Each Baby Counts. 140322.docx

1) How many admissions of children (under 18’s) presenting with eating disorders your trust has recorded in the past five years?
2) I would like to know how many of these children treated were male/female/transgender.
3) Please present all this information simply and clearly and break it down by year. Please provide as much detail as possible about the nature of their illness (I understand that some children may present with multiple illnesses). I would like this information broken down by type of eating disorder e.g. bulimia, anorexia etc.

Download response Eating disorders. 160119

Please provide the following for the last five years, from Jan 1 2019 until December 31 2023.
Please break each of the following down by year (i.e. January 1 2023-December 31 2023; January 1 2022- December 31 2022, etc), and only include each case once (i.e. not the number of occasions one individual attempts to access services):
1. How many cases or suspected cases of FGM have been identified?
2. How many of these cases were identified of children under 18?
3. Of the cases identified in children under 18, how many cases were referred to the police?
4. Of all the cases recorded, how many cases were referred to the police?
5. Of the cases identified, how many individuals requested reconstructive surgery via the NHS? Please include the type of reconstructive surgery.
6. How many of these individuals underwent reconstructive surgery via the NHS? Please include the type of reconstructive surgery.
7. Where this data is recorded, please provide the number of individuals who underwent reconstructive surgery out of the NHS.
8. How many of the people identified as victims of, or likely victims of, FGM were referred to psychological or mental health support services?
9. How many people were referred to specialist FGM support clinics?
Again, please provide all the above for the last 5 years (from Jan 1 2019-Dec 31 2023), broken down by each year.

FGM in England and Wales.300124.docx

1. Do you distribute any free promotional disposable nappies (such as Pampers) or reusable nappies to parents at any services, including (but not exhaustive of) antenatal, maternity, midwife, post-natal and family services?
If the answer is yes to 1, please answer questions 2-7.
2. Which disposable or reusable nappy brand do you allow to distribute their promotional nappies?
3. Which services are they distributed at and how many parents use these facilities annually?
4. How frequently a year have these disposable or reusable nappy brands been able to distribute their promotional material at these services?
5. What is the process for allowing disposable or reusable nappy brands to distribute at your services and who signs it off?
6. Is there any remuneration for the NHS from these disposable or reusable nappy brands for distributing their promotional material?

Download response Free promotional disposable nappies.260219

1. Total number of children currently on your waiting lists and for each of the past five years.
2. The average waiting time from referral to treatment by year for each of the past five years.
3. The total number of children currently on the waiting list who have waited more than a) six months b) one year c) 18 months
3. The five longest waits faced by people currently on the waiting list in days.
4. The number of children (under 18s) who have a surgical procedure cancelled or delayed at your trust, in each of the past five calendar years (2022, 2021, 2020, 2019, 2018).

General anaesthesia (GA) paediatric dental waiting times.140223.docx

I write under the Freedom of Information Act to request copies of all Clinical policies and procedures, guidelines and standards that were in use to govern the clinical decisions concerning the treatment of Haemolytic disease of the newborn (HDN) also known as Rhesus Disease/Maternal Antibodies made in the Neo-natal units within the Maidstone & Tunbridge Wells NHS Trust from 1998 to 2002.

These documents will include but not be limited to the management of :

Rhesus Disease
Haemolytic Disease of the newborn (HDN)
Neo natal jaundice in pre-term and term neonates
Hyperbilirubinemia in the newborn
Phototherapy
Exchange transfusions in neonates

And any other interventions/guidelines into how to treat Haemolytic Jaundice in newborns.

These documents pre-date NICE guidelines and the parameters of 1998 – 2002 are especially important.

Download response Haemolytic disease of the newborn (HDN) also known as Rhesus Disease-Maternal Antibodies. 300920

1. An anonymised list of babies born in the Trust who underwent controlled cooling as result of confirmed or suspected hypoxic ischemic encephalopathy(HIE), between 1 September 2010 and 1 September 2020;
a. the grade of HIE; and
b. the ethnic origin of mother and baby
2. An anonymised list of babies born in the Trust who died as a result of confirmed or suspected hypoxic ischemic encephalopathy(HIE), between 1 September 2010 and 1 September 2020;
a. the grade of HIE; and
b. the ethnic origin of mother and baby

Download response Hypoxic ischemic encephalopathy (HIE). 271120

Request 1
Please confirm or deny if Maidstone and Tunbridge Wells NHS Trust has a specific policy on provision of support for all forms of infant feeding, specifically breastfeeding, formula feeding, and combination feeding.
If confirm, please provide a copy of this policy.
Request 2
Please confirm or deny if Maidstone and Tunbridge Wells NHS Trust holds information on the number of infants breastfed, formula fed, and combination fed.
If confirm, please release this data.
Request 3
Please confirm or deny if Maidstone and Tunbridge Wells NHS Trust provides information on all forms of infant feeding (including breastfeeding, formula feeding, and combination feeding) at the 28-week antenatal appointment as outlined in the NICE guideline NG201, post-birth before the family has been discharged and at any other times.
If confirm, please provide a copy of the information on infant feeding that is provided and confirm how as well as when it is delivered.
Request 4
Please confirm or deny if Maidstone and Tunbridge Wells NHS Trust requires mothers to sign a consent form before any information or advice is given on formula feeding OR before an infant receives formula milk in the hospital instead of or alongside breastmilk.
If confirm, please publish a copy of the associated policy and corresponding form.
Request 5
Please confirm or deny if Maidstone and Tunbridge Wells NHS Trust holds information on the number of infants admitted with malnutrition every year, over the last 5 years.
If confirm, please release this data and please publish the Maidstone and Tunbridge Wells NHS Trust policy for addressing infant malnutrition.

Infant feeding.300623.docx

1. Details of the brand(s) of infant formula milk provided in maternity services and the form in which it is provided (e.g. powdered, ready-made bottles, ready-made bottles with teets etc.)

2. Details of your infant formula milk provider, the amount paid and volume received in the last available financial year, and details of whether the infant formula milk is purchased from them at full price, a reduced rate (including details of the reduction if applicable) or received free of charge.

Download response Infant Formula. 140319

1. What antenatal advice does the trust routinely give to mothers about infant skincare including the bathing of babies?
2. What postpartum advice does the trust routinely give to mothers about infant skincare including the bathing of babies?

Infant skincare advice.031022.docx

Please can you provide me with the following information regarding the initiation of the following Insulin Patch Pumps for both Adult and Paediatric Patients at Maidstone Hospital, Pembury Hospital, Tunbridge and Abbey Court
2019 – 2020: Number of Omnipod Patch Pump Users
Number of Medtrum TouchCare Nano Patch Pump Users
2020 – 2021: Number of Omnipod Patch Pump Users
Number of Medtrum TouchCare Nano Patch Pump Users
2021 – 2022: Number of Omnipod Patch Pump Users
Number of Medtrum TouchCare Nano Patch Pump Users

Insulin Patch Pumps for both Adult and Paediatric Patients.290322.docx

1. For each of the years 2010 and 2020, how many investigations under section 47 of the Children Act 1989 involved any of these terms in the referral:
a. Fabricated or Induced Illness or FII
b. Munchausen Syndrome by Proxy or MSbP
c. Perplexing Presentation or PP
d. Factitious Disorder Imposed on Another or FDIoA
e. Snomed Code System Concept Code: 95637005
2. How many of those investigations led to a child protection plan, and how many resulted in no further action being taken?

Download response Investigations under section 47 of the Children Act 1989. 050721

I would like to understand how patients with juvenile ideopathic arthritis are being treated. So, in the last 6 months, how many patient(s) with juvenile ideopathic arthritis have been treated with:
Humira (adalimumab)
Amgevita (adalimumab)
Imraldi (adalimumab)
Hyrimoz (adalimumab)
Hulio (adalimumab)
Tocilizumab
Abatacept
Enbrel (etanercept)
Erelzi (etanercept)
Benepali (etanercept)
Golimumab
Remicade (infliximab)
Remsima (infliximab)
Inflectra (infliximab)
Flixabi (infliximab)
Canakinumab
Anakinra

Download response Juvenile Idiopathic Arthritis. 031219

Could you send me your policy relating to the Kangawrap/kangaroo care and skin to skin please?

Download response Kangawrap or Kangaroo Care and skin to skin. 270918

1. Between 1 September 2018 and 1 September 2022, how many complaints of sexual misconduct were made by patients, visitors and Trust employees against staff members in your NHS Trust.
2. How many of the complaints were upheld?
3. What was the outcome of the upheld complaints? Outcomes can include but are not limited to verbal warning, written warning, suspension, or dismissal
If it does not push the request over the cost limit, please can you also include:
4. The nature of the allegation
5. The gender of the complainant
6. The gender of the staff member

Allegations of sexual misconduct.040123.docx

1. A list of every amputation operation at your hospital over the past ten years.
2. The amount of cases of the above that have resulted in claims of medical negligence.
3. The amount of cases of the above that have resulted in your informing your insurers of a possible claim for medical negligence.
4. The details of each incident.

Download response Amputation operations. 201119

1. How much money has been paid out in compensation for botched breast augmentation or botched breast enlargements? Please provide information for the last three years.
2. How many people have made successful compensation claims for botched breast augmentation or botched breast enlargements? Please provide information for the last three years.
3. How many unsuccessful claims for compensation for botched breast augmentation or botched breast enlargements has there been in the last three years?
By last three years I mean 2015, 2016 and 2017. Please provide information for each calendar year.

Download response Breast augmentation claims. 010319

Could you please tell me between 1st March 2020 and the date of this email (31st July 2020):
1) How many PALS enquiries and official complaints your Trust has received from patients concerned about
a) the impact of the coronavirus pandemic and your Trust’s response on their access to cancer treatment
b) and access to cancer testing – including tests to find out whether their cancer has spread, returned or occurred for the first time
NOTE: I suggest you search for these complaints by using the keywords ‘cancer treatment’, ‘chemotherapy’, ‘cancer testing’, ‘coronavirus’, ‘COVID-19’ and other relevant terms.
2) For the five most recent PALS enquiries/official complaints received, please provide me with
a) a summary of the complaint (e.g. a patient with stage 4 lung and breast cancer has contacted PALS to complain about their chemotherapy being indefinitely suspended)
b) the exact wording of the complaint, with redactions to remove potentially identifying information
c) what action the Trust took in response

Download response Cancer complaints. 170820

1. How many hospital negligence claims have been made against the Trust relating to deep vein thrombosis and pulmonary embolism (blood clots) in the last five financial years?
2. Of the legal claims referred to in question 1, how much money has been paid to those who have brought claims against the Trust?
3. Please break down the data to questions 1 and 2 by hospital.

Download response Claims relating to deep vein thrombosis (DVT) and pulmonary embolism (PE). 010319

1. Between January 2018 and February 2022 how much in total did the Trust spend on compensation pay outs, including court costs
2. Could you also provide the number of claims by category and the total amount of compensation for this category since 2018? e.g. ‘inadequate nursing care’ or ‘maternity

Compensation pay outs and court costs.010422.docx

1) How many compliments did your trust receive in 2017?
2) Do you have a procedure for handling compliments?
3) Do you respond to the authors?
4) Do you pass the compliments onto to the complimentees?
5) Do management see copies of compliments?
6) Do you analyse the content of compliments?

Download response Complaints. 090719

I am seeking information about the number of complaints received by your hospital trust in the past five years for the following specialties: neurosurgery, orthopaedic surgery, cardiothoracic surgery, and vascular surgery.
Specifically, I would like to request the following information for each specialty:
1. The total number of complaints received for each specialty in each of the past five years;
2. The nature of the complaint;
3. The outcome of the complaint, including any actions taken by the hospital trust to address the issue;
I did have a quick question as to whether I could incorporate two further questions into my request. This would put any complaint data you able to provide into an appropriate context (e.g. to contextualise 10 complaints with the fact 1,000 operations were performed):
4. Number of operations performed in the past five calendar years for the following specialties: neurosurgery, orthopaedic surgery, cardiothoracic surgery, and vascular surgery;
5. Number of reportable / recordable patient safety incidents in the past five calendar years for the following specialties: neurosurgery, orthopaedic surgery, cardiothoracic surgery, and vascular surgery
a. Breakdown by incident category (if available);
Complaints.220323.docx

All questions are shown as received by the Trust.
Between 1st September 2022 and 31st August 2023 (inclusive). Specifically, I would like to know:

How many women inpatients complained that a trans woman inpatient was being cared for in the same ward as the complainant?

For the avoidance of doubt, it may be helpful for me to note that my question is in reference to written complaints (which may have been originally made orally and subsequently recorded in writing) received by the Trust.

Complaints.241123.docx

1. Does the Trust routinely publish the complaints data it reports to NHS Digital (KO41a) via any other public channel, i.e. on your website (please indicate YES or NO in the box below)? If YES, please provide details of where and how frequently you publish this data.
Further information on publication:
2. Does the Trust routinely publish, make public or evidence the outcomes and/or learning taken from complaints received (please indicate YES or NO in the box below)? If YES, please provide details of where and how frequently you publish this data.
Further information on publication:
3. Do you record complaints made by third parties who don’t have the expressed consent of the patient(s)? I.e. members of the public, people visiting other patients and/or external non-medical contractors who have concerns about the way patients are being treated or cared for.
4. If you record complaints made by third parties, please could you provide the numbers of complaints received by your NHS Trust for the following financial years?
5. Do you record complaints made by third parties in your official complaints figures as reported to NHS Digital (KO41a)?

Download response Complaints. 280119

All questions are shown as received by the Trust.
1. Have you implemented any EDI (equality, diversity and inclusion) policies/initiatives on race in your trust?
2. Have you received any complaints, either from staff or the general public, about these policies/initiatives?
3. If so, please provide details of the total number of complaints you have received, reasons given for the complaint/s and any actions taken.

Complaints about EDI Policies.160524.docx

I would like to know how many complaints/issues have been lodged or raised in any way about this/these consultants.

Complaints against consultants.270422.docx

All questions are shown as received by the Trust.
1. How many complaints has the trust received from July 2022 to July 2023?
2. How many of these complaints are related to poor or substandard care?
3. How many medical negligence claims were lodged against the trust in the same period?
4. How much compensation has the trust paid out in medical negligence claims in the past 12 months irrespective of when the claim was made?

Complaints and Claims.131023.docx

1) Please can you tell me the name of your Trust?
2) How many patient complaints has your Trust received, for any given reason?
Please break down into the following calendar years
2017
2018
2019
3) How many patient complaints has your Trust received, citing racism as one of the problems during the patient’s treatment?
Please break down into the following calendar years
2017
2018
2019
4) How many complaints relate to the treatment of women who have given birth in your Trust?
Please break down into the following calendar years
2017
2018
2019
5) How many of those from Q4 included racism in their complaint?
2017
2018
2019
6) How many members of staff have received some form of disciplinary action due to a complaint by a patient?
Please break down into the following calendar years and please list what action was taken.
2017
2018
2019
7) How many members of staff have received some form of disciplinary action, whereby racist behaviour towards the patient was included? Please break down into the following calendar years and please list what action was taken where possible.
2017
2018
2019
8) How many members of staff have made a complaint regarding racism from a patient?
Please break down into the following calendar years
2017
2018
2019

Download response Complaints and Racism. 040121

1. How many complaints were upheld by the Ombudsman?
2. How many complaints were partly upheld by the Ombudsman?
3. What was your complaints (3 working days) performance as a percentage?
4. What was your complaints (final response) performance target in days?
5. What was your performance as a percentage in response to this target? (e.g. 75% of complaints are answered within 25 working days or as agreed with the complainant)
6.How many days does it take on average for you to respond to a complaint?

Download response Complaints data for 2018-19. 151119

1. For each of the last three calendar years (2019, 2018, 2017), please provide a monthly list of the chief complaints for patients admitted to A&E, broken down by:
• The name of the chief complaint.
• The number of patients admitted to A&E for each chief complaint.
• The number of male patients admitted for each chief complaint.
• The number of female patients admitted for each chief complaint.
Please note that the Chief Complaint is the presenting symptom rather than the primary diagnosis.
2. For each of the last three calendar years (2019, 2018, 2017) please disclose the total number of patients that were admitted to A and E.
3. For each of the last three calendar years (2019, 2018, 2017) please disclose the total number of patients admitted to A and E that were not GP registered.

Download response Complaints for patients admitted to A&E.241219

1. In your trust, in each of the last 5 calendar years, how many formal patient/family complaints were made regarding communication?
2. How many of these complaints were regarding lack of updates to Next of kin or patient families?
3. In your trust in the last 5 years, what were the top 5 categories for complaints? For example, ‘communication’ or ‘clinical care’ may be examples

Complaints made regarding communication.201222.docx

Please detail the number and type of complaints made to your End of Life Care Strategy Group in the last four years. Please break the information down into complaints per month (where possible) and whether the complaint was to do with, for example poor communication, issues to do with consent or the care itself etc. Where recorded, please also detail the outcome of the complaint.

Download response Complaints made to the End of Life Care Strategy Group. 070219

Q1.) For each of the past five years please state the number of complaints reported by members of staff (including locums, agency workers or casual staff) against other members of staff received of:
2016 2017 2018 2019 2021
a) Sexual Misconduct
b) Sexual Harassment
c) Sexual Assault
d) Rape Allegation
Q2.) By year for each of the complaints recorded above can you state the outcome following each allegation:
a) Complaint withdrawn
b) Insufficient evidence to make a finding of fact.
c) Perpetrator cautioned – or similar note made on their employment file
d) Disciplinary action
e) Sacked
Q3.) By year can you state in each category in the table how many of the complaints were referred to the police?
Q4.) By year, please state the number of settlement/compromise agreements which contain non-disclosure clauses your organisation made with current or former staff which involve or relate to sexual misconduct, sexual harassment, sexual assault, rape. For each of these, please state the number and financial value of the settlements.

Complaints reported by members of staff (including locums, agency workers or casual staff) against other members of staff. 030322.docx

1. How many people does your organisation employ?
2. What is the total annual expenditure budget of your organisation?
3. How many full-time employment staff does your organisation employ dedicated to counter fraud activities?
4. If you employ such staff, how many full-time employment staff are directly employed by your organisation?
5. If any of your counter fraud staff are supplied by another organisation, could you identify the name of the organisation(s) which supplies them?
6. Approximately how much did you spend on counter fraud activities in the last reporting year?
7. How many referrals for fraud investigation has your counter fraud team received in the last reporting year?
8. How many fraud cases has your counter fraud team successfully investigated? I.e. leading to sanction and/or recovery of monies in the last reporting year.

Download response Counter Fraud. 030619

1. Staff headcount at your organisation?
2. Annual budget of your organisation for the financial year 2019-2020?
3. What is your organisation provider type (as recorded on your SRT submission – i.e. Acute teaching, Ambulance)?
4. Who provides your organisations counter fraud provision? (In house – NHS consortium – Private provider)
5. How many days were recorded for proactive counter fraud work (Strategic governance, Inform and Involve & Prevent & Deter) carried out at your organisation during the financial year 2019-20?
6. How many days were recorded for carrying out reactive investigation work at your organisation during the financial year 2019-20 (hold to account)?
7. How many counter fraud referrals did your organisation receive during the financial year 2019-2020?
8. What was the recorded fraud loss identified by your organisation during the financial year 2019-2020?
9. What was the amount of fraud losses recovered by your organisation during the financial year 2019-2020?
10. How many criminal sanctions relating to fraud, bribery and corruption did your organisation apply during the financial year 2019-2020?
11. How many disciplinary sanctions relating to fraud, bribery and corruption did your organisation apply during the financial year 2019-2020?
12. What was the cost of counter fraud staffing or outsourced counter fraud provision to your organisation during 2019-2020 for – Strategic Governance, Inform and Involve and Prevent and Deter?
13. What was the cost of counter fraud staffing or outsourced counter fraud provision to your organisation during 2019-20 for – Hold to Account?

Download response Counter fraud provision. 230920

1. “Since 01 January 2017, please specify the number of individual cases where the Court has had to intervene in the treatment of a critically ill child, when there has been a difference of opinion between parents and doctors, over the course of treatment for that child?”

Download response Court intervention. 141119

All questions are shown as received by the Trust.
1. How many complaints of each of the following types of discrimination were reported to your organisation in 2021, 2022 and 2023:
a) Disability discrimination
b) Race or ethnicity discrimination
c) Sexual orientation discrimination
2. How many complaints were reported to your organisation about discrimination related to a person’s HIV status in:
a) 2021
b) 2022
c) 2023
3. If HIV-related discrimination complaints were reported to your organisation, how many of the following incidents were reported?
(a) Refusal of a service after HIV status was shared.
(b) Failure to make reasonable adjustments for a person’s HIV status.
(c) Harassment related to a person’s HIV status.
(d) Use of an organisational policy that discriminated against a person based on their HIV status.
(e) Another kind of HIV discrimination incident.
4. If HIV-related discrimination complaints were reported to your organisation, were they reported by?
(a) Members of the public.
(b) Employees of your organisation
5. If HIV-related discrimination complaints were reported to your organisation, how many complaints were upheld?
6. Does your organisation have a policy to deal with incidents of HIV discrimination reported to them at a strategic level? If so, could you explain what the policy is or attach a copy of said policy?

Discrimination complaints.130524.docx

All questions are shown as received by the Trust.
I am requesting information from the following financial years: 2018/19; 2019/20; 2020/21; 2021/22; 2022/23; and 2023/24 to the present day.
Please disclose the following:
1. How many employment tribunal (ET1) claims have been made against the organisation since 2018/19;
If possible, please break this down by type (e.g., public interest disclosure, unfair dismissal, discrimination). If this breakdown takes too long to respond to the FOI then please omit it.
2. Of those ET1 claims, how many have been defended against by the organisation since 2018/19;
Again, continue with a breakdown by type. If this exceeds the time limit then please omit it from the FOI request.
3. The outcomes from each claim (e.g., 12 were in favour of the claimant, 24 were in favour of the respondent, 53 were discontinued/settled out of court);
4. How much (£) has the organisation spent on defending claims since 2018/19; and
If possible, please provide total figures based on case outcomes (e.g., £200,000 where the tribunal favoured claimant, £120,000 where the tribunal favoured respondent).

If this takes too much time, please provide the total figure for each financial year (e.g., £500,000 in 2018/19, £250,000 in 2019/20).
5. Of the cases defended, how many led to an employment tribunal ruling the organisation must pay costs to the claimant;
If possible, please provide figures for each individual case alongside the total. If this takes too much time, please provide the total figure for each financial year (e.g., £500,000 in 2018/19, £250,000 in 2019/20).
Please also break this down by case type. However, as with above, if this takes too long then please omit it from the FOI.
If question 5 takes too long to answer alongside questions 1-4, then please omit it from the FOI request.

Employment tribunal claims and costs.081123.docx

In the recent BBC health news, published on 23rd May 2023, suggesting that more than 35,000 incidents of sexual misconduct and sexual violence were recorded on NHS premises between 2017 to 2023.
I seek information regarding the ethnicity or national identity of the perpetrators and the victims in cases of sexual misconduct and violence in your Trust.

Ethnicity or national identity of the perpetrators and the victims in cases of sexual misconduct and violence.060723.docx

1. What is your spend with external law firms
2. Do you use eBilling technology to manage your law firms billing (e.g. systems such as Legal Tracker, Brightflag, Apperio, CT Tymetrix, Mitratech etc.)
3. Who is your head of legal / general counsel
4. Do you have a law firm panel / preferred supplier list / use a framework to buy your external law firm services

Download response External law firm services. 161121.docx

All questions are shown as received by the Trust.
1. What is your spend with external law firms (please provide for the last 4 financial years)?
2. Do you use eBilling technology to manage your law firms billing (e.g. systems such as Legal Tracker, Brightflag, Apperio, CT Tymetrix, Mitratech etc.)?
3. Who is your head of legal / general counsel (please provide email address)?
4. Do you have a law firm panel / preferred supplier list / use a framework to buy your external law firm services? Please provide details where possible.

External Law Firms.030124.docx

1) How many official complaints and PALS concerns your Trust received from patients alleging they had been discriminated against or badly treated by a member of staff because of their being overweight or obese
2) Can you select the first five such complaints from 2021 and provide me with the following details:
a. What type of staff member was the complaint levelled against? E.g. healthcare assistant, junior doctor, consultant, cleaner, kitchen staff
b. Please quote the words allegedly used by the hospital staff or summarise the offending action
c. Please tell me what, if any, action was taken by your trust in response to these five sample complaints from the beginning of 2021

Fat shaming 2021.270522.docx

Could you please tell me for the calendar year 2019:
1) How many complaints through the patient advice and liaison system (PALS) your Trust received from patients alleging they had been discriminated against or badly treated by a member of staff because of their being overweight or obese
Please do this by searching for complaints containing any of the words “weight”, “fat”, “obese”, “overweight” and “bariatric” and filtering these to find those that refer to fat-shaming comments made by a member of staff.
2) Can you select the first five such complaints from 2019 and provide me with the following details:
a. What type of staff member was the complaint levelled against? E.g. healthcare assistant, junior doctor, consultant, cleaner, kitchen staff
b. Please quote the words allegedly used by the hospital staff or summarise the offending action
c. Please tell me what, if any, action was taken by your trust in response to these five sample complaints from the beginning of 2018

Download response Fat shaming complaints. 020620

1) How many complaints through the patient advice and liaison system (PALS) your Trust received from patients alleging they had been discriminated against or badly treated by a member of staff because of their being overweight or obese
Please do this by searching for complaints containing any of the words “weight”, “fat”, “obese”, “overweight” and “bariatric” and filtering these to find those that refer to fat-shaming comments made by a member of staff.
2) Can you select the first five such complaints from 2020 and provide me with the following details:
a. What type of staff member was the complaint levelled against? E.g. healthcare assistant, junior doctor, consultant, cleaner, kitchen staff
b. Please quote the words allegedly used by the hospital staff or summarise the offending action
c. Please tell me what, if any, action was taken by your trust in response to these five sample complaints from the beginning of 2020

Download response Fat shaming complaints. 140521

Could you please tell me for each of the years 2016, 2017 and 2018

How many complaints through the patient advice and liaison system (PALS) your trust received from patients alleging they had been discriminated against or badly treated by a member of staff because of their being overweight or obese.

Please do this by searching for complaints containing any of the words “weight”, “fat”, “obese”, “overweight” and “bariatric” and filtering these to find those that refer to fat-shaming comments made by a member of staff.

Can you select the first five such complaints from 2018 and provide me with the following details:

1. What type of staff member was the complaint levelled against? E.g. healthcare assistant, junior doctor, consultant, cleaner, kitchen staff

2. Please quote the words allegedly used by the hospital staff or summarise the offending action

3. Please tell me what, if any, action was taken by your trust in response to these five sample complaints from the beginning of 2018

Download response Fat-shaming complaints. 210519

1. How many inpatients developed food poisoning (relating to E.coli, listeria, campylobacter, salmonella or other) during a stay at the hospitals in your trust between the end of May 2018 and the end of May 2019?
2. How many inpatients developed food poisoning (relating to E. coli, listeria, campylobacter, salmonella or other) during a stay at the hospitals in your trust between the end of May 2013 and the end of May 2014?
3. Are meals prepared on site or off the premises by an outside provider?
4. How many complaints did you receive about hospital food between the end of May 2019 and the end of May 2018?
5. How many complaints did you receive about hospital food between the end of May 2013 and the end of May 2014?

Download response Food poisoning. 020819

All questions are shown as received by the Trust.
1. The number of Formal Grievances lodged by employees at Maidstone and Tunbridge Wells NHS Trust since the 1st January 2015.
2. The number of occasions on which the Trust employed the use of a protected conversation in their handling of a Formal Grievance by an employee in the same time period.
3. The number of those protected conversations which went on to lose their legal protection as a result of improper behaviour on behalf of the Trust’s representative. Improper conduct includes but is not limited to:
• all forms of harassment, bullying and intimidation, including through the use of offensive words or aggressive behaviour;
• physical assault or the threat of physical assault and other criminal behaviour;
• all forms of victimisation;
• discrimination because of age, sex, race, disability, sexual orientation, religion or belief, transgender, pregnancy and maternity and marriage or civil partnership; and
• putting undue pressure on a party

Formal Grievances.080923.docx

1. Please can you detail the number of grievances & bullying and harassment complaints that have been raised in the last 5 years.
1st April 2018 – 31st March 2019
1st April 2019 – 31st March 2020
1st April 2020 – 31st March 2021
1st April 2021 – 31st March 2022
1st April 2022 – 31st November 2022
2. How many of the above cases remain unresolved as of 31st November 2022.
3. What number of employees, who have raised a grievance or B&H complaint since 1st April 2018, remained at the Trust, in their same role, one year after their complaint was concluded?
4. What number of respondents* involved in grievance or B&H complaints since 1st April 2018, remained at the Trust, in their same role, one year after their complaint was concluded?
*respondent refers to the person who is the subject of the grievance or bullying and harassment complaint.

Grievances and bullying and harassment complaints.141222.docx

I understand the HSIB have written a “letter of concern” to MTW about maternity services (particularly about Crowborough Birthing Centre).

Under the FOI, could I see a copy of their correspondence please and the Trust’s response.

Download response Healthcare Safety Investigation Branch (HSIB). 220921.docx

A) Have you instructed external lawyers for advice about how your hospital has performed since March 2020? (If possible, please restrict this advice to Covid related matters and if you are able, describe the issue that the advice was sought. for example death of patient or guidance over treatment of patients with disabilities).
B) Have you paid for an “expert independent external opinion” since March 2020? (if you are able, please say the issue that this related to, for example, care of people with disabilities during Covid19).

Download response Legal advice. 230721.docx

1. How much was spent on legal fees by your Trust on defending employment tribunal cases relating to (a) discrimination; (b) unfair dismissal and (c) public interest disclosure in each year since 2016?

Download response Legal fees. 010719

• Number of serious incidents involving ligature points, occurring within the trust grounds, in the following years; 2018-19 (to date) 2017-18, 2016-17, 2015-16
• Number of patient deaths involving ligature points, occurring within the trust grounds, in the following years; 2018-19 (to date) 2017-18, 2016-17, 2015-16
• Of the serious incidents listed above how many of the patients involved were under 18?
• Of the patient deaths listed above how many of the patients involved were under 18?
• How much has the trust spent on specific programmes to tackle ligatures points in each of the following years; 2018-19 (to date) 2017-18, 2016-17, 2015-16

Download response Ligature points. 280119

1) A copy of any correspondence sent and received by the trust about listeria from hospital sandwiches since 1 January 2016.
2) A copy of any reports prepared by the trust about listeria and hospital sandwiches from 1 January 2016.
3) The number of patients found or suspected to have contracted listeria from hospital sandwiches in each calendar year from 1 January 2016, including the current calendar year.
4) Any correspondence with The Good Food Chain about listeria since 1 January 2016.

Download response Listeria and hospital sandwiches. 140819

I’d like to know the number of electronic items reported missing at your trust over the last three calendar years broken down by year, 2018, 2017, 2016.
• Mobile phones
• Laptops
• Tablet computers
If possible, please list the make of the devices e.g. ‘Apple’, no worries if this is not possible.

Download response Lost property. 261119

1. How much did your Trust have to pay to patients to replace lost, stolen or damaged property in the period July 1st 2021 to July 1st 2022 inclusive?
2. How many reports of lost, stolen or damaged property were there in total during this period?
3. How much did your Trust have to pay to patients to replace lost, stolen or damaged property in the period July 1st 2015 to July 1st 2016 inclusive?
4. How many reports of lost, stolen or damaged property were there in total during this period July 1st 2015 to July 1st 2016 inclusive in total?

Lost, stolen or damaged property.250523.docx

1. Please can you provide the total amount of compensation you have paid out to maternity claims in 2022/23.
a. Can you please provide the highest amount of compensation paid out to a single maternity claim in 2022/23?
b. Please could you split the 2022/23 figure on maternity claims into how much was spent on compensation and how much was spent on legal and other costs?

Maternity claims.120623.docx

All questions are shown as received by the Trust.
I would like to request data on the number of written complaints at Pembury maternity services between January 2020 and December 2023 with a breakdown of the complaints for each month and the nature of the complaint.

Maternity complaints.210324.docx

1. How many complaints you have received from mothers who used your maternity services between 1 January 2018 and 24 April 2021.
2. A breakdown of the allegations made in each complaint.
3. What the outcome was of each complaint.

Download response Maternity service complaints. 020721

Background Information:
How many clinical staff do you employ and how many are BAME? (inc locum/bank/agency)?
Questions:
1.How many BAME staff and how many non BAME staff have been working in ‘Covid wards’:
• In March/In April/In May so far.
2.How many redeployment requests were received from BAME and non BAME staff (inc locums/bank/agency)? And how many have been redeployed as a result?
• In March/In April/In May so far.
3.Since the NHS England guidance on Risk Assessments was issued during the Covid crisis, how many Risk Assessments have you carried out of your BAME staff?
4.How many BAME staff (inc locums/bank/agency) have been successfully redeployed since this Risk Assessments guidance was issued, as a direct result of it?
5.How many complaints or reports of discrimination by BAME and non BAME staff (inc locum/bank/agency) have been made regarding deployment since Covid hit i.e start of March?

Download response BAME staff. 131120

Q1. Please state (yes or no) whether your trust has carried out a risk-assessment of staff at potentially greater risk of COVID-19, including people from Black, Asian and Minority Ethnic backgrounds. [If answer to Q1 is yes, please answer questions 2-5]
Q2. Please state when this risk assessment was carried out.
Q3. Please provide a short summary of what the risk assessment entailed.
Q4. Please provide a copy of the findings of the risk assessment.
Q5. Please list and provide brief details of any measures that your trust has subsequently put in place to offer protection to staff who are at higher risk from COVID-19.

Download response BAME staff risk assessments. 100620

“1) Bed Capacity – last 5 years: Please provide average bed capacity for the previous five years as follows:
Total Bed Capacity (all wards).
Covid-19 Bed Capacity
2) Bed Capacity for 2021: Please provide bed capacity for the current year so far. For comparative purposes please use the following period each month: The first Wednesday of every month between the hours of 12noon and 4.00pm.
Total Bed Capacity (all wards)
Covid-19 Bed Capacity
3) Hospital Admissions – last 5 years: Please provide number of Admissions (all causes) for the previous five years as follows:
All Admissions
Admissions – where the patient has received 1 or more dose of an authorised Covid-19 Vaccination
Admissions – where the patient has NOT received any Covid-19 vaccination
4) Hospital Admissions for 2021: Please provide total number of admissions (for all causes) by month for the current year so far, split by Covid-19 vaccinated and unvaccinated.
All Admissions
Admissions – where the patient has received 1 or more dose of an authorised Covid-19 Vaccination
Admissions – where the patient has NOT received any Covid-19 vaccination
5) PCR Result of Hospital Admissions: Please provide breakdown of number of patients testing positive/negative with a Covid-19 PCR Test 2019 and 2020
Number of Patients testing positive with a Covid-19 PCR Test
Number of Patients testing negative with a Covid-19 PCR Test
6) PCR Result of Hospital Admissions for 2021: Please provide breakdown of number of patients testing positive/negative with a PCR test for the current year
At the time of Admission
No of Patients testing positive
No of patients testing Negative
7) Covid-19 Specific Admissions: Please provide total number of patients admitted where the primary reason for treatment was Covid-19 in 2019 and 2020.
Total number of Admissions where the primary treatment was for Covid-19
8) Covid-19 Admissions for 2021: Please provide number of Covid-19 admissions for 2021 where the primary reason for treatment was Covid-19
Total number of patients admitted where the primary reason for treatment was Covid-19”

Bed capacity and hospital admissions.110722.docx

Could I please ask for an honest breakdown of your covid admissions? A surgeon in your employment has shared the above information and I’d just like to know how many are completely unvaccinated and who have had one or more vaccinations.

Completely unvaccinated Covid-19 admissions and those who have had one or more vaccinations. 170322.docx

Due to recent concerns and government changes in advice related to working (regarding the Coronavirus), we are putting together our plan for our staff that are working from outreach locations.

We are getting in touch with all outreach locations our staff work from to ask for their plans/policies in light of the Coronavirus. Are we able to get your plan also?

Download response Coronavirus outreach working. 310320

1. The number of patients in your hospital(s) who tested positive for Covid-19, having tested negative at their time of admission
2. The number of these patients who subsequently died from Covid-19.

Download response Coronavirus transmission in hospital. 071020

1. Confirmation that all reported cases of SARS-COV2 in your Trust have been diagnosed and confirmed by PCR test;
2. If not with a PCR test, provide details of what method was employed to confirm the presence of SARS-COV2;
3. Details of the laboratories performing the PCR tests producing the confirmation of SARS-COV2 on behalf of your Trust;
4. Details of the Ct thesholds currently employed in the PCR tests performed by the labs at 3.;
5. Details of the Ct thresholds used to confirm all reported cases of SARS-COV2 in your Trust between 01/01/2020 and 18/12/2020;
6. Details of the manufacturers of the PCR tests used to confirm the presence of SARS-COV2 in your Trust;
7. In the document “Understanding cycle threshold (Ct) in SARS-CoV-2 RT-PCR” published on the UK government website, page 7 includes the statement “Some commercial RT-PCR techniques are closed ‘black box’ systems whereby the operator cannot observe the reaction in real-time and the result is interpreted by software into a qualitative non-interrogatable positive or negative result.”
a. Please confirm which manufacturers have been engaged that employ such a ‘black box’ method,
b. which labs have used such a manufacturer, and
c. which results confirming the presence of SARS-COV2 in the UK have been based on such techniques;
8. Where such results have been produced using the ‘black box’ method, please describe what further action was taken to confirm the results produced by the ‘black box’ method.

Download response Covid-19. 020321